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Abstract
The endothelial cells lining the brain microvasculature make up the blood-brain 
barrier (BBB) of the central nervous system (CNS), physically restricting access 
of blood-borne compounds to the brain. Very few drugs possess the narrow set 
of physicochemical characteristics required to cross the BBB, causing a hurdle 
in delivering therapeutics to the CNS without using invasive methods or 
disrupting the BBB. However, several transporters at the BBB mediate import 
and export of macromolecules in a process called transcytosis. The work 
presented in this thesis explores the use of polymeric nanoparticles or 
‘polymersomes’ as drug delivery vehicles to the brain. Through attaching a 
peptide ligand to LRP-1 receptor expressed at the BBB, polymersomes were 
provided with a targeting mechanism to achieve transportation across the 
blood-brain barrier in a non-disruptive manner. It is shown herein that 
Angiopep-2-POEGMA-PDPA (A-EP) polymersomes are able to transverse brain 
endothelial cells through transcytosis upon interaction with the LRP-1 receptor. 
However, transcytosis at the BBB is a poorly characterised process. Efforts to 
elucidate the mechanism by which LRP-1 mediates A-EP transcytosis at the 
BBB were undertaken through 3D or 4D confocal microscopy in conjunction 
with immunocytochemistry or small molecule inhibitors of various endocytic 
processes. This work was completed in parallel with fluorescence quantification 
of A-EP fluorescence in the rat brain, confirming that A-EP polymersomes enter 
the brain in vivo. Finally, applications for delivery of macromolecular 
therapeutics to the CNS in vivo were explored with the chief aim to achieve 
clinical translation.
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Chapter 1
Chapter 1. 
The Central Nervous System and its Barriers
_____________________________________________________________________
1.1.  Clinical Motivation
1.1.1. Introduction to the Central Nervous System
The brain and spinal cord together comprise the central nervous system (CNS). 
Neurons of the CNS transmit electrical impulses in the form of action potentials to 
control complex conscious functions, as well as essential unconscious functions such 
as respiration and temperature regulation. Neuron-neuron communication via synapses 
is essential for these roles, which is reflected in the high extensive vascularisation and 
metabolic demand of the brain compared to the rest of the body. Synapses require a 
specialised environment to function, with precise ionic gradients and neurotransmitters 
controlling the function of synapses. Glial cells (from Greek γλοία meaning ‘glue’) 
assist with the maintenance of the specialised extracellular conditions of the brain. 
These cells regulate the local environment in the brain by releasing signalling 
molecules, supplying nutrients, and removing neurotransmitter metabolites which can 
be harmful if allowed to accumulate. Figure 1.1 shows a brief summary of the different 
cells found in the CNS.
The CNS is able to carry out its highly specialised functions due to the separation of 
the brain and spinal cord from the rest of the body by several barriers. The molecular 
‘microenvironments’ present within the brain are maintained through orchestrated 
efforts of the brain barriers, glia, and fluids bathing the CNS. Malfunction of any of 
these regulatory systems can cause a range of pathologies that are often difficult to 
treat.
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Figure 1.1. Cells of the central nervous system: a summary of structure and function.
1.1.2. Diseases of the Central Nervous System
A distinct number of CNS diseases lack adequate treatment. This is true for 
pathologies ranging from stroke and spinal cord injuries to neurodegenerative disorders 
such as Alzheimer’s disease or Parkinson’s disease. One of the deadliest CNS 
diseases is stroke, i.e. the deprivation of oxygen (ischaemia) to the brain due to arterial 
occlusion. The 10-year cumulative mortality rate is around 32% (Prencipe, Culasso et 
al. 1998). Treatment is often performed during the acute stage of stroke, which entails 
regaining circulation to the ischaemic area before widespread damage such as cell 
death and oedema occurs. The only drug on the market for the acute phase of stroke is 
recombinant tissue plasmogen activator (rtPA, generic name alteplase), which breaks 
down blood clots. This drug is administered to less than 2% of patients, and was 
furthermore found to have an associated mortality rate of approximately 10% (Reed, 
Cramer et al. 2001). There is currently no treatment available for the long-term damage 
associated with ischaemic stroke.
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Dementia is another example highlighting the lack of CNS targeted therapeutics on the 
market. Dementia is the progressive decline in cognitive function caused by 
widespread neurodegeneration. In 2005 the World Health Organisation estimated 
nearly 25 million people worldwide to suffer from dementia, a number set to rise to 
double every 20 years until 2040 (Ferri, Prince et al. 2005). Nearly 50% of elderly 
patients in the U.K. live in institutions due to cognitive impairments, costing £4.6 billion 
a year (Comas-Herrera, Wittenberg et al. 2007). Alzheimer’s disease (AD) constitutes 
approximately 50% of all dementia cases, with vascular dementia or mixed cases 
making up the remainder. AD is characterised by the hallmark presence of amyloid β 
protein aggregates. There are five FDA-approved drugs on the market for AD, four of 
which belong to the group of anticholinesterase agents which primarily improve 
cognitive function in mild to moderate cases. There are no drugs on the market treating 
the underlying cause of dementia, i.e. extensive neurodegeneration. Between 2002 
and 2012 there were 413 clinical trials in the U.S. for novel Alzheimer’s disease 
therapeutics, 99.6% of which failed (Cummings, Morstorf et al. 2014).
1.1.3. Bottleneck in CNS Drug Development
The significant lack of drugs on the market to treat CNS disorders is due to a 
combination of factors. Firstly, our knowledge of many CNS diseases is incomplete. 
Many neurodegenerative diseases are highly complex, manifesting in a range of 
malfunctions at the cellular level such as oxidative stress and protein aggregation 
which results in death of entire cell populations in specific areas of the brain. Many 
drugs are focused on a specific mechanism of aspect of the pathology, for example 
focused efforts to develop anti-amyloid agents for AD. Secondly, the clinical 
manifestation of symptoms in neurodegenerative diseases often occur decades after 
cell death has begun (Rosen, Hansson et al. 2013). Thirdly, the current animal models 
of CNS disorders are inadequate with major discrepancies between pre-clinical and 
clinical results (Markou, Chiamulera et al. 2009). Finally, perhaps most importantly, the 
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highly restrictive barriers isolating the CNS from the rest of the body are a significant 
obstacle in achieving clinical efficacy due to keeping most drugs from entering the 
brain. A review of >7500 small molecule drugs found that <5% are active in the CNS, of 
which most are for affective disorders such as schizophrenia and depression (Ghose, 
Viswanadhan et al. 1999). Drugs must in order enter the CNS be <500Da, lipophilic, 
and form <8 hydrogen bonds with solvent water (Ajay, Bemis et al. 1999). 100% of 
macromolecules cannot enter the brain, unless they are nutrients imported by 
transporters at the brain. The barriers of the CNS have evolved over millions of years, 
and are extremely efficient in protecting the CNS from exogenous compounds (Abbott 
2005). Expanding current knowledge of these barriers is essential to develop strategies 
in targeting putative therapeutics to the CNS.
1.2. Anatomy of the Central Nervous System 
1.2.1. Fluids
The brain and spinal cord are immersed in and surrounded by fluids functionally and 
physiologically distinct from blood. The brain parenchyma is bathing in brain interstitial 
fluid (ISF), a low-protein solution similar to plasma. The different ion composition 
compared to plasma must be maintained for homeostasis in neurotransmission. The 
physiological differences in composition of the blood and the brain interstitial fluid are 
highlighted in table 1.1.
The other major fluid of the CNS is cerebrospinal fluid (CSF). It surrounds the outer 
membranes of the brain, where it reduces the effective weight and provides cushioning. 
CSF is continuously secreted by choroid plexus (CP) epithelial cells lining the 
cavernous ventricles of the brain. The choroid plexus is also a source of secreted 
nutrients such as insulin growth factor II (IGF-II) and transthyretrin, which are 
distributed throughout the brain via CSF (Dickson, Aldred et al. 1986, Stylianopoulou, 
Herbert et al. 1988). CSF is secreted at a rate of approximately 600 ml per 24 hours, or 
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the equivalent to replacing the entire CSF volume of the human brain 4 times a day 
(Brown, Davies et al. 2004). Efficient fluid drainage from the skull is thus essential to 
eliminate waste and to avoid dangerous pressure build-up due to fluid retention. 
Secreted CSF moves in bulk flow along the ventricles and out to the perivascular space 
(also called the Virchow-Robin space), which is located underneath the pial membrane. 
In the perivascular space CSF flows along the outside of blood vessels in the 
subarachnoid space, before it drains via arachnoid villi into sinuses leading into the 
venous blood of the systemic circulation.
Table 1.1. Differences in solute and protein concentrations in blood plasma and brain 
interstitial fluid. (Janigro 2012)
1.2.2. Barriers
The highly specialised environment of the CNS is maintained through the separation 
from the rest of the body by several physical and metabolic barriers. The concept of a 
brain barrier crystallised following two critical experiments performed by Edwin 
Goldmann (1909;1913): in the first experiment he confirmed an earlier observation by 
Paul Ehrlich that trypan blue, when injected intravenously, stained an animals tissues 
generally but not the central nervous system (Goldmann 1909, Goldmann 1913). The 
crucial second experiment demonstrated that when the trypan blue was injected into 
CSF via the cerebral ventricles, the brain became stained. Thus access of the dye to 
the nervous tissue was a crucial factor. In 1969 Brightman and Reese further noted that 
injected contrast agent peroxidase accumulated along the borders of brain capillaries, 
Nutrient Blood conc. Brain 
conc.
Notes
K+ 4.6 mM 2.9 mM High [K+] in brain can cause seizures
pH
[K+]
7.4
39 pM
7.3
57 pM
Higher [H+] causes faster neuronal repolarisation 
after action potential firing
Albumin 6 g/dl 0.02 g/dl
Free [Ca2+] 2.4 mM 1.2 mM Low calcium and glutamate reduces risk for 
neuronal damage due to overexcitation
Glutamate 40 μm 0.05 μm
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unable to enter the CNS due to the presence of intercellular physical barriers or 'tight 
junctions' which inhibit the paracellular movement of solutes (Brightman and Reese 
1969). The efficiency of this barrier is further illustrated in an experiment by Pardridge 
et al., in which injections of the radiolabelled small molecule histamine (~100 Da) in 
mice penetrated every tissue except the brain and spinal cord (figure 1.2) (Pardridge 
2005).
Figure 1.2. The CNS is protected by barriers. Radiolabelled histamine in the mouse systemic 
circulation, illustrating the presence of a barrier separating the CNS from the rest of the body 
(Pardridge 2005).
The barriers control all molecular traffic to and from the CNS. They facilitate import of 
nutrients from blood to brain and export of metabolites into the blood, while keeping the 
CNS inaccessible to the majority of blood-borne compounds. Barriers are classified 
according to their anatomical location and function, as illustrated in figure 1.3 and 
described in the following sections.
1.2.1.1. Arachnoid Epithelium
The arachnoid membrane is an avascular membrane that extends along the subdural 
space and encloses CSF and ISF in the skull. Secreted CSF is ultimately drained 
through the arachnoid epithelium, which is equipped with tight junctions to separate 
CSF from the venous blood in the sagittal sinus (see figure 1.3). Villi on the arachnoid 
epithelial cells increase the surface area efficiently to facilitate the drainage of CSF into 
venous blood. Drug delivery through the arachnoid epithelium would be impractical, as 
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it would grant limited access to the brain. Additionally, the drug would have to diffuse 
against the bulk flow of CSF being drained into the veins (Abbott, Patabendige et al. 
2010).
Figure 1.3. Anatomy of the brain barriers and properties of barrier capillaries. (Kandel, 
Schwartz et al. 2012)
1.2.1.2. Blood-Cerebrospinal Fluid Barrier
The choroid plexus epithelium is highly vascularised to accommodate for the high 
secretion rate of CSF. Microvilli on the basolateral side of the epithelium facing the 
ventricles maximises the surface area available for secretion (Keep and Jones 1990). 
Furthermore, the epithelium is supplied by fenestrated or ‘leaky’ capillaries. To maintain 
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a barrier between the blood and the CSF, tight junctions are present at the apical side 
of the epithelium which prevents the paracellular movement of most large water-soluble 
molecules into the CSF.
The blood-cerebrospinal fluid barrier (BCSFB) is considered distinct from the blood-
brain barrier (BBB), which separates blood from brain interstitial fluid. Indeed, some 
drugs can affect the CNS without entering the brain parenchyma. For example, 
systemic administration of radiolabelled anti-HIV drug azidothymidine (AZT) has 
neurological effects despite its absence from the parenchyma and inability to cross the 
BBB. Instead, AZT enters CSF through the BCSFB (Wu, Clement et al. 1998). 
However, research suggests that exchange between CSF and ISF occurs across the 
barriers. Rhesus monkeys that had their choroid plexuses removed only had a 30% 
reduction in CSF production, suggesting that the majority of the CSF is produced by 
other means than the choroid plexus (Milhorat, Hammock et al. 1971). Recent evidence 
using in vivo two-photon microscopy in mice showed that CSF and ISF can mix along 
several points of the perivascular space (Iliff, Wang et al. 2012). The ability for the 
fluids of the brain to mix explains the high turnover rate of CSF.
Further work is required to investigate the efficiency of delivering therapeutics via the 
BCSFB. The high turnover rate of CSF makes it a ‘sink’, efficiently eliminating 
metabolites and also therapeutics from the brain. For example, intracerebroventricular 
injections of brain-derived neurotrophic factor (BDNF) results in very little uptake into 
the brain parenchyma, limited to the ipsilateral site of injection (Yan, Matheson et al. 
1994). On the other hand, the ependyma lining the ventricles are exposed to very high 
doses of the drug, with detrimental consequences such as astrogliosis (Cho, Lee et al. 
2002). An alternative strategy for drug delivery would be to gain access via the vast 
capillary network supplying the CNS, forming the interface of the blood-brain barrier 
(BBB). With a total surface area of 21 m2, the need to maintain the CNS 
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microenvironment separate arises at the capillary level (Pardridge 2001). Specialised 
brain endothelial cells (BECs) line the brain capillaries, serving as the ‘gatekeepers’ of 
the CNS. The blood-brain barrier will be discussed further in section 1.4.
1.3. The Neurovascular Unit
The blood-brain barrier is induced and maintained through constant communication 
between brain endothelial cells and their neighbouring CNS resident cells. Figure 1.4 
depicts the extended network of cells surrounding the blood-brain barrier. The brain 
endothelial cells adhere to a basal lamina (BL1), a sheet of collagenous extracellular 
matrix. A second basal lamina (BL2) separates the endothelial basal lamina and the 
brain parenchyma, forming a ‘perivascular space’. In this space, support cells such as 
pericytes and smooth muscle cells wrap around the endothelial cells. Finally, on the 
brain side of the second basal lamina astrocyte end-feet processes cover almost all of 
the capillary endothelial cells.
Although brain endothelial cells inherently have a different phenotype from peripheral 
endothelial cells, induction of the BBB phenotype requires interactions with adjacent 
neural tissue during embryogenesis (Stewart and Wiley 1981). Pericytes are essential 
for the embryonic induction of the BBB, as mice deficient in the Pdgfr pericyte gene 
formed abnormal blood brain barriers with leakier vessels compared to wildtype mice 
(Daneman, Zhou et al. 2010).
The phenotype of brain endothelial cells in the adult brain is regulated by CNS resident 
astrocytes and pericytes in the vicinity, which has led to the term ‘neurovascular 
unit’ (NVU) to reflect the local synergy of the cells (Hawkins and Davis 2005). Astrocyte 
end-feet can release soluble factors such as glial-derived neurotrophic factor (GDNF) 
and β-fibroblast growth factor (β-FGF) which locally increase or decrease endothelial 
cell permeability (Abbott, Rönnbäck et al. 2006). Every neuron is surrounded by 
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approximately 6 astrocytes, and together they function as the relay between neurons 
and vasculature as a separate unit (Gabbott and Stewart 1987). In vivo imaging has 
shown that cortical astrocytes are able to rapidly cause vasodilation in response to 
stimuli such as increased neural activity (Takano, Tian et al. 2006). Pericytes can  also 
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directly modulate the function of endothelial cells, constricting or relaxing in order to 
regulate brain capillary diameter and thus blood flow (Peppiatt, Howarth et al. 2006). 
There is also evidence for a passive pericyte impact on brain endothelial permeability. 
Pericyte-deficient mice had an increased BBB permeability to water and tracers of a 
range of molecular weights (Armulik, Genove et al. 2010). Pericytes may therefore 
enhance the BBB phenotype of brain endothelial cells by decreasing the transportation 
occurring across the BBB, possibly through the regulation of gene expression pattern in 
brain endothelial cells. 
In summary, pericytes and astrocytes help establish the BBB phenotype of brain 
endothelial cells in the embryo and help maintain this phenotype in the adult brain. The 
neurovascular unit provides bidirectional communication between the brain endothelial 
cells and other cells in the vicinity, and modulate the barrier properties as necessary. 
The NVU interactions in the developing nervous system and in the adult brain make 
brain endothelial cells take on a different, more impermeable phenotype compared to 
peripheral endothelial cells.
1.4. The Blood-Brain Barrier
1.4.1. Properties of the Vasculature
All blood vessels are lined by a monolayer of endothelial cells, which have different 
properties depending on location. Endothelia can be classified into two relevant types: 
fenstrated (‘leaky’) or continuous. Fenestrated endothelia are found in tissues such as 
the kidney and intestine, and have pores spanning 50-60 nm in diameter which allows 
for the diffusion of many proteins. Continuous endothelia are a continuous sheet held 
together by intercellular junctions, found in tissues such as skin and muscle. The 
endothelial cells at the blood-brain barrier are also continuous. This type of endothelia 
has tight junctions preventing paracellular transportation. Instead these cells perform a 
highly regulated process of intracellular cargo transport. Endothelial protein expression 
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is polarised to maintain different environments at the apical and basolateral side. An 
essential component of these polarised cells are tight junctions, physical links between 
adjacent cells which prevent the paracellular movement of polar molecules and 
macromolecules. All CNS barriers express tight junctions to maintain a separate 
environment, but the brain endothelial cells have a number of specialised and 
enhanced barrier properties compared to any other barrier.
1.4.2. Barrier Properties
Brain endothelial cells (BECs) are polarised cells with the apical layer facing the blood 
vessel lumen and the basolateral side facing the basement membrane they adhere to. 
The polarity helps maintain separate environments at the apical (‘blood’) side and 
basolateral (‘lumen’) side, but requires strict regulation of all molecular traffic between 
the environments. Brain endothelial cells differ from peripheral endothelial cells in a 
number of ways: firstly, the composition of tight junctions is different even to other 
continuous endothelia. The combined expression of tight junction proteins claudin-5, 
occludin and zonula occludens 1 (ZO-1) contribute to a ‘tighter’ tight junction phenotype 
(Wolburg and Lippoldt 2002). Secondly, endothelial cells in peripheral tissues transfer 
nutrients across constitutively and non-selectively via a process called 
micropinocytosis. Tracing injections of peroxidase, Reese and Karnovsky noted a lack 
of micropinocytic vesicles at the BBB (Reese and Karnovsky 1967). Instead, certain 
molecules are shuttled intracellularly across the brain endothelium. This occurs 
passively for a narrow set of small lipophilic molecules, or actively via intracellular 
vesicular transport upon interaction of a ligand with specific receptors or transport 
proteins.
The ‘tightness’ of a polarised cell layer can be quantified by transendothelial electrical 
resistance (TEER), a measure of resistance to electrical charge moving across a 
polarised membrane such as endothelial or epithelial monolayers. In all effect TEER 
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measures ion transport across the monolayer. Resistance increases with barrier 
tightness, corresponding to a decrease in permeability of the cell layer. Brain capillary 
endothelial cells are by far the tightest continuous layer in the body with values up to 
2000 Ω/cm2, compared to <200 Ω/cm2 in the choroid plexus epithelium and <40 Ω/cm2 
in muscle capillary endothelium (Olesen and Crone 1983)(Crone and Olesen 1982)
(Saito and Wright 1983).
In addition to the enhanced physical barrier properties, the BBB is also a metabolic 
barrier. BECs express drug efflux transporters more than any other barrier cells 
(Loscher and Potschka 2005). Efflux transporters include Breast Cancer Resistance 
Protein (BCRP), P-glycoprotein (Pgp) and Multidrug Resistance Protein 1 (MRP-1). 
The efflux transporters can have a significant impact on the half-life of a drug entering 
the CNS, with a wide range of substrates including anticancer drugs, antibiotics, 
antihistamines and human immunovirus (HIV) suppressants (Schinkel and Jonker 
2012). Additionally, BECs express enzymes for intracellular degradation of compounds. 
The cytochrome P450 group of enzymes metabolise a wide range of compounds 
including neurotransmitters and centrally acting drugs, and its mRNA is expressed at 
the human BBB (Dauchy, Dutheil et al. 2008)(Dutheil, Jacob et al. 2010).
Brain endothelial cells thus possess physical and metabolic properties which make 
them the ‘first frontier’ of the BBB. The neurovascular unit significantly influences the 
local permeability of the BBB. Regulation of molecular transport occurring across the 
BBB will be discussed in the following section.
1.4.3. Transport Across the Blood-Brain Barrier
Many nutrients that the brain requires are synthesised peripherally and must pass 
through the BBB. There are a number of routes for molecules to be transported across 
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the brain endothelium, as explained in the following sections. The routes are 
summarised in figure 1.5.
1.4.3.1. Passive Diffusion
At the BBB, tight junctions restrict the paracellular diffusion of all molecules except 
water and oxygen. Furthermore, only highly lipophilic small molecules of <500 Da and 
with less than 8 hydrogen bonds can passively diffuse through the endothelium 
(Pardridge 2001). Active transcellular transport is therefore a highly important 
mechanism to import and export compounds to the CNS.
1.4.3.2. Carrier-Mediated Transport
Some small (<5nm) hydrophilic molecules are shuttled across BECs by transport 
proteins in carrier-mediated transport (CMT). Export of compounds from the brain to 
the blood by ABC efflux transporters has been covered in section 1.4.2. The second 
group of transporter expressed at the brain microvasculature falls under the gene 
classification of Solute Carrier (SLC), of which 53 genes have been identified (Hediger, 
Clemencon et al. 2013). These transporters mediate import of nutrients from the blood 
to the brain, the most commonly characterised transporters including L-type amino acid 
transporter 1 (LAT-1) for import of amino acids and glucose transporter 1 (GLUT-1) for 
import of glucose. CMT operates on the millisecond scale through the formation of 
stereospecific pores by the transmembrane regions of the transport proteins, and has a 
high ligand-transporter specificity.
1.4.3.3. Macromolecules
Macromolecular nutrients gain access to the brain from the blood by interacting with 
receptors expressed at the brain endothelial cell surface. Ligand-receptor interaction 
results in internalisation of cargo by the cell, intracellular shuttling and finally export to 
the other side of the cell. Receptors at the BBB involved in macromolecular 
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transendothelial transport include the insulin receptor (IR) which imports insulin; 
transferrin receptor (TfR) for the import of iron-transferrin (Fe-Tf) complexes; and low 
density lipoprotein receptor related protein 1 (LRP-1) for LDL-cholesterol. These 
transporters are expressed on the apical and basolateral sides of the endothelium, 
allowing bi-directional movement across the BBB via a transcellular route. 
Figure 1.5. Transport pathways across brain endothelial cells. Tight junctions stop the 
paracellular movement of all molecules except water and oxygen. Transcellular lipophilic 
pathways and transport proteins shuttle smaller molecules across the endothelium. Transport of 
macromolecules occurs by receptor-mediated transcytosis. (Abbott, Rönnbäck et al. 2006)
1.5. Transcytosis
The process of active, receptor-mediated transcellular transport in a polarised cell is 
called transcytosis. In continuous endothelia in which paracellular transport is severely 
limited, transcytosis is an important and highly regulated means to transport polar 
molecules or macromolecules which are unable to passively diffuse across the 
membrane. Transcytosis can be divided into three distinct sequential parts: i) extensive 
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plasma membrane remodelling and internalisation of ligand as cargo in endocytosis, ii) 
intracellular trafficking to the opposing plasma membrane, and iii) membrane 
remodelling and externalisation of cargo in exocytosis. In endocytosis, part of the 
plasma membrane folds inwards together with lipids and proteins and pinches off into 
discrete vesicles inside the cell together with the cargo. Endocytosis is essential to 
cells for uptake of nutrients, but also for purposes such as regulation of signalling at the 
plasma membrane (Shibata, Yamada et al. 2000) and remodelling of the plasma 
membrane lipid composition (Bu, Maksymovitch et al. 1994). The mirror event of 
endocytosis is exocytosis, where intracellular membrane vesicles fuse with the plasma 
membrane to secrete cargo from the cell interior. Endocytosis and exocytosis are 
highly energy-dependent processes, as plasma membrane remodelling is energetically 
unfavourable. The exact cellular machinery operating under the different stages of 
transcytosis may differ between cells with different phenotypes expressed by the 
polarised cell. The processes of endocytosis, intracellular trafficking and exocytosis are 
outlined in the following sections.
1.5.1. Endocytosis
Endocytosis occurs when a ligand binds and activates its target receptor, resulting in 
internalisation of the ligand-receptor complex through intracellular vesicles. The protein 
and lipid composition of these intracellular vesicles varies, and the different pathways 
of endocytosis have been well characterised in model organisms such as yeast as well 
as different kinds of mammalian cells. Some pathways involve uptake of molecules of 
the micrometre scale, such as phagocytosis and micropinocytosis. These processes 
are absent at the blood-brain barrier, and will therefore not be discussed herein 
(Brightman and Reese 1969). 
There are several mechanisms of internalisation upon ligand-receptor interaction. The 
major pathway of uptake is clathrin-mediated endocytosis (CME). In CME, ligand-
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receptor interaction triggers the formation of pits in the plasma membrane adjacent to 
the binding site. The pits are surrounded by the protein clathrin, which self-assemble 
into triskelia or ‘cage-like’ structures, and clathrin supporting adaptor proteins. Many 
types of clathrin adaptor proteins have been identified and maintain specific subcellular 
localisations, and only adaptor protein 2 (AP2) associates with clathrin at the plasma 
membrane to mediate endocytosis. Clathrin and AP2 surround the pits, forming 
clathrin-coated vesicles (CCVs) as they fold inwards (Brodsky, Chen et al. 2001). The 
deformation of the plasma membrane into clathrin-coated vesicles is completed by 
fission into complete intracellular vesicles. This is commonly mediated by the GTPase 
dynamin, which assembles around the thin phospholipid neck of the vesicle and severs 
it in an energy-dependent manner (Tuma, Stachniak et al. 1993). Additionally, the 
cytoskeleton helps in vesicular biogenesis and actin is essential for the invagination 
process of endocytosis. The lifetime of a clathrin-coated vesicle is around 20-120 
seconds, and can be up to 200 nm depending on cargo size (Ehrlich, Boll et al. 2004)
(Canton and Battaglia 2012).
The most studied clathrin-independent mechanism is caveolae-mediated endocytosis. 
There is also a clathrin- and caveolae-independent endocytosis pathway mediated by 
Arf6, but this will not be discussed here. Caveolae are plasma membrane-resident 
50-70 nm diameter flask-shaped pits, coated with the protein caveolin-1. They are 
present in many cell types and often abundant in vascular endothelial cells, with the 
exception of at the BBB where they are sparse (Frank, Woodman et al. 2003). Upon 
stimulation they can undergo endocytosis after dynamin pinches off the necks of the 
infolded vesicles (Henley, Krueger et al. 1998, Oh, McIntosh et al. 1998).
1.5.2. Intracellular Trafficking
The cell is compartmentalised into several subcellular organelles specialised for certain 
tasks. Once cargo is internalised through the endocytic pathway, it can have one of the 
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following fates: recycling to the plasma membrane, targeting to a specific organelle, or 
degradation. All cargo must therefore come with an ‘address label’ which directs its fate 
once inside the cell. This destination information often comes in specific sequences of 
amino acids. For example, nuclear localisation signals often consist of a stretch of 
basic amino acids, whereas proteins resident at the endoplasmic reticulum have a 
KDEL or KKXX amino acid sequence. Some ligands are targeted for lysosomal 
degradation. This endo-lysosomal pathway follows a pH gradient and becomes 
increasingly acidic along the pathway, from pH 7.4 to approximately pH 5 in lysosomes. 
It is unclear to what extent this pathway is utilised in cells capable of transcytosis, as 
cargo must avoid lysosomal degradation. Cargo can be recycled from endosomes to 
the plasma membrane, common for receptors which have undergone endocytosis 
together with their cargo. Indeed, recycling endosomes are frequently implicated in 
epithelial cell transcytosis (Tuma and Hubbard 2003). A simplified summary of the 
common endocytosis pathways is outlined in figure 1.6, though their relative 
contributions to transcytosis are likely to differ as discussed in section 1.6.
All organelles of the endosomal pathway are distinguished by their unique plasma 
membrane domains, containing different combinations of phosphatide inositols (PIs) 
and Rab GTPases (Sönnichsen, De Renzis et al. 2000). The Rabs are a group of 
proteins which use energy from guanosine triphosphate (GTP) hydrolysis to exert 
regulatory roles in various stages of membrane trafficking, from vesicle docking to 
fusion (Stenmark 2009). Some Rabs implicated in endocytosis include Rab5 in early 
endosomes, Rab4 and 11 in ‘recycling’ endosomes returning to the plasma membrane, 
and Rab7 in late endosomes (Bucci, Parton et al. 1992, Vitelli, Santillo et al. 1997, 
Sönnichsen, De Renzis et al. 2000, Stow and Jennifer 2005). More than 70 Rabs have 
been identified in humans, and 75% or more are believed to have roles in endocytic 
trafficking (Wandinger-Ness and Zerial 2014).
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Figure 1.6. The endosomal sorting pathway (simplified). Adapted from (Gould and 
Lippincott-Schwartz 2009).
1.5.3. Exocytosis
Exocytosis is the fusion of an intracellular vesicle with the plasma membrane. 
Constitutive exocytosis occurs in all cell types as a means for cells to recycle lipids and 
proteins to the plasma membrane, and is very slow. In specialised cells such as 
neurons, there is additionally a highly regulated form of exocytosis which 
synchronously releases many vesicles of intracellular contents into the extracellular 
environment on a millisecond scale. Here, the final steps of fusion between the 
vesicular and target plasma membrane is under tight temporal control by specialised 
proteins which also provide the energy for fast fusion.
The protein machinery regulating exocytosis has been identified mostly through 
studying neuron transmission of synaptic vesicles. In neurons, vesicles containing the 
neurotransmitters fuse with the plasma membrane at the synapse and release all 
cargo. Using affinity chromatography, Rothman and colleagues initially identified three 
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main components essential for membrane fusion in synaptic vesicle exocytosis: N-
ethylmaleimide Soluble Factor (NSF), Synaptosomal Associated Proteins (SNAPs), 
and SNAREs (SNAP-Receptors) (Söllner, Whiteheart et al. 1993). He subsequently 
coined the SNARE hypothesis, which states that membrane fusion is dependent on the 
association of SNARE proteins on the vesicular and target membranes. Experimental 
evidence in support for this hypothesis is strong: knockout of SNARE proteins vesicle-
associated membrane protein (VAMP) and SNAP-25 in mice is lethal (Schoch, Deak et 
al. 2001). Furthermore, exocytosis and synaptic transmission is inhibited by botulinum 
toxins and clostridium neurotoxins, which target SNAPs or SNAREs for proteolysis (Xu, 
Binz et al. 1998).
The essential step of membrane fusion involves the association of SNARE proteins 
expressed on the intracellular vesicle (v-SNARE) and the opposing target membrane 
(t-SNARE). All SNAREs have the same SNARE motif of 60-70 amino acids, which in 
their monomeric state lacks structure. However, the appropriate combination of 4 
SNAREs on the vesicle and target membrane intertwine into stable core complexes of 
4 α helices (sometimes referred to as a SNARE-pin). As this transmembrane trans-
SNARE complex assembles or ‘zips up’, it docks the vesicle to the membrane. When 
both bilayers of lipids have merged, a pore opens throughout the membranes to form a 
channel. This pore collapses eventually, releasing cargo and trapping all proteins in the 
target membrane. After fusion has occurred, the membrane fusion ATPase NSF 
disassembles the SNARE complexes via SNAP, its adaptor protein. This ‘recycling’ of 
cis-SNARE complexes is essential for membrane fusion to occur again.
Although SNARE complexes are critical for membrane fusion, they are too slow to 
mediate it alone. SNARE regulatory proteins assist with the fusion process, and are 
especially significant in quick regulated exocytosis such as neurotransmission. A range 
of both positive and negative regulators of secretion have been identified, and fine-tune 
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the exocytosis process. Knockout studies have identified the protein family of Sec1/
Munc18 (SM) as regulators essential to every fusion step in neuronal exocytosis 
(Dulubova, Khvotchev et al. 2007). SM proteins bind to the syntaxin family of t-
SNAREs in the plasma membrane, and can take on open or closed conformations to 
negatively regulate secretion. Total Internal Reflection Fluorescence (TIRF) microscopy 
of fluorescently labelled cargo in Munc18 knockout adrenal chromaffin cells showed 
that Munc18 is required for stable vesicle docking, causing average a vesicular 
membrane residency of >10 seconds (Toonen, Kochubey et al. 2006). The regulatory 
role of SM proteins appears to be conserved in cell types other than neurons. For 
example, expression of the isoform Munc18c was detected in human microvascular 
endothelial cells. Furthermore, exocytosis was inhibited upon treating cells with siRNA 
to syntaxin 4 which directly interacts with Munc18c (Fu, Naren et al. 2005). 
1.6. Transcytosis in Brain Endothelial Cells
Transcytosis occurs in situ in the microvasculature of several tissue types, including 
intestinal epithelial cells, lung, brain, and liver (Brightman and Reese 1969). It has 
frequently been studied in epithelial cell lines such as liver or kidney cell lines MDCK 
and Caco-2, and the fate of cargo such as immunoglobin complexes has been well 
characterised in epithelia (Kaetzel, Robinson et al. 1991). However, epithelial cells 
have a largely different phenotype to brain endothelial cells. A particular discrepancy is 
size: epithelial cells span 10 μm across, compared to 0.2 μm across the thinnest parts 
of brain endothelial cells (Keep and Jones 1990). Endothelial cell transcytosis has 
mostly been studied in pulmonary endothelial cells, which are more permeable and 
have a higher occurrence of transcytosis than brain endothelial cells (Brightman and 
Reese 1969, Abbott, Patabendige et al. 2010). Because of the specialised structure 
and function of BECs, the cellular machinery of BEC transcytosis might differ from that 
in peripheral transcytosis. 
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Studying transcytosis by the endothelial cells at the BBB is complicated, as 
transportation may be bi-directional from blood to brain and vice versa. Also, it is 
unclear what signalling cues endothelial cells receive which determines when to direct 
the cargo to the opposite side of the plasma membrane and when to target it to 
intracellular organelles or lysosomal degradation. There are many questions that need 
to be answered about transcytosis in general, but especially at the BBB. Current 
knowledge of the stages of transcytosis are outlined below.
1.6.1. Endocytosis
Endothelial cells often have a number of intracellular vesicles with openings facing the 
capillary lumen, as displayed in figure 1.7. Many morphological studies performed in 
peripheral tissues such as the myocardium or pulmonary microvasculature have 
identified these vesicles as caveolae. However, evidence supporting a role for caveolae 
in brain endothelial cell transcytosis is lacking, not least because very few studies 
examining vesicular transcytosis have been performed in the brain endothelium. 
Indeed, the role of caveolae in transcytosis is controversial. A paper reported that 
caveolae are completely static at the plasma membrane and do not transport cargo 
whatsoever (Thomsen, Roepstorff et al. 2002). On the other hand, work by Predescu et 
al. provides plenty of electron microscopy data supporting a role for caveolae in 
transcytosis. Specifically, this group concluded that 95% of the vesicular population in 
endothelial cells are caveolae, and subsequently stated that ubiquitously, 95% of 
vesicles mediating endothelial cell transcytosis are caveolae (Predescu, Predescu et 
al. 2007). This claim remains unsupported. Furthermore, a significant caveat to notice 
is the extrapolation of findings in murine microvascular pulmonary tissue to apply to ‘all’ 
endothelia (Oh, Borgström et al. 2007). Although caveolin-1 is expressed by human 
BECs, endothelial cell transcytosis has mainly been studied in peripheral endothelia 
(Frank, Woodman et al. 2003)(Virgintino, Robertson et al. 2002). Further data is 
required on transcytosis in brain endothelial cells, but there is some evidence against 
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the hypothesis of caveolae being the intracellular vesicles mediating transcytosis at the 
brain endothelium. A study reported deficient in vivo internalisation of caveolar ligand 
albumin by mouse endothelial cells devoid of caveolae (Schubert, Frank et al. 2001). 
However, brain endothelial cells do not express the albumin receptor (Pardridge, 
Eisenberg et al. 1985). Although caveolar proteins are expressed by brain endothelial 
cells, these cells are known to contain by far the lowest vesicular population with <100 
vesicles per μm3 (Henley, Krueger et al. 1998). Perhaps the most important evidence 
against a role for caveolae in BBB transcytosis is that mice devoid of caveolar coat 
protein caveolin-1 are viable, suggesting that removing these structures does not 
disturb the essential process of import and export of compounds across the BBB (Drab, 
Verkade et al. 2001).
Figure 1.7. Morphology of endothelial cell intracellular vesicles. Electron micrograph of cat 
myocardium. (Fawcett 1965)
The role of caveolae in transcytosis remains controversial. The vast majority of 
endocytosis occurs through clathrin-mediated vesicles, and evidence exists for an 
important role of these structures in transcytosis. A recent study using TIRF microscopy 
and siRNA gene knockdown of CCVs in adipose microvasculature endothelial cells 
showed that transcytosis of insulin was mediated by CCVs (Azizi, Zyla et al. 2015). In 
brain endothelial cells, transcytosis of iron-transferrin complexes occurs via clathrin-
coated vesicle internalisation in vivo (Roberts, Sandra et al. 1992). However, there is a 
lack of studies following the complete steps of transcytosis, from apical to basolateral 
or vice versa. 
 43
Chapter 1
1.6.2. Intracellular Trafficking
The intracellular trafficking events in endothelial cell transcytosis are not well known. At 
the BBB, it is uncertain whether cargo is trafficked through endosomes at all. 
Experiments tracking cargo with tracer dyes in clathrin-mediated endocytosis showed 
up in early endosomes within 1-5 minutes of incubation, late endosomes after 10-15 
minutes and lysosomes after 30 minutes (Pfeffer 2001). Internalisation by caveolae can 
take as long as 1-2 hours (Schnitzer, Oh et al. 1994, Pelkmans, Kartenbeck et al. 
2001). In both cases the timing is inconsistent with the rapid transcytosis rates 
observed in vivo, which has been observed using live imaging to occur in <60 seconds 
in the lung endothelium (Oh, Borgström et al. 2007). Another discrepancy is the 
mechanism of Fe-Tf transcytosis across the brain endothelium. One theory is that after 
internalisation in clathrin-coated vesicles, Tf shuttles iron across to the opposing 
plasma membrane, and then recycles in an unbound state (Moos and Morgan 2000). 
Normally in the case of ligand-receptor interactions, dissociation occurs as a result of 
encountering the acidic pH of endosomes. This raises question whether Fe-Tf 
undergoes transcytosis at the brain endothelium through a pathway independent of 
acidifying endosomes.
It would be energetically favourable for cargo to be shuttled from membrane to 
membrane by travelling the shortest distance possible. Brain capillary endothelial cells 
are approximately 40% thinner than peripheral endothelial cells (Coomber and Stewart 
1986), and the non-nuclear area can be as thin as 0.2-0.5 μm. As a result, cargo 
requires shorter transportation distances from one membrane leaflet to the other, which 
facilitates rapid transcytosis. Interestingly, there is ultrastructural evidence for a network 
of endothelial intracellular vesicles which have merged into ‘tubes’ or pores. 
Transendothelial channels can be defined as chains of fused intracellular vesicles 
which are simultaneously open on the endothelial cell apical and basolateral sides. 
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Bundgaard and colleagues performed electron microscopy of frog mesenteric 
capillaries to investigate transcytosis, where the addition of electron dense tannic acid 
seemed to fill out intracellular clusters of 2-5 vesicles which had fused (Bundgaard, 
Frøkjaer-Jensen et al. 1979). Repeating these studies in hagfish brain endothelium, 
they found through 3D reconstructions of serial EM sections that many of the vesicles 
traditionally observed in 2D electron micrographs appeared to be part of a larger 
branching network when reconstructed in the z plane. An illustration of the network of 
tubes observed in the hagfish brain is displayed in figure 1.8. These branching 
networks of intracellular vesicles were also observed in the EM work of Simionescu et 
al, investigating caveolar transcytosis of gold-labelled albumin in the mouse lung, heart 
and diaphragm (Simionescu, Popov et al. 2009). An example of a single 
transendothelial channel can be seen in figure 1.9. However, this section was obtained 
from a choroid plexus, which have leaky capillaries without tight junctions. Instead, the 
branching networks of vesicles seem a more plausible hypothesis for the blood-brain 
barrier as these networks are more frequent at the BBB; a study used 3D 
reconstructions of serial ~20nm electron micrographs to compare the number of 
transendothelial channels in microvasculature from different origins, and found an 
average of 8 channels per μm2 in mouse BECs, compared to 4 in choroid plexus. 
These channels were located at the thinnest area of the cell, and were approximately 
the size of a single vesicle rather than a network of fused vesicles, although the latter 
were also present (Coomber and Stewart 1986). 
A caveat of the channel hypothesis is that evidence is predominantly electron 
microscopy based. Electron microscopy of cell or tissue samples requires the fixation 
and processing with harsh lipid removal techniques, which undoubtedly affect 
membrane structures including intracellular vesicles. Further evidence for 
transendothelial channels should ideally be obtained through alternative methods 
which do not require processing with fixatives.
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Figure 1.8. Tubular networks in the brain endothelium. Illustration of 3D serial EM 
reconstructions of hagfish brain endothelium. From Bundgaard et al (1987).
Figure 1.9. Electron micrograph of a transendothelial channel. Mouse choroid plexus, L: 
lumen, E: endothelial cell. Arrows point to a fused multivesicular channel as well as a single 
transendothelial channel. (Coomber and Stewart 1986)
In summary, knowledge of the intracellular transportation stages of transcytosis is 
lacking. It is possible that brain endothelial cell transcytosis is a system completely 
independent of the endosomal pathway, and instead potentially consists of tubulation of 
intracellular vesicles into a fused network to facilitate rapid transcytosis. However, more 
evidence must be obtained regarding the existence of these tubes and their 
involvement in transcytosis.
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1.6.3. Exocytosis
Although SNAREs have been well characterised in neurons, the roles of SNAREs and 
their regulatory proteins in transcytosis is far less understood. There have been several 
reports of inhibition of myocardial vasculature transcytosis in vivo transcytosis through 
the use of NSF inhibitor N-Ethylmaleimide (NEM) (Predescu, Horvat et al. 1994). The 
addition of recombinant NSF rescued NEM-inhibited transcytosis in hepatic cell-free 
systems (Sztul, Colombo et al. 1993). However, implicating certain SNAREs important 
for brain endothelial cell transcytosis is proving complicated. More than 100 SNARE 
proteins have been identified in mammalian cells, with 36 members in humans (Hong 
2005). Only certain combinations out of the hundreds available fuse, meaning that 
SNAREs provide specificity to membrane fusion (Südhof and Rothman 2009). This 
targeting mechanism may indeed be conserved in transcytosis. However, a 
combination of SNAREs specific to transcytosis have not been identified. In polarised 
cells there may be some asymmetrical distribution of SNAREs in the apical and 
basolateral leaflets, as reviewed by Tuma and Hubbard (Tuma and Hubbard 2003). 
Also, co-immunoprecipitation of lung microvasculature identified a few molecular 
mediators of transcytosis in a complex containing syntaxin, cellubrevin, SNAP-23, 
Rab5, NSF, and α- and γ-SNAP (Predescu, Predescu et al. 2001). However, further 
work needs to be done in order to elucidate the role of SNAREs and their associated 
proteins in transcytosis. Interestingly, the SNARE components identified in lung 
microvasculature by Predescu et al. were associated with lipids in supramolecular 
protein-lipid complexes, highlighting the role of lipids as protein segregating platforms 
in advanced membrane signalling and remodelling events such as exocytosis.
1.6.4. Cholesterol in Endothelial Cell Transcytosis
It is a widely accepted hypothesis that the plasma membrane is organised into lipid 
rafts, i.e. dynamic assemblies of sphingolipids and cholesterols which form functional 
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domains on the nanometre scale (Simons and Ikonen 1997). The selective 
incorporation or exclusion of specific proteins into lipid rafts is a protein sorting 
mechanism, and facilitates cell-cell signalling, endocytosis and exocytosis (Simons and 
Vaz 2004). Predescu et al. identified an essential role for cholesterol in the organisation 
of t-SNAREs syntaxin-4 and SNAP-23 in endothelial cells, which was required for 
transcytosis (Predescu, Predescu et al. 2005). Although their study was performed in a 
cell-free system with t-SNAREs they had previously identified in lung microvascular 
endothelial cells, the findings are still interesting in terms of cholesterol dependence 
(Predescu, Predescu et al. 2001). It is possible that SNAREs are also organised into 
cholesterol-enriched lipid rafts to mediate exocytosis in brain endothelial cells. 
1.7. Low Density Lipoprotein Receptor Related Protein 1
Receptors with reported roles for transcytosis across the BBB include the insulin 
receptor, transferrin receptor, and low density lipoprotein related protein 1 (LRP-1). 
LRP-1 was first identified as receptor involved in lipoprotein metabolism, due to its high 
structural similarity to the low density lipoprotein receptor (LDL-R) and also because of 
its binding to Apolipoprotein E (ApoE) (Herz, Hamann et al. 1988)(Beisiegel, Weber et 
al. 1989). LRP-1 has since been reported to bind more than 30 different ligands, in 
contrast to TfR and insulin receptors which are single-ligand receptors at the BBB 
(Lillis, Van Duyn et al. 2008). LRP-1 is expressed in several tissues including the liver, 
kidneys and gastrointestinal tract, as well as the central and peripheral nervous 
systems. However, expression is enriched approximately 100-fold in the CNS 
compared to the liver (Moestrup, Gliemann et al. 1992). The enriched CNS expression 
combined with the number of different ligands makes LRP-1 a highly interesting 
receptor mediating transcytosis at the BBB.
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1.7.1. Structure of LRP-1
The structure of LRP-1 is shown in figure 1.10. It is present on the cell surface as a 
two-chain molecule: a 585kDa α chain which consists of several ligand binding 
domains, and a 85kDa β chain transmembrane domain (Beisiegel, Weber et al. 1989). 
The two chains are non-covalently associated: the extracellular α chain is subject to 
shedding by proteolysis, and can be found circulating in human plasma and serum 
(Herz, Hamann et al. 1988, Quinn, Grimsley et al. 1997). The β chain contains 
intracellular sorting motifs, including a YXXL motif essential for receptor endocytosis, 
and a binding motif for Sortin Nexin 17 which is required for receptor recycling from the 
early endosome (Li, Marzolo et al. 2000, van Kerkhof, Lee et al. 2005). The 
extracellular domain has four different ligand binding clusters (I-IV), where specific 
ligand binding has been identified partially through screening with ‘mini-receptors’ 
expressing one of the four clusters(Goto and Tanzi 2002, Ranganathan, Cao et al. 
2011). Ligands with a particularly high binding affinity to LRP-1 have very diverse roles, 
and include the serine protease tissue plasminogen activator (tPA) (Tooyama, 
Kawamata et al. 1995); lipoprotein lipase (Chappell, Fry et al. 1992); and the 
chylomicron endocytosis inhibitor lactoferrin (Huettinger, Retzek et al. 1992, Willnow, 
Goldstein et al. 1992).
1.7.2. LRP-1 in the Central Nervous System
Through immunohistochemistry, LRP-1 expression in the human brain has been 
strongly localised to the cerebral cortex, cerebellum, hippocampus and midbrain (Bu, 
Maksymovitch et al. 1994). On the cellular level, LRP-1 expression is high in neurons, 
and moderate in astrocytes, glia, and pericytes (Moestrup, Gliemann et al. 1992, Wolf, 
Lopes et al. 1992, Tooyama, Kawamata et al. 1995). Electron microscopy combined 
with immunolabelling of LRP-1 in glioblastoma cells located the receptor confined to 
clathrin-coated pits at the plasma membrane, but also has a minor intracellular 
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association with the endoplasmic reticulum and Golgi complex (Bu, Maksymovitch et 
al. 1994). 
LRP-1 has been implicated in the pathogenesis of Alzheimer’s disease, but the roles 
and contributions are not entirely clear. LRP-1 mediates bidirectional transport of 
amyloid-β aggregates across the BBB through the association with clathrin-coated pits 
(Pflanzner, Janko et al. 2011). Knockdown of clathrin or removal of the cytoplasmic tail 
of LRP-1 inhibited its ability to undergo endocytosis, which also decreased uptake of 
Amyloid β-42 plaques (Fuentealba, Liu et al. 2010). Isoforms of amyloid plaques bind 
with differential affinity to LRP-1. ‘Normal’ amyloid β-40 bind with high affinity to ligand 
clusters II and IV and are subsequently transported out of the brain. By contrast, AD 
isoform amyloid β-42 transcytosis is significantly reduced, resulting in accumulation of 
plaques in the mouse brain (Deane, Wu et al. 2004). Furthermore, the soluble 
extracellular α chain (soluble LRP-1 or sLRP-1) may act as a “peripheral sink” of 
plaques, as administering sLRP-1 increased learning in mice and reduced plaque 
presence in the brain (Zlokovic, Deane et al. 2010).
Li and colleagues found that out of the lipoprotein receptors, LRP-1 has the fastest 
endocytosis rate, with a half life of 30 seconds to recycle to the membrane (Li, Lu et al. 
2001). This makes it a superior receptor to target for drug delivery in terms of 
kinetics ,compared to the TfR with a half life of 3 minutes (Iacopetta and Morgan 1983), 
and 18 minutes for the insulin receptor (Bottaro, Bonner-Weir et al. 1989). Once 
internalised, it is unclear whether LRP-1 shuttles with its ligand to the opposing plasma 
membrane, or is recycled back to its original membrane. Further work utilising in vitro 
models of the blood-brain barrier may prove useful in elucidating the physiological roles 
of LRP-1 in transcytosis, and applications for drug delivery.
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Figure 1.10. Structure of the LRP-1 receptor. The extracellular domain contains four ligand 
binding clusters, with example ligands for each as indicated.(Herz and Strickland 2001)
1.8. In Vitro Models for Studying the Blood Brain Barrier
In vivo, the blood-brain barrier is a synchronised effort of more than the endothelial 
cells lining brain capillaries. However, simplistic in vitro models of the BBB may be 
applied in order to enable the use of a range of molecular biology methods for the 
elucidation of BBB characteristics. The cell models of the BBB are centred around 
brain endothelial cells differentiated in a three-dimensional environment similar to the 
extracellular matrices present at the BBB. A common 3D model of the BBB utilises a 
transwell setup, in which brain endothelial cells are coated onto a porous layer of 
collagen-coated thin filter membrane which is analogous to the basal lamina. The 
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transwell is inserted into a regular wellplate, separating into two compartments 
analogous to the ‘apical’ and ‘basolateral’ sides of the endothelial cells.
The in vitro transwell BBB models have gained merit in the last couple of decades, 
though with widely varying parameters. For example, in the 1990s it was the norm to 
conduct studies with bovine endothelial cells, which changed as a result of stricter 
regulations after the discovery of bovine encephalitis virus. Bovine BBB cultures were 
replaced with murine cultures, and recently porcine cells have become an alternative. 
Porcine brain endothelial cells (PBECs) display some of the highest TEERs achieved in 
vitro to date, averaging 800 Ω/cm2 (Patabendige, Skinner et al. 2013). Recent efforts 
have also yielded human models. Lippman et al. generated a human BBB model by 
directing human induced pluripotent stem (iPS) cells into endothelial cells and 
astrocytes, yielding a TEER of approximately 1450 Ω/cm2 (Lippmann, Azarin et al. 
2012). However, both iPS and PBEC cells are laboursome to obtain and maintain 
compared to established murine cell lines.
As one might expect from the need for pericytes to induce BBB properties in vivo 
(Daneman, Zhou et al. 2010), brain endothelial cells in vitro may not intrinsically show 
full blood-brain barrier properties. It is unclear precisely which soluble factors are 
released by pericytes and other adjacent cells during development to direct 
differentiation of endothelial cells into a blood-brain barrier phenotype. The addition of 
soluble factors such as adenosine antagonists is known to improve barrier-like 
properties in vitro (Gao, Qian et al. 2014). Although soluble factors or cells could be 
added to cell culture in order to enhance barrier-like properties, there is a balance to be 
struck between mimicking the BBB without overly complicating the system and also 
maintaining reproducibility.
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Choosing the appropriate in vitro BBB model should depend on the research questions 
and aims. Firstly, the species origin of cells is particularly useful to consider when 
comparing data to previously obtained in vivo data. Genetic variance should be taken 
into account, e.g. whether the receptor expression is the same between rats and 
humans for a particular gene of interest. Cells with an origin of larger mammals such as 
bovine and porcine cells may be more relevant in terms of in vitro to in vivo translation, 
but porcine cells generally lack commercially available antibodies established to 
identify the proteins transcribed by relevant genes, complicating common research 
methodologies such as immunohistochemistry. Secondly, whether the cells are primary 
(i.e. directly extracted from tissue) or immortalised also makes a difference: cells which 
have been transformed into cell lines via expression of tumour cell genes may show a 
differing phenotype to primary cells, but are on the other hand homogeneous and 
already characterised. It should also be noted that the use of ‘surrogate’ cells of a 
different nature in the assessment of barrier properties, such as epithelial MDCK and 
Caco-2 cells, is outdated for BBB studies as many better alternatives exist. Finally, 
protocols between labs inevitably differ, and as does physically quantifiable properties 
of in vitro BBB models such as TEERs.
 53
Chapter 2
Chapter 2.
Drug Delivery to the Central Nervous System
_____________________________________________________________________
2.1.  Drug Delivery
Because the majority of cell-surface receptors are expressed ubiquitously in the body, 
drugs targeting a specific receptor inevitably bind and affect tissues in addition to the 
target tissue. Paul Ehrlich coined the notion of a ‘magic bullet’, referring to an ideal 
therapeutic able to destroy its target but leave all other cells unharmed. (Ehrlich 1908) 
Developing smart drug delivery vehicles through manipulation of materials at the 
nanoscale may be essential in accomplishing this concept. 
The drug must be present systemically to obtain the desired concentration at the target 
tissue, which means that the drug will potentially cause off target binding and adverse 
effects in addition to undesired target related effects. A frequently discussed example of 
off-target effects concerns cancer chemotherapy, which is highly toxic to healthy cells in 
addition to cancer cells. If chemotherapeutics would selectively bind to receptors 
expressed by cancer cells in addition to having high affinity and potency, the undesired 
target and off-target related effects would decrease.
2.2. Hurdles to Overcome in Drug Delivery
There are a number of hurdles which therapeutics must overcome in order to reach 
and exert effects at the target.
2.2.1. Solubility
Regardless of the route of administration, drugs must be soluble in plasma at the target 
site in order to become absorbed by the target tissue. Poor aqueous solubility results in 
poor uptake of the drug at the target. More than 40% of new agents developed in the 
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pharmaceutical industry are insoluble in water, requiring further physicochemical 
modification before they can be used (Savjani, Gajjar et al. 2012).
2.2.2. Protein Fouling
Drugs or nanoparticles dispersed in the circulation are susceptible to become coated 
by opsonin proteins present in plasma. Due to attractive intermolecular interactions, 
proteins in the plasma interact with the particles. The adsorption of proteins onto the 
particle surface is called protein fouling. This process results in the formation of a 
protein corona on the particle surface, which can be classified as ‘soft’ or ‘hard’. 
Proteins are continuously attaching and detaching in a soft corona due to weak 
intermolecular interactions, whereas adsorption and detachment in hard coronas 
occurs with much slower kinetics (Lynch, Salvati et al. 2009). The proteins involved in 
adsorption are referred to as ‘opsonins’, and include immunoglobulins, albumin, 
fibronectin among other plasma proteins. As particles become opsonised they become 
recognisable by the mononuclear phagocyte system (MPS), which recognises the 
adsorbed opsonins as a phagocytosis signal. Opsonisation can be quick, as elimination 
of nanoparticles by macrophages can occur just seconds after intravenous 
administration (Gref, Minamitake et al. 1994).
2.2.3. The Physiological Barrier
Protein fouling results in the detection and subsequent elimination by the macrophages 
and monocytes of the MPS. Another potential issue is excretion. The glomeruli of the 
kidneys are the porous filtration units, acting as molecular sieves with pores spanning 
approximately 12 nm (Gagliardini, Conti et al. 2010). Unbound drugs eventually 
become excreted by the kidney. By contrast, drugs bound to plasma proteins are poorly 
filtered through the glomeruli, and remain in circulation.
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2.2.4. The Cell Membrane
Drug candidates aiming for intracellular targets must pass through the plasma 
membrane (i.e. possess permeability). One strategy is to target receptors at the plasma 
membrane to gain access via endocytosis. However, crossing lipid membranes can 
occur passively, depending on the lipid solubility of the drug. For passive diffusion to 
occur, the drug be hydrophilic enough to dissolve in plasma and lipophilic to penetrate 
cell membranes. One measure of this is the partition coefficient (LogP), giving the ratio 
of distribution of a compound in octanol and water in equilibrium. LogP can be 
measured experimentally (MLogP) or calculated computationally (CLogP). Attempting to 
make rules for pharmaceuticals, Lipinski’s rule of five was formulated in 2001 as an 
experimental and computational approach to estimate drug solubility and permeability 
(Lipinski, Lombardo et al. 2001). These rules state that poor drug absorption and 
permeation is more likely to occur when the drug has:
>5 H-bond donors
>10 H-bond acceptors
>Mw of 500 Da
>5 CLogP or >4.15 MLogP.
Lipinski’s rules have been under debate for potentially being misleading, as many new 
drugs do not fit the set of rules. A new method of ‘drug-likeness’ has been formed by 
Hopkins and colleagues, which also takes into account the drug potency at the target 
(Bickerton, Paolini et al. 2012). 
2.3. Approaches to Crossing CNS Barriers
In addition to the obstacles discussed in section 2.2, CNS targeting drugs are faced 
with additional barriers. Two different types of approach can be adapted: the disruptive 
approach involves bypassing these barriers through invasive surgery or to break the 
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barriers temporarily or permanently. Here, ‘disruptive’ is defined as any mechanism 
compromising the integrity of the CNS barriers, whether temporary or permanent. The 
alternative is to design drugs or drug delivery vehicles to use the transport mechanisms 
in place at the barriers, e.g. transcytosis.
2.3.1. Invasive Surgery
Gaining access to the brain via surgery is a highly invasive and risky procedure. The 
main goal is frequently intracerebral (IC) or intracerebroventricular (ICV) injections of a 
drug, or to place an implant for extended drug release. The latter often involves 
implanting a biodegradable hydrogel matrix into the ventricles to slowly emit a drug. 
Controlled release over time is essential for these materials, but can be difficult to 
achieve. Nevertheless, IC or ICV injections have produced therapeutic results in some 
instances. One group implanted ‘microspheres’ which released nerve growth factor 
(NGF) into the rat striatum as a protectant against neuron cell death, and observed 
neuroprotectant effects in the striatum 2.5 months after the surgery (Menei, Pean et al. 
2000). Biodegradable polymers have also been used to deliver macromolecules over 
time to treat glioblastomas (Guerin, Olivi et al. 2004). In addition to the inherent risks of 
surgery and risk of inflammation, a major limiting factor of invasive CNS drug delivery is 
the limited spread of the drug. This is because once in the brain parenchyma, the 
distribution of the drug depends largely on diffusion. The time taken for a drug to diffuse 
can be expressed in equation [1], 
 [1]
where x is the diffusion distance of the molecule, D is the diffusion coefficient (cm2/s), 
and t is time (s). The diffusion coefficient is inversely related to molecular weight and 
size, and diffusion times for some example molecules present in the brain are given in 
table 2.1. The equation shows that the efficacy of diffusion decreases with the square 
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of the distance. Indeed, the radial spread of chemotherapeutics from intracerebral 
implants in rats decreased by 90% just 0.5 mm2 after the origin (Fung, Shin et al. 
1996). Additionally, the implantation procedure is not readily repeatable. 
Consequentially, drugs injected IC or ICV have to carry high initial concentrations of a 
drug in order account for this effect. These high concentrations far exceed physiological 
values, and can result in adverse affects such as astrogliosis and Schwann cell 
hyperplasia (Winkler, Ramirez et al. 1997) as has been observed in rodents (Yamada, 
Kinoshita et al. 1991, Winkler, Ramirez et al. 1997). Similar results have been observed 
in clinical trials: in 1999, ICV infusions of GDNF into a patient with Parkinson’s disease 
was discontinued due to extensive neurotoxicity (Kordower, Palfi et al. 1999).
Table 2.1. Diffusion times for some molecules in the brain. (Pardridge 2001)
Another strategy for bypassing the barrier obstacle involves disruption of the BBB. This 
can be achieved through the injection of hyperosmolar agents such as mannitol, which 
disrupts brain endothelial tight junctions by shrinking the endothelial cells (Rapoport 
1970). Several clinical trials have been completed using mannitol in conjunction with 
chemotherapeutics to treat aggressive gliomas (Boockvar, Tsiouris et al. 2011)(Hall, 
Doolittle et al. 2006). Nevertheless, mannitol injections require direct access to the 
carotid artery, which must be exposed through surgery under general anaesthesia. 
A recently established technique involves the focal use of ultrasound in gas 
microbubbles to disrupt the BBB. Magnetic resonance imaging (MRI)-guided focused 
Molecule Mw (Da) D (cm2/s) Time taken to 
diffuse 5 mm
Na2+ 23 20 x 10-6 3.5 hours
Myoglobin 17500 1.1 x 10-6 2.7 days
Albumin 68000 0.7 x 10-6 4.2 days
Glucose 180 6 x 10-6 11.7 hours
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ultrasound has also been used to deliver chemotherapeutic monoclonal antibody 
Herceptin to the mouse brain (Kinoshita, McDannold et al. 2006), with clinical trials 
currently being prepared for similar applications (Ellens, Kobelevskiy et al. 2015). 
Ultrasound can be focused on areas as small as a few millimetres, and the combination 
with MRI allows for real-time target planning, making this method advantageous for 
achieving localised drug delivery e.g. to a tumour lesion. Thus far this is the only CNS 
delivery method simultaneously achieving localised delivery and also incorporating an 
element of personalised medicine where treatment is tailored to the patient. Although 
the ultrasound method does not require surgery, it does disrupt the blood-brain barrier 
which results in exposing the CNS to other compounds in the bloodstream that would 
normally be excluded. Even ubiquitous plasma proteins such as albumin can have 
adverse effects in the CNS such as neuroinflammation as a direct result of activating 
microglia and initiating BBB breakdown (Hooper, Pinteaux-Jones et al. 2009). The 
long-term safety issues of this method are a high priority area to investigate.
In summary, invasive or disruptive CNS targeting often provide limited efficacy and high 
risk. Instead, targeting the BBB in CNS drug delivery in a non-invasive manner is 
desirable for several reasons: i) not requiring surgery, ii) not disrupting homeostasis, iii) 
gaining access to the entire capillary network supplying the brain, leading to 
widespread delivery of the therapeutic rather than relying on diffusion from the origin of 
an implant.
2.3.2. Stealthing Through the CNS Barriers
Exploiting the transport mechanisms present at the blood-brain barrier provides the 
putative therapeutic with access to virtually the entire CNS without disrupting 
homeostasis. Drugs can cross the BBB via endogenous transporters in carrier-
mediated transport or transcytosis. CMTs expressed at the BBB include GLUT1 
glucose transporter, and large amino transporter LAT1. Targeting CMTs for drug 
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delivery is a viable option for low molecular weight drugs. For example, the dopamine 
pro-drug L-dopa is imported across the BBB via LAT-1, and is enzymatically converted 
into dopamine in the parenchyma (Kageyama, Nakamura et al. 2000). By contrast, 
targeting the transcytosis receptors opens the possibility of delivering macromolecular 
therapeutics. Receptors mediating transcytosis at the BBB include the insulin receptor 
(IR), transferrin receptor (TfR) and Low Density Lipoprotein Receptor Protein 1 
(LRP-1). Of these, IR and TfR are highly specific to their ligands. There is no insulin 
mRNA expressed in the brain, therefore the IR on the BBB imports all of the brain 
insulin supply (Coker, Studelska et al. 1990). Similarly, the only endogenous ligand of 
TfR is the iron binding protein transferrin (Fishman, Rubin et al. 1987). Receptor for 
advanced glycation end products (RAGE) transports some glycated ligands across the 
blood-brain barrier, including amyloid-β peptides which thus implicates the receptor as 
a therapeutic target for Alzheimer’s disease (Deane, Du Yan et al. 2003). LRP-1 is by 
far the most diverse receptor expressed at the BBB, with over 30 different ligands 
reported such as lipoproteins, proteases, viruses and toxins (Herz and Strickland 
2001). 
2.4. Drawing Inspiration from Nature: Biological Agents Crossing the Barriers
Nutrients, immune cells and many pathogens are all capable of crossing CNS barriers. 
Understanding the process by which these biological agents enter the brain is a step 
towards engineering smart materials for CNS drug delivery. Viruses are of special 
interest because they are unlike bacteria reliant on host cells to replicate and survive, 
and have therefore evolved advanced ways to enter mammalian cells. Commonly, 
viruses interact with membrane receptors to gain entry to the cell interior, thus avoiding 
detection by the immune system. They can be internalised by clathrin-mediated 
endocytosis, caveolae, macropinocytosis, or other mechanisms (Mercer, Schelhaas et 
al. 2010).
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2.4.1. Immune cells
The barriers protect the CNS from pathogens. Inflammation is normally a useful 
immune system response to pathogens, and serves to limit cell and tissue damage as 
it typically culminates in the death of the pathogen-carrying cell followed by 
replacement by a new identical cell. However, unlike most cells of the body, neurons 
are not mitogenic, i.e. do not divide in the adult organism. The nervous system thus 
has a highly limited capacity for regeneration and repair. Inflammation is mostly 
considered to be detrimental to the CNS, and is indeed often present in CNS 
pathologies. For example, one of the hallmarks of multiple sclerosis is increased 
leukocyte trafficking to the CNS, and postmortem examinations often look for the 
presence of leukocytes in the perivascular space (Stolp and Dziegielewska 2009). 
Similarly, increased leukocyte presence in the CNS has been linked to other CNS 
pathologies such as stroke (Frijns, Kappelle et al. 1997), neurodegeneration (Cifelli, 
Arridge et al. 2002), and infection (Liu, Lossinsky et al. 2002).
Leukocytes can migrate across the BBB in a paracellular manner (paracellular 
diapedesis), but also through a phagocytosis-like transcellular mechanism 
(transcellular diapedesis). Both pathways start with leukocyte communication with the 
brain endothelial cells, and binding to I-CAMs expressed by the BECs (Adamson, 
Etienne et al. 1999). The paracellular mechanism involves the release of soluble 
factors by both leukocytes and endothelial cells to disrupt endothelial cell tight 
junctions, opening a gap between two or more endothelial cells. Transcellular leukocyte 
migration is more complex, involving extensive endothelial cell remodelling into large 
transient transcellular pores (Carman and Springer 2004). When leukocytes adhere to 
BECs, they extend their long cell protrusions (invadosomes) into BECs to probe for 
areas to migrate through (Carman 2009). In areas of low physical resistance (i.e. 
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remote from the basal lamina of the nucleus), the leukocyte extends the invadosomes 
deeper until the endothelial cell is breached. Upon breaching endothelial cells or their 
tight junctions, leukocytes use matrix metalloproteases MMP2 and MMP9 to cleave the 
basement membrane anchorage of astrocyte end-feet via a dystroglycan receptor 
(Agrawal, Anderson et al. 2006). Leukocyte infiltration is accompanied by an increase 
in BBB permeability due to partial breakdown of the BBB tight junctions (Bolton, 
Anthony et al. 1998).
Immune cell presence in the healthy brain is low, but there is constant interaction 
between brain endothelial cells and leukocytes to maintain a basal immune system 
surveillance in the CNS (Greenwood, Heasman et al. 2011). An estimated 2-5% of BBB 
tight junctions may show signs of opening at any time, which facilitates immune cell 
patrolling (Plumb, McQuaid et al. 2002). However, the reduced immune system 
presence in the CNS relative to the rest of the body reduces the propensity for a 
pathogen or foreign body to be eliminated. As a result, pathogens have evolved a 
range of strategies for entering the CNS.
2.4.2. Pathogens
Pathogens in the bloodstream can enter the CNS via the BBB. One strategy involves 
disrupting the tight junctions. For example, anthrax toxin (Bacillus anthracis) 
downregulates ZO-1 at the BBB (Ebrahimi, Kern et al. 2009). Pathogen disruption of 
the BBB can result in haemorrhagic encephalitis, as occurs in infection with anthrax or 
Nipah virus in humans (Maisner, Neufeld et al. 2009). Other pathogens enter through 
exploiting the barrier transporters: C. neoformans may enter the BBB via caveolae-
mediated transcytosis, as knockdown of Cav1 in a human in vitro BBB model reduced 
transcytosis of the pathogen (Long, Huang et al. 2012). Furthermore, HIV is able to 
traverse brain endothelial cells via macropinocytosis (Liu, Lossinsky et al. 2002). 
Neisseria meningitides, Streptococcus pneumoniae and Cryptococcus neoformans can 
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cause meningitis by propagating in CSF of the subarachnoid spaces. In vitro, C. 
neoformans pathogens can cross the BBB via transcytosis, providing a mechanism for 
entry through meningeal vessels.(Vu, Weksler et al. 2009)
Some pathogens use leukocytes as ‘Trojan horses’ to infect the CNS. Pathogens such 
as Herpes simplex, Listeria monocytogenes and Toxoplasma gondii replicate within 
white blood cells and “hitchhike” across the BBB in this way (Kristensson 2011). Other 
pathogens use white blood cells in more opportunistic but indirect ways. The parasite 
Trypanosoma brucei is able to cross the CNS without white blood cells in the more 
advanced stages of the disease, when cells have already disrupted the BBB through 
opening tight junctions and basement membranes (Kristensson, Nygard et al. 2010). 
Malaria carried by red blood cells causes cerebral malaria through an association with 
the cerebral vessel walls, but without entering the CNS. Cells infected with malaria 
release ‘microparticles’ which stimulate macrophages to secrete pro-inflammatory 
cytokines, causing disruption of the BBB and neurovascular units (Couper, Barnes et 
al. 2010).
There are other ways for pathogens to enter the central nervous system without going 
through the blood brain barrier. Microbes can exploit weaknesses in peripheral nerve 
fibres to enter, often travelling a long way before reaching the cell bodies located within 
the CNS. Neurons in the peripheral nervous system are shielded by the perineurium, a 
sheet of connective tissue surrounding a bundle of nerves. However, unshielded nerve 
endings are potential entry routes for pathogens, which can exploit endosomal 
retrograde axon transport to infect the cell (Kristensson and Olsson 1973). Rabies virus 
replicates in skeletal muscle, and enters neuromuscular junctions to advance into the 
spinal cord via retrograde transport (Klingen, Conzelmann et al. 2008)(Lafon 2004). 
Finally, the olfactory system is directly exposed to the external environment and 
provides entry routes for viruses such as rhabdoviruses and paroxymaviruses. 
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Pathogens are transported along axons through the cribriform plate and to the olfactory 
bulb, where they can spread further by retrograde axon transport or by anterograde 
axon transport in the monoaminergic neurons of the brainstem (Mohammed, Norrby et 
al. 1993). Evidence for bacterial entry through the olfactory system can be seen 
through the presence of bacteria in the brain but absence from the blood, as is 
observed in cases of Pneumococcal bacteria (van Ginkel, McGhee et al. 2003).
Some of the aforementioned pathways are being explored for drug delivery; intranasal 
delivery is a conventional method, and as an example several formulations of opioids 
have been approved on the market for intranasal delivery (Grassin-Delyle, Buenestado 
et al. 2012). However, as discussed in previous sections, to maximise the spread of the 
drug it should enter through the dense capillary network supplying the brain 
parenchyma. The blood-brain barrier may therefore be the most profitable barrier to 
target for drug delivery. The use of ‘Trojan horse’ nanoparticles targeting the blood 
brain barrier has been reported (Pardridge 2006). The advantages of using 
nanocarriers to exploit endogenous transportation mechanisms are explored in the 
following sections.
2.5. Nanocarrier Requirements
The manipulation of materials on the nanoscale has given rise to a multitude of ‘smart’ 
nanomaterials able to carry drugs, or ‘nanocarriers’. Nanocarriers engineered to enter 
the central nervous system via the blood-brain barrier must fulfil a number of criteria, 
which can be considered as part of the nanoparticle’s journey from injection to entering 
the brain parenchyma:
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i) Solubility in blood plasma
Nanocarriers must be able to disperse homogeneously in water in order to achieve 
optimal uptake at the target. Note that the commonly used method of dispersion of 
nanoparticles in a surfactant may compromise the integrity of the blood-brain barrier.
ii) Avoidance of protein fouling and immune system
The nanocarrier should be biologically compatible. Furthermore, the ability to avoid the 
immune system (‘immune stealth’) is essential in order to avoid detection as a foreign 
agent and subsequent elimination (unless the target is the immune system). 
Poly(ethylene) glycol (PEG) is a FDA-approved polymer used heavily in the medical 
field which is both biocompatible and confers immune stealth. PEG forms hydrogen 
bonds with water, making the particle it is attached to prefer water to protein and 
therefore avoid protein fouling. PEGylation (i.e. the addition of PEG chains) to a range 
of drugs, peptides and proteins has been reported to prolong the blood circulation half-
life through decreasing immunogenicity and degradation (Veronese and Pasut 2005).
iii) Getting out of the bloodstream, i.e. equipped with CNS targeting
An increasingly used strategy to gain access to the cell interior is to exploit the active 
process of endocytosis by designing ligands which bind to specific receptors. In doing 
so, the ‘drug-likeness’ rules for passive diffusion across plasma membranes no longer 
apply. To exploit endocytosis, a different set of rules apply: first and foremost, size of 
the therapeutic determines the extent and kinetics of internalisation. Mammalian cells 
actively and selectively endocytose a range of ligands in the size range of 10-300 nm 
(Ehrlich, Boll et al. 2004). Therefore, nanocarriers are highly suitable for combination 
with targeting ligands inducing endocytosis. However, there are a number of factors to 
consider when choosing the receptor to target, especially as cargo entry into the cell is 
highly regulated at the plasma membrane. Important considerations include receptor 
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expression, i.e. whether it is ubiquitous in the body or enriched at the target tissue; 
endogenous ligands to the receptor, and whether they compete with the ligand; efficacy 
of ligand-receptor interactions; and receptor half-life or rate of recycling to the plasma 
membrane after endocytosis.
To achieve delivery to the CNS via the blood-brain barrier, carriers need a targeting 
sequence which not only targets BBB receptors but also induces complete transcytosis 
of the drug. Targeting moieties can include antibodies or a short peptide targeting 
sequence. Once in the parenchyma, the nanocarrier must additionally target receptors 
for endocytosis.
iv) Delivery of cargo at the target site
The main purpose of a drug delivery vehicle is to carry cargo to a specific location and 
release it selectively at the target. Vehicles must thus be able to efficiently carry cargo, 
and also ideally have a controlled release mechanism. 
2.6. Types of Nanocarriers
A number of nanocarriers have been used as strategies to deliver therapeutics to the 
brain. Nanoparticles created for biomedical purposes come in many shapes, sizes and 
materials. They can be categorised into ‘soft’ or ‘hard’ systems on the basis of the 
intramolecular bonds they form: ‘hard’ nanoparticles consist of strong bonds such as 
metallic, covalent or ionic bonds. Weaker interactions make up ‘soft’ nanoparticles, and 
include hydrogen bonds, Coulombic forces, the hydrophobic effect, and combinations 
of them all. The use of hard or soft systems for drug delivery has been extensively 
reported, as reviewed by Akinc and Battaglia (Akinc and Battaglia 2013). The following 
sections summarise the properties of these carriers as well as their suitability for CNS 
drug delivery.
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2.6.1. Antibodies
Antibodies are proteins produced by the immune system as a response to foreign 
molecules in the body. Monoclonal antibodies (MAbs) respond to a single epitope or 
sequence of amino acids, whereas polyclonal antibodies recognise several similar 
sequences. Because of the specificity of MAbs and the techniques available to produce 
antibodies in batches, MAbs are of high therapeutic value in diseases where a single 
protein target can be defined. This is reflected in the pharmaceutical industry, where 
there is currently a range of approved therapeutic antibodies. For example, the 
humanised anti-epidermal growth factor receptor 2 (HER2) MAb Herceptin 
(trastuzumab) has been largely successful in treating breast cancer patients 
overexpressing the HER2 protein (Vogel, Cobleigh et al. 2002). However, clinically 
approved antibodies for targets within the CNS are lacking, as they cannot penetrate 
the BBB unless they are engineered specifically to target a BBB receptor. 
Approaches for using antibodies for CNS delivery have included the antibody itself as a 
treatment, or when fused to a delivery construct. A MAb against the human insulin 
receptor (HIR) was pioneered for the use of radiolabelled brain imaging probes. 
Furthermore, the 83-14 antibody complexed with a radiolabelled amyloid β 1-40 
complex entered the rhesus monkey brain in vivo via transcytosis (Pardridge, Kang et 
al. 1995, Wu, Yang et al. 1997). Another example is the engineered llama-derived 
single domain antibody (sdAbs) FC5, which crosses a human model of the BBB via 
clathrin-mediated transcytosis. Upon interaction with the α(2,3)-sialoglycoprotein 
receptor, FC5 entered early endosomes but bypassed later stages of the endosomal 
pathway, and was exocytosed in an intact state (Abulrob, Sprong et al. 2005). The use 
of sdAbs over conventional antibodies is advantageous, as their immunogenicity is 
reduced due to the absence of the light chain from the antibody (Muyldermans, 
Atarhouch et al. 1994). Nevertheless, antibodies developed in different species require 
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chimerisation or humanisation before they can be used in a clinical setting. 
Furthermore, the short plasma half-life and high production costs are limitations to 
consider for therapeutic antibodies (Chames, Van Regenmortel et al. 2009).
2.6.1.1. Affinity
Targeting transcytosis at the BBB relies on ligand-receptor interactions. The 
engineered ligand needs to bind and activate its target receptor, induce complete 
transcytosis, and then release the cargo. Ligand-receptor interactions are quantified in 
affinity: the strength of interaction between the antibody’s antigen binding site and the 
epitope. In practical terms, affinity refers to the number of ligand-receptor complexes in 
equilibrium. The cumulative intermolecular interactions between the complex is 
quantified in avidity, measuring the overall stability of the complex. Avidity is influenced 
by several components: intrinsic affinity; valency, i.e. the number of arms in an antibody 
to bind the antigen; and the spatial orientation of the interacting components. 
Paradoxically, higher affinity does not guarantee more effective delivery. At the BBB, 
the efficiency of the monoclonal TfR-targeting antibody OX26 was questioned after 
reported findings in the rat that OX26 predominantly accumulates inside brain 
capillaries instead of entering the brain parenchyma (Moos and Morgan 2001). Similar 
studies tracking OX26 and OX26-conjugated liposomes showed that neither was 
present in the choroid plexus epithelium, neurons or glia despite using in situ perfusion, 
a method to increase uptake to the brain by bypassing the systemic circulation (Gosk, 
Vermehren et al. 2004). It was concluded that OX26 with or without liposomes had 
previously yielded false positives and does not cross the BBB. In 2011, further 
clarification was provided by Yu et al. who showed that if the antibody affinity is too 
high, the cargo is never released and consequently shuttles back and forth at the BBB 
remaining complexed with the antibody. They were able to boost uptake into the 
parenchyma through reducing the affinity of the antibody to its transcytosis target (Yu, 
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Zhang et al. 2011). There is thus an inverse correlation between affinity and brain 
uptake, which must be taken into consideration when using antibodies for targeting the 
BBB.
2.6.2. Hard Nanoparticles
The ‘hard’ nanomaterials include metals such as gold and silver nanoparticles, 
quantum dots, and carbon nanotubes. A number of in vivo applications have been 
reported for hard nanoparticles: quantum dots are 2-10 nm fluorescent semiconductor 
crystals particularly useful for in vivo imaging and diagnostics (Gao, Cui et al. 2004, 
Michalet, Pinaud et al. 2005); silver nanoparticles (AgNPs) have been engineered with 
potential applications for antibiotics-resistant bacteria (Siddhartha, Tanmay et al. 2007); 
gold nanoparticles (AuNPs) can be used as a non-invasive imaging agent in gliomas 
(Cheng, Dai et al. 2014); and glucose-coated gold nanoparticles are able to cross the 
BBB in vitro and enter astrocytes (Gromnicova, Davies et al. 2013). Although there are 
merits to these nanoparticles, they tend to contain heavy metals such as cadmium and 
mercury and therefore pose a considerable toxicity concern to biological systems 
(Longmire, Choyke et al. 2008). Quantum dots accumulate in the liver, where their 
cadmium core causes acute liver toxicity due to oxidative stress (Derfus, Chan et al. 
2004). Inhaled silver nanoparticles are internalised by alveolar macrophages, which 
within 24 hours produce inflammatory responses (Carlson, Hussain et al. 2008). 
Furthermore, gold nanoparticles were recently reported to enter the CNS through 
opening BBB endothelial cell tight junctions (Li, Jhan et al. 2015).
‘Hard’ nanoparticles have solid cores and can therefore only carry drugs through 
surface conjugation. Attaching drugs to the surface of the nanoparticle exposes the 
drug to premature degradation by the extracellular environment, e.g. by proteases. The 
engineering of nanoparticles with hollow cores provides the possibility to carry the drug 
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within the vehicle, protected from the extracellular environment. Designing 
nanoparticles with hollow cores is possible in the case of ‘soft’ nanoparticles. 
2.6.3. Amphiphiles
‘Soft’ materials are more biologically compatible than hard nanoparticles, partially 
because the intermolecular interactions holding soft nanoparticles together are on a 
similar level to those in living systems. Amphiphiles are a major category of ‘soft’ drug 
delivery vehicles, and are a class of molecules with a hydrophobic and a hydrophilic 
component linked together. Common amphiphilic materials include lipids and polymers. 
In water, only the hydrophilic part of the amphiphile dissolves, and the hydrophobic 
parts prefer to pack together as it is more energetically favourable. This hydrophobic 
effect causes the rearrangement of amphiphiles into ordered structures, with a 
hydrophilic corona and a hydrophobic core.
The resulting structure of the assembled amphiphile depends on the dimensionless 
packing parameter p, the calculation of which is given in equation 2:
                                                           [2]
Where v is hydrophobic block volume, lc is hydrophobic chain length and a0 is the 
optimal surface area of the assembled polymer. A low packing parameter p <1/3 
causes high membrane curvatures and favours the formation of micelles, p between 
1/3 and 1/2 creates micellar filostructures or ‘tubes’, and p >1/2 causes low membrane 
curvatures and the formation of bilayer membrane vesicles with an aqueous core 
(Smart, Lomas et al. 2008). The different structures formed by different packing 
parameters in the case of a polymer are shown in figure 2.1.
p = va0lc
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Micelles of either lipid or polymer compositions have been used for drug delivery 
applications. However, vesicles offer a number of advantages to micelles: the 
encapsulation of hydrophobic compounds in addition to hydrophilic; higher drug release 
kinetics (Chen, Meng et al. 2010); and protection of cargo from degradation by the 
extracellular environment (Simone, Dziubla et al. 2008). Furthermore, the vesicular 
nature of liposomes and polymersomes confers better cargo carrying capacities than 
antibodies. The ability to encapsulate drugs into amphiphilic nanocarriers such as 
liposomes or polymersomes, which can be chemically modified to display targeting 
moieties on the surface, is a major advantage. Antibodies targeting the BBB can carry 
1-4 individual drug molecules per antibody, compared to >10,000 drug molecules per 
individual ~100nm liposome or polymersome. (Huwyler, Wu et al. 1996, Pegoraro, 
Cecchin et al. 2013)
Figure 2.1. Amphiphilic block copolymer self-assembly into different structures.(Smart, 
Lomas et al. 2008)
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2.6.3.1. Liposomes
The pioneering amphiphiles used for drug delivery are liposomes, i.e. lipids self-
assembled into a vesicular membrane. The hollow nature of these vesicles confers the 
ability to encapsulate hydrophobic or hydrophilic drugs, and liposomes are furthermore 
biocompatible due to their phospholipid composition. Because different lipids can be 
used to create liposomes, there is some versatility in physicochemical properties such 
as size and surface charge. These nanocarriers have been used since the 1960s for 
targeted delivery of antiretrovirals (Hostetler, Stuhmiller et al. 1990), genes (Gao and 
Huang 1995), chemotherapeutics (Yang, Cui et al. 2007), and many other agents. 
However, liposomes are rapidly recognised in the body and cleared by the MPS. This 
problem can be addressed through PEGylation, which prolongs plasma circulation in 
by decreasing opsonisation and therefore ‘stealthing’ from macrophages. However, 
there are some issues with PEGylation. For instance, PEGylated liposomes with 
conjugated mAbs can lose their tumour targeting selectivity due to steric hindrance 
between the mAb and the targeted receptor (Klibanov, Maruyama et al. 1991). 
Additionally, only a small total surface area of liposomes can be PEGylated as addition 
of PEG chains destabilises the vesicle. This is due to a change in the packing factor 
with the addition of long hydrophilic PEG chains, and the hydrophilic/hydrophobic ratio 
essential for vesicle formation is destabilised if PEG is added above a certain amount. 
Indeed, liposome stability is a common issue and they are prone to leakage upon 
encountering serum (Allen and Cleland 1980).
PEGylated liposomes have been used in conjunction with antibodies for targeting 
transcytosis at the BBB. Immune-evading liposomes are sometimes referred to as 
‘Trojan horses’ due to their ability to stealth through the blood-brain barrier. The OX26 
monoclonal anti-TfR antibody fused to PEGylated immunoliposomes has extensively 
been reported to cross the BBB in rats (Huwyler, Wu et al. 1996). Attempts to translate 
 72
Chapter 2
OX26 delivery into mice were complicated by the transferrin sequence differing 
between mice and rats, but was achieved eventually after re-engineering the sequence 
(Lee, Engelhardt et al. 2000). Further reports have also highlighted that OX26 may give 
a false positive of CNS entry but in fact accumulates inside the endothelial cells, 
indicating restricted transport to the brain (Moos and Morgan 2001, Paris-Robidas, 
Emond et al. 2011).
Liposomes have been used as a non-invasive alternative for CNS delivery. Despite 
equipping liposomes BBB endogenous transporter targeting moieties, many liposome 
preparations require stabilisation in surfactants. The BBB is like other lipid membranes 
disrupted by surfactants and organic solvents such as ethanol and dimethyl sulphoxide.
(Hanig, Morrison et al. 1972, Saija, Princi et al. 1997). It is not clear whether liposomes 
can cross the BBB without the co-injection of surfactants (Pardridge 2001). 
Furthermore, the above putative therapies have thus far achieved limited efficacy in 
delivery. The brain uptake, as quantified in injected dose/g (%ID), is 0.2-0.3% for OX26 
liposomes (Friden, Olson et al. 1996). In comparison, a human insulin receptor HIR 
monoclonal antibody achieved corresponding injected dose values of 3-4% (Pardridge, 
Kang et al. 1995).
2.7. Polymersomes
More recently, amphiphilic block copolymers have been used to obtain polymer 
vesicles, or polymersomes (Discher and Eisenberg 2002). The structure of a 
polymersome is depicted in figure 2.2. A diverse range of applications have been 
reported for polymersomes, such as carriers for imaging agents, nano-reactors, and 
theranostics in addition to their uses for drug delivery.
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2.7.1. Physical Chemistry
Polymersomes offer a number of improved physicochemical advantages to liposomes. 
Firstly, the polymersome membrane is 20x less permeable than their liposome 
counterparts, which provides improved stability and more efficient protection of cargo 
from degradation (Battaglia, Ryan et al. 2006). Secondly, the use of polymers approved 
by governmental regulatory bodies such as FDA also creates potential for quick 
translation into the clinic. Thirdly, polymersome physicochemical properties such as 
size and surface topology can be precisely controlled via altering block copolymer 
architecture and chain length. The virtually inexhaustible resources of polymers created 
through polymerisation methods allows for the creation of sophisticated controlled-
release vehicles with more options than lipid counterparts can offer, as summarised in 
figure 2.3.
Figure 2.2. Schematic of a polymersome.(Smart, Lomas et al. 2008)
Polymersome membrane topology can be precisely engineered. Polymersomes formed 
from a diblock copolymer in which the two blocks differ significantly in molecular weight 
undergo phase separation in the polymersome membrane over time. Effectively, phase 
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separation creates segregated nano-domains in the polymersome (LoPresti, 
Massignani et al. 2011). The membrane of viruses is often arranged into such nano-
scale domains, which are essential to their endocytosis by mammalian cells (Canton 
and Battaglia 2012). Indeed, phase-separated polymersomes with “patches” on their 
membrane have faster internalisation kinetics than pristine polymersomes, making 
polymersomes akin to ‘synthetic viruses’ (Massignani, Lopresti et al. 2009). The ability 
to fine tune physical properties combined with amphiphilic cargo loading and controlled 
release capabilities makes polymersomes optimal vehicles for drug delivery.
Figure 2.3. Comparison between liposomes and polymersomes. (Messager, Gaitzsch et al. 
2014).
2.7.2. Stealth
Liposomes require PEGylation to obtain stealth properties, but the hydrophilic 
character of PEG destabilises the lipid head group in liposomes which can result in 
drug leakage (Tirosh, Barenholz et al. 1998). Conversely, polymersomes can be 
formed in a stable manner from PEG-based block copolymers, with improved stability 
as PEG molecular weight increases (Lee, Bermudez et al. 2001). Polymersomes can 
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be 100% PEGylated in the brush as long as hydrophobic chain length is increased to 
compensate for it.
2.7.3. Stimulus Responsiveness
The design of polymersomes responsive to various triggers such as UV, pH or calcium 
has been reported (Li and Keller 2009). Work by the Battaglia group has established 
the use o f po ly [2 - (methacry loy loxy )e thy l phosphory lcho l ine ] -b lock -
poly((diisopropylamino)ethyl methacrylate) (PMPC-PDPA) polymersomes for drug 
delivery (Lomas, Canton et al. 2007). The PMPC block is non-protein fouling, and 
polymersomes are internalised by a wide range of cells with no signs of toxicity 
(Lomas, Massignani et al. 2008). The PMPC block can be substituted for other 
polymers with similar properties. For example, the Poly(ethylene) Glycol (PEG) 
derivative Poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) is both 
stable and non- protein fouling in vitro (Tugulu and Klok 2008). The PDPA block confers 
pH sensitivity to the polymersomes: above its pKa of approximately 6.4 the block is 
hydrophobic. Below this pKa, de-protonation of the tertiary amine groups causes the 
normally hydrophobic PDPA block to become hydrophilic and thus causes rapid 
disassembly of polymersomes due to a change in intermolecular forces, as depicted in 
figure 2.4. When polymersomes are internalised by cells, they are sorted into the endo-
lysosomal trafficking pathway. The acidic pH of endosomes (5.5-6.1) causes a drop in 
pKa, prompting a quick disassembly of pH sensitive polymersomes. The major 
increase in the concentration of unimers in the endosomal compartment causes an 
osmotic shock, temporarily lysing the endosomal membrane and allowing the unimers 
and the cargo to escape into the cell cytosol (Lomas, Massignani et al. 2008). pH 
sensitive polymersomes have been used for delivery of a range of therapeutics, 
including anti-cancer drugs, imaging agents and antivirals (LoPresti, Lomas et al. 
2009).
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2.7.4. Conjugation of Peptides Targeting the Blood-Brain Barrier
A major advantage of polymersomes is the ability to chemically incorporate targeting 
moieties such as peptides or antibodies. Indeed, the 83-14 antibody against HIR has 
recently been combined with a polymersome delivery vector to obtain an efficient drug 
delivery system targeting the BBB (Dieu, Wu et al. 2014). Furthermore, peptide 
sequences can be derived synthetically to target transcytosis at the BBB and are less 
immunogenic than antibodies. A peptide which has been used for CNS entry is Rabies 
Virus Glycoprotein (RVG), which was used as a targeting mechanism to deliver siRNA 
to the mouse CNS through transvascular delivery (Kumar, Wu et al. 2007). RVG is a 29 
amino acid peptide which binds specifically to nicotinic acetylcholine receptors 
expressed by neurons. However, attempts to combine the RVG peptide with pH-
sensitive polymersomes failed to induce transcytosis in vitro (Tian, Nyberg et al. 2015). 
In vivo CNS entry of a RVG-mannitol-PEI polymer siRNA drug delivery system was 
reported, although no endeavours to confirm receptor colocalisation were undertaken 
(Park, Singh et al. 2015).
Figure 2.4. pH sensitivity mechanism of POEGMA-PDPA polymersomes. Adapted from ref 
(Lomas, Massignani et al. 2008).
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Conjugation of the GM1-targeting peptide G23 to polymersomes resulted in a small 
amount of accumulation in the mouse brain in vivo via transcytosis. The transcytosis 
efficiency was comparable to that of polymersomes with a transferrin receptor targeting 
moiety (Stojanov, Georgieva et al. 2012). GM1 is a ganglioside strongly concentrated in 
caveolae (Parton 1994). However, GM1 is not recycled to the membrane with 
caveolae, which indicates that GM1 only enters caveolae in endocytosis but not 
complete transcytosis (Balasubramanian, Scott et al. 2007). Further work is required to 
elucidate the mechanism by which GM1 induces transcytosis at the BBB.
A Kunitz protease inhibitor domain was identified as the essential domain required by 
amyloid precursor protein to enter the brain via LRP-1-mediated transcytosis (Kounnas, 
Moir et al. 1995). Based on this discovery, Demeule et al. developed a series of 
peptides derived from the Kunitz domain and screened the peptide transcytosis ability 
in a blood-brain barrier model. Subsequently the synthetic 19 amino acid peptide 
Angiopep-2 was identified to have a high transcytosis capacity in vitro, and furthermore 
confirmed to enter the parenchyma in vivo via a vascular route (Demeule, Regina et al. 
2008). It does so through transcytosis mediated by the LRP-1 receptor at the BBB 
(Demeule, Currie et al. 2008). Data suggests that the transcytosis of Angiopep-2 is only 
partially inhibited by other LRP-1 ligands (Demeule, Regina et al. 2008), and uptake is 
not affected by Pgp inhibition.(Demeule, Currie et al. 2008)  Furthermore, human serum 
albumin (HSA) nanoparticles coated with ApoE cross the blood brain barrier in vitro and 
in vivo via transcytosis (Zensi, Begley et al. 2009) which may also be mediated by 
LRP-1 as ApoE is a LRP-1 ligand. LRP-1 is thus a promising receptor to target for drug 
delivery across the BBB. 
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Aims and Objectives
There are several aims and objectives for this thesis project, entitled ‘LRP-1-Mediated 
Blood Brain Barrier Transcytosis: Mechanisms and Therapeutic Applications’.
Previously, several peptides were conjugated to the diblock copolymer 
poly[oligo(ethylene glycol) methyl methacrylate]-block- poly((diisopropylamino)ethyl 
methacrylate) (POEGMA-PDPA). Polymersomes with peptide targeting systems (RVG 
and Angiopep-2) were subsequently screened in vitro for their transcytosis capabilities, 
and Angiopep-2-POEGMA-PDPA (A-EP) were shown to have a high capacity for 
transcytosis whereas RVG-POEGMA-PDPA or non-targeting POEGMA-PDPA (EP) 
polymersomes did not undergo transcytosis at all. Furthermore, A-EP polymersomes 
were successfully delivered into the mouse CNS after intravenous injections (Tian, 
Nyberg et al. 2015). Subsequently, A-EP polymersomes were chosen for further 
investigation as CNS drug delivery vehicles. However, characterisation of A-EP 
transcytosis in vitro and in vivo is required.
i) Aim:
To elucidate the kinetics of A-EP transcytosis across the blood-brain barrier, using an in 
vitro brain endothelial cell transwell model.
Hypothesis:
A transwell model of the BBB can be used to probe A-EP transcytosis kinetics. LRP-1 
induces transcytosis of A-EP polymersomes in a saturable manner, and the optimum 
density of number of Angiopep-2 molecules on the polymersome membrane can be 
found through using transcytosis assays with varying number of ligands conjugated.
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ii) Aim:
To elucidate the mechanisms of A-EP transport across the blood-brain barrier.
Hypothesis:
Because LRP-1 mediates transcytosis of the peptide Angiopep-2 in vivo, it is 
hypothesised that LRP-1 induces transcytosis of A-EP polymersomes across the brain 
endothelium. This is followed by transportation through membrane-bound organelles 
which may or may not form a tubular network, and is caused by clathrin-mediated 
endocytosis and not caveolae as frequently implicated in peripheral endothelia. 
Importantly, it is hypothesised that transcytosis by brain endothelial cells does not 
occur through acidifying endosomal trafficking pathway, but may go through a tubular 
network instead. It is further hypothesised that the protein machinery involved in 
exocytosis is likely to be somewhat conserved between regulated exocytosis 
machinery in neurons, with non-neuronal isoforms of the SNARE proteins having an 
essential role.
iii) Aim:
To confirm CNS uptake of polymersomes in a living system, and to quantify uptake of 
fluorescently labelled polymersomes in vivo.
Hypothesis:
In situ perfusion can be used as a delivery method of polymersomes to the rat brain. 
Because this method increases uptake into the brain, polymersome fluorescence may 
be sufficient for quantification through methods such as fluorescence spectroscopy or 
high-performance liquid chromatography.
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iv) Aim:
Deliver macromolecular therapeutics to the CNS using A-EP polymersomes as a drug 
delivery vehicle.
Hypothesis:
Because LRP-1 is expressed in neurons and glia in addition to brain endothelial cells, it 
is hypothesised that A-EP polymersomes can be used to deliver macromolecular cargo 
intracellularly within the CNS. The use of pH sensitive polymersomes provides the 
adequate controlled release mechanism upon internalisation through acidifying 
endosomal compartments in non-transcytosing cells. LRP-1 transcytosis is non-
acidifying, keeping cargo-carrying polymersomes intact. By contrast LRP-1 endocytosis 
by glia or neurons operates through a canonical endocytosis pathway, resulting in 
cargo release  into the cytosol upon encountering the acidic endosomal environment. 
The chief hypothesis of the project can be summarised as follows: A-EP polymersomes 
can be used as a CNS macromolecular drug delivery vehicle through targeting LRP-1 
transcytosis at the BBB.
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Chapter 3.
Materials and Methods
_____________________________________________________________________
3.1. Block Copolymer Synthesis
All polymers were synthesised by Steven Armes’ group (Department of Chemistry, The 
University of Sheffield, U.K.). Poly (ethylene glycol) methyl ether methacrylate 
(P(OEG10MA)25) block poly- (diisopropylamino)ethyl methacrylate (PDPA)114 or 
abbreviated as EP was synthesised by atom transfer radical polymerisation (ATRP)
(Madsen, Warren et al. 2011). The structure of EP (Mw = 33000) is depicted in figure 
3.1. The POEGMA block is hydrophilic, and PDPA is hydrophobic at a pH above its pKa 
of ~6.4.
Figure 3.1. Chemical structure of POEGMA-PDPA. Blue denotes hydrophobic blocks and red 
hydrophilic, functional group R (here R = maleimide).
It is possible to add a functional group (R) onto the POEGMA chain via chemical cross-
linking. A maleimide linker was used as the strategy for addition of functional R groups 
onto the backbone of POEGMA. Angiopep-2 was ordered from Pepceuticals 
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(Nottingham, England), with an additional cysteine added to the N terminus of the 
amino acid sequence, as specified below:
CTFFYGGSRGKRNNFKTEEY
Angiopep-2 was conjugated onto POEGMA-PDPA (A-EP) via a maleimide, and 
conjugation measured by HPLC. Approximately 40% of the polymer was successfully 
functionalised (Tian, Nyberg et al. 2015). The resulting structure is displayed in figure 
3.2.
Figure 3.2. Chemical structure of Angiopep-2-POEGMA-PDPA (A-EP). Mw: 33000.
3.1.1. Functionalisation of POEGMA-PDPA with Cy3
Cy3-maleimide from Lumiprobe (Germany) (mw = 615.20 g/mol, λex 555nm, λem 
570nm) and PDPA100-POEGMA20-SS-POEGMA20-PDPA100 (mw = 45000 g/mol) were 
weighed out in a 2:1 molar ratio and dissolved in 2:1 ChCl3 and MeOH mixture. The 
solution was N2 purged for 20 minutes in room temperature (21°C). 1.2 equivalents of 
PPh3 was added, and N2 purged for 1 minute. After 48 hours, the solution was run 
through a 1000 Da MWCO dialysis membrane against EtOH, left in RT for 6h before 
changing to fresh EtOH and leaving it overnight. EtOH was changed to milli-QH2O 
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(Millipore, U.S.), left for 8 hours, followed by flash freezing in liquid N2 and freeze dried 
in -50°C.
3.2. Polymersome Preparation
All polymersomes for in vitro experiments were labelled with 10% (mol) Cy3-POEGMA-
PDPA polymer. All polymersomes for in vivo experiments were labelled with 20% (mol) 
Cy3-POEGMA-PDPA. Where polymersomes were functionalised with Angiopep-2-
POEGMA-PDPA, the final Angiopep-2 functionalisation was 1.2% (mol) unless 
otherwise specified. 
Polymersomes were prepared via a bottom-up pH switch approach. Polymers were 
dissolved at a total concentration of 10 mg/ml in pH 2 PBS, sterilised with a 0.2 μm 
filter and gradually brought up to pH 7.4 using 0.5M NaOH under magnetic stirring. In 
cases where Angiopep-2-POEGMA-PDPA was part of the polymer mixture, it was 
added at pH 6.0 in order to avoid peptide denaturation, and left to stir for approximately 
10 minutes to disperse into the polymer mixture. The solution was subsequently filter 
sterilised. Once pH 7.4 was reached, polymersome size was assessed with dynamic 
light scattering (DLS) and if necessary, polymersomes were sonicated on ice for 20 
minutes to decrease the presence of aggregates formed in the pH switch process. 
Polymersomes were stored in 4°C until use.
3.2.1. Purification via Gel Permeation Chromatography
Polymersomes produced via pH switch were purified using gel permeation 
chromatography (GPC). GPC is a form of size exclusion chromatography (SEC), in 
which particles are eluted through a column in a size-dependent manner. Here, a 
column filled with sepharose 4B (Sigma-Aldrich, U.K.) was used as the substrate. 
Polymersome samples containing larger polymersomes (e.g. tubes) or micelles are 
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suitable for purification via GPC, but this method is often limited to a few millilitres per 
column to allow adequate column length for sample separation.
3.2.2. Purification via Centrifugation
Centrifugation causes particles of different sizes in a sample to sediment at different 
rates, with large particles sedimenting first. It is a technique commonly used to purify 
different subcellular organelles, and has recently been shown to work in the separation 
of PMPC-PDPA polymersome tubes from spheres (Robertson, Yealland et al. 2014).
100 mL of Angiopep-2-POEGMA-PDPA polymersomes were produced as a single 
batch via the pH switch method, and measured into centrifugation tubes at 25 mL each. 
Samples were centrifuged at 1000 RCF (rotational centrifugal force) for 20 minutes, 
resulting in a pellet and a supernatant. The pellet was resuspended in PBS, and 
samples were characterised with DLS and TEM before and after centrifugation.
3.3. Physicochemical Characterisation of Polymersomes
3.3.1. Dynamic Light Scattering
Dynamic Light Scattering (DLS) is a frequently used method to determine the size of 
particles in solution. Essentially, the method derives size from measuring the Brownian 
motion of particles. The speed of particle diffusion is measured by measuring the rate 
at which the intensity of scattered light fluctuates. Two assumptions are made in order 
to calculate size from light scattered in the solution: i) that the particle is spherical, and 
ii) that particles in solution undergo Brownian motion. Scattered light is fitted to a 
correlation function, which is useful in assessing the quality of the sample (e.g. whether 
concentration is in range and detecting whether there are aggregates present in the 
sample, which indicates polymersomes have precipitated). The correlation function 
compares the similarity between two signals, or one signal with itself at different time 
intervals (t+δt). If signals at t+2δt, t+3δt etc are compared with t then correlation will 
slowly decrease from 1 to 0. If particles are large, the signal will change slowly and 
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correlation will persist for a long time. The correlation reduces quickly if particles are 
small and moving rapidly. The time at which correlation starts to significantly decay is 
an indication of the mean size of the sample, and is illustrated in figure 3.3.
DLS was used to assess the size of polymersomes in PBS, using a Malvern Zetasizer 
Nano ZS laser light scatterer equipped with a He-Ne 4mW 633 nm laser. 
Polymersomes were diluted in filtered PBS in 1 ml disposable cuvettes, and 
experiments were an average of n=3 runs at a set angle of 173°.
3.3.2. Transmission Electron Microscopy
Polymersomes in filtered PBS were also assessed for morphology using transmission 
electron microscopy (TEM). Samples were mounted on glow-discharged copper grids 
by submerging the grids into the polymersome solution for 60 seconds, followed by 
blotting and staining for 5 seconds with 0.75% (w/w) phosphotungstic acid (PTA). Grids 
were then washed with PBS, dried under vacuum and assessed via a JEOL 
microscope using 100 kV voltage tension.
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Figure 3.3. Correlation function of dynamic light scattering.
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3.4 GPC-HPLC for Quantification of Polymer-Protein Interactions
To evaluate the potential interactions between POEGMA-PDPA or Angiopep-2-
POEGMA-PDPA and model protein IgG, GPC was used in conjunction with HPLC for 
detection. Samples were run through a 1.5 x 30 cm column with Sepharose 4B (Sigma-
Aldrich) connected to HPLC (Dionex Ultimate 3000). 150 μl of samples of either 
polymer, protein, or both were injected into the GPC and eluted with PBS at a flow rate 
of 260 μl/min, with a total elution time of 180 minutes. HPLC detection was set to UV/
Vis absorbance at 220 nm for POEGMA-PDPA and IgG. Areas under the detected 
peaks were measured using Chromeleon software.
3.5. Electroporation for Cargo Encapsulation Within Polymersomes
To encapsulate cargo into polymersomes, cargo was electroporated into purified 
polymersomes as previously reported (Wang, Chierico et al. 2012). In general, stock 
solutions of 3 mg/ml polymersomes were loaded together with protein stock solutions 
dissolved in PBS into 800 μl electroporation cuvettes (BioRad). For the encapsulation 
of carnosine (Sigma-Aldrich), a stock of protein stock was dissolved in PBS at 10 mg/
ml and filter sterilised before use. For IgG-FITC or IgG-Gold, 0.1 μg/ml was loaded with 
polymersomes into the cuvettes. Electroporation was performed with an Eppendorf 
2510 electroporator, with a total of 10 pulses applied at a voltage of 2500 kV. 
Electroporated polymersomes were left in room temperature for 30-60 minutes before 
purification, to allow the pores to re-seal. Finally, samples were purified by GPC with 
sepharose 4B as a substrate to remove residual free protein. Purified samples were 
assessed for size via DLS, and the protein encapsulation was determined via HPLC. 
3.5.1. Quantification of Polymer and Cargo Content with HPLC
High Performance Liquid Chromatography (HPLC) was performed using a Dionex 
Ultimate 3000 instrument. To detect total polymer and protein content, polymersomes 
were disrupted in 0.05% trifluoroacetic acid (TFA) (Sigma-Aldrich). This step was 
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performed to obtain a pH below 6.4, causing polymersomes to disassemble and thus 
allowing for quantification of polymer and cargo content. A multi-step gradient of HPLC 
grade methanol (Sigma-Aldrich) as eluent A and milliQ water (Millipore) in 0.05% 
trifluoroacetic acid as eluent B was used to elute samples over 30 minutes with a C18 
column (Phenomenex® Jupiter C18 300Å, 150 x 4.60 mm, 5 μm) as reported 
previously (Wang, Chierico et al. 2012). The gradient profile used was as follows: (1) 
20 to 40% B in 6 min; (2) 40 to 45% B in 10 min; (3) 45 to 50% B in 3 min; (4) 50% B 
for 1 min; (5) 50 to 70% B in 3 min; (6) 70 to 100% B in 1 min; (7) 100% B for 1 min; (8) 
100 to 20% B in 2 min; (9) 20% B for 3 min. 
Cy3-labelled polymersomes were detected with an excitation wavelength of 540 nm 
and emission at 565 nm. Using the conditions specified, Cy3-labelled POEGMA-PDPA 
polymer can be detected within the UV/Vis channel (220 nm) or in the fluorescence 
emission channel of 565 nm. To quantify protein content of electroporated 
polymersomes, a standard curve for the protein was created under the same conditions 
for polymer elution, but with detection at an additional channel excitation at 274 nm and 
emission at 303 nm due to the presence of tyrosine residues in the peptide sequence. 
Areas under the detected peaks were measured using Chromeleon software.
3.6. Transwell Cell Culture
3.6.1. Maintenance culture
For maintenance and expanding cells, bEnd.3 cells (ATCC® CRL-2299) were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 2 mM L-glutamine, 
10% foetal bovine serum (FBS), 100 U/ml streptomycin, 100 U/ml penicillin, and 1 μg/
ml Fungizone. Mouse C8-D1A astrocytes (ATCC® CRL-2541) were cultured in DMEM 
supplemented with L-glutamine and 10% FBS. Mesenchymal stem cells (MSCs, 
Gibco® Mouse C57BL/6) previously shown to have pericyte properties (Tian 2014), 
henceforth referred to as pericytes, were cultured in DMEM F12 media supplemented 
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with 10% FBS, gluta-max-I and 5 μg/ml gentamicin. In the case of BEnd.3, flasks or 
well-plates were pre-coated with 0.4 mg/ml collagen type I from rat tail (Sigma-Aldrich), 
incubated in room temperature for 2 hours and washed with PBS before seeding cells. 
Cultures were kept in 37°C and 5% CO2. Sub-culture was performed by incubating with 
0.25% trypsin-EDTA for 5 minutes at 37°C, followed by centrifugation and re-
suspension in new media.
3.6.2. bEnd.3 monoculture
For the purposes of mimicking the blood-brain barrier in vitro, immortalised CNS cells 
were seeded in a transwell setup. 12-well transwell filter inserts (Corning) have a cell 
growth area of 1.12 cm2 and contain a transparent polystyrene membrane with 0.4 μm 
diameter pores (membrane thickness 10 μm, 4 x 106 pores per cm2). The inserts were 
coated with rat tail collagen type I 0.4 mg/ml on both sides, and left in room 
temperature to polymerise for 2 hours before rinsing with PBS and media. bEnd.3 cells 
were seeded on the upper side of the transwell membrane at a density of 20 000 – 40 
000 cells per well, in a total of 0.5 ml of media in the top compartment and 1.5 ml in the 
bottom compartment. Transwell cultures were kept in 37°C and 5% CO2 for 
approximately 7 days until fully confluent, after which TEER was measured and 
experiments were performed. Media was changed every 2-3 days.
3.6.3. bEnd.3 co-culture
For co-culture, bEnd.3 cells were seeded on the top of 12-well transwell filter 
membranes as specified in section 3.6.2. bEnd.3 monocultures were incubated in 37°C 
and 5% CO2 to grow for 3-4 days. After this time, astrocytes or pericytes seeded on the 
bottom of the well (non-contact co-culture) at a density of 10 000 cells. After seeding 
with a second cell type, transwell cultures were kept in 37°C and 5% CO2 for 
approximately 3-4 days until the bEnd.3 monolayer reached full confluency, after which 
TEER values were measured and experiments were performed. Media used for co-
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culture was DMEM F12 media supplemented with 10% FBS, gluta-max-I and 5 μg/ml 
gentamicin. Media was changed every 2-3 days, and was added at a volume of 0.5 ml 
in the upper compartment and 1.5 ml in the lower compartment.
3.6.4. Transendothelial Electrical Resistance (TEER) Measurements
In order to measure barrier-like properties of the cells, trans-endothelial electrical 
resistance (TEER) was assessed using an EVOM2 Epithelial Voltohmmeter with STX3 
electrodes (World Precision Instruments). TEER values were obtained from an average 
of n=5 wells and by subtracting the values from a cell-free transwell from the obtained 
value. TEER values were measured at day 6-7 after seeding bEnd.3, and before each 
experiment.
3.7. MTT Viability Assay
Cell viability was quantified by assessing the mitochondrial dehydrogenase reduction of 
3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) into purple 
formazan crystals. Cells grown in 96-well plates were treated with the sample for 24 or 
48 hours or PBS for the control. At the end of the incubation time, solutions were 
aspirated from the plate and rinsed 2x with PBS, followed by addition of 5 mg/ml of 
MTT to each well and incubated at 37°C for 60 minutes. The MTT solution was 
aspirated carefully, and the formazan was solubilised using acidified isopropanol. 
Absorbance was read with a spectrophotometer plate reader at 570 nm with a 
reference at 630 nm. Readings were obtained for n=3 samples per well, n=3 per 
treatment in n=3 independent experiments.
MTT was also assessed after incubation with pharmacological inhibitors used in 
sections 6.4, 6.5 and 6.8, as some inhibitors can be cause cell stress. bEnd.3 cells in 
96 well plates were incubated with the inhibitor, followed by rinsing in PBS and adding 
new media to the cells. Cells were returned to the incubator for 24 hours to recover, 
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and were incubated with MTT solution at the end of the recovery period. The following 
concentrations of inhibitor were used for the specified incubation times before washing 
the cells: 10 mM cyclodextrin 1h, Dynasore 80 μM 10 min, N-ethylmaleimide 500 μM 
1h. The MTT results for the inhibitors can be seen in figure 3.4.
Figure 3.4. MTT of pharmacological inhibitors in bEnd.3. Error: st.dev., student’s t-test, n=9 
readings in n=3 experiments, *p<0.05.
3.8. FITC-Dextran Permeability Assay
A working solution of 1 mg/ml Cy3-labelled Angiopep-2-POEGMA-PDPA, Cy3-
POEGMA-PDPA, or FITC-Dextran (mw = 70kDa, Sigma) was prepared in DMEM 
imaging media (Gibco), supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/
ml streptamycin, 1 μg/ml fungizone and 2 mM L-glutamine. bEnd.3 monolayers in 12-
well transwells were aspirated from media and rinsed with PBS at the start of the 
experiment. 0.5 ml of 1 mg/ml FITC-dextran or polymersomes in medium was applied 
to the bEnd.3 monolayer at the top transwell compartment (n=6), and 1.5 ml of media 
was added to the bottom compartment. A transwell insert without cells was used as a 
control (n=3). After the FITC-dextran had been added, transwells were incubated at 
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37°C in 5% CO2 for up to 24 hours. At each timepoint, 50 μl samples were transferred 
from the bottom chambers to a black 96-well plate and read in a fluorimeter with 
excitation set to 495 nm and emission to 518 nm for FITC-Dextran or excitation 540 nm 
and emission 565 nm for Cy3-polymersomes. Concentration was converted to 
cumulative apical to basolateral flux of fluorescence, accounting for the gradual 
dilutions of the basolateral compartment media over time due to sampling 50 μl per 
time point.
3.9. Fluorescence Quantification of Polymersome Transcytosis In Vitro
bEnd.3 cells were seeded on collagen-coated 12-well transwell filters and allowed to 
grow to a confluent monolayer. TEER values were measured in order to ensure 
confluence. At the beginning of each experiment, media was changed to supplemented 
DMEM imaging media and added to the transwells at a volume of 500 μl to the upper 
and 500 μl to the lower compartment. Cy3-labelled polymersomes were added at a 
concentration of 1 mg/ml to the upper compartment, incubated at 37°C and 5% CO2 for 
time points between 0-24 hours, followed by collection of media from both 
compartments. 100 μl of collected media was transferred to black fluorescence 96-
wellplates, n=3 wells per compartment and timepoint, and fluorescence was measured 
with a fluorescence spectrometer (Varian CaryEclipse) with excitation set to 540 nm 
and emission of 565 nm.
3.10. Calculation of Angiopep-2 Density in Polymersome Membrane
In order to calculate the number of Angiopep-2 ligands per vesicle, the number of 
polymers (Nagg) in a vesicle of radius r must be calculated first (figure 3.5). First, the 
membrane volume was calculated by subtracting the volume of the sphere of the inner 
edge of the membrane from the volume of the sphere of the outer edge of the 
membrane. To do so, the radius of the inner and outer spheres must be calculated from 
particle radius r, brush length b and membrane thickness t. For POEGMA, the brush 
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length scales with hydrophilic chain length (see ref (Battaglia and Ryan 2005)) and is 
equal to:
[1]
   
Thus, for POEGMA25-PDPA114 the brush length is
b = 0.247 x 25 = 6.187 nm.
Membrane thickness t scales to the length of hydrophobic repeating units (NPDPA) 
according to a power law of 2/3(Battaglia and Ryan 2005, Smart, Mykhaylyk et al. 
2009, Pearson, Warren et al. 2013):
[2]
Thus, for POEGMA25-PDPA114 the membrane thickness is
t = 0.359 x (114)2/3 = 8.44 nm.
The average diameter of polymersomes was determined to be 80 nm by dynamic light 
scattering. Using the values of r = 40 nm, b = 6.187 nm and t = 8.44 nm, the 
membrane volume (V) can be calculated as:
   
[3]
 
Which gives a membrane volume v of 93511.3 nm3.
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The molecular volume of each PDPA polymer (MvPDPA) was then calculated from 
molecular weight of DPA (MwDPA), number of repeating units (NPDPA), polymer density 
(p) and Avogadro’s number (NA). The MwPDPA was calculated first:
   
[4]
Equal to 24516.2 g/mol for a PDPA length of 114.
Molecular volume was then calculated:
 
   
[5]
The density of POEGMA-PDPA is estimated to be the same as water, 1 g/cm3. 
Therefore, for a PDPA length of 114, MvPDPA = 40.37 nm3.
To calculate Nagg, the whole membrane volume [equation 3] was divided by the 
molecular volume of each PDPA chain [equation 5]:
 
[6]
To calculate the number of ligands, the total number of polymers were distributed 
according to the ratio of the outer versus inner membrane surface area RO/I. 
   
[7]
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And finally, the number of ligand (NLigand) per vesicle is obtained from the molar 
percentage functionalisation of ligand (F%):
   
[8]
Figure 3.5. Schematic of calculations for Nagg. and NLigand.
3.10.1. Calculation of Transcytosis Efficiency
Polymersome fluorescence in transwell compartments was converted to % transcytosis 
efficiency by obtaining the fluorescence (F) of polymersomes shifted over from the 
apical to basolateral compartment: 
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3.11. FACS For Quantification of Polymersome Uptake
For Fluorescence Activated Cell Sorting (FACS) quantification of polymersome uptake, 
bEnd.3 cells were seeded in collagen-coated 6-wellplates. Poly-L-lysine (Sigma-
Aldrich) was prepared at 300 μM in PBS and lactoferrin (Sigma-Aldrich) was prepared 
in PBS at a concentration of 250 nM. Cy3-labelled Angiopep-2-POEGMA-PDPA 
polymersomes were prepared via pH switch and purified. When cells had reached 
confluency, they were pre-incubated with poly-L-lysine, lactoferrin or PBS (control) for 
30 minutes, followed by incubation with A-EP for 60 minutes in 37°C and 5% CO2. At 
the end of the incubation time, cells were rinsed 2x with PBS and treated with 0.25% 
trypsin-EDTA at 37°C for 5 minutes to detach the cells. Detached cells were centrifuged 
at 1000 RCF for 5 minutes, and the pellets were resuspended in 4°C PBS to 500 μl. 
150 μl of cells in suspension were pipetted into 96-wellplate for FACS. FACS was 
performed with a BD FACSArray instrument with a flow rate set to 0.5 μl/s. For the 
detection of Cy3-labelled polymersomes, excitation wavelength was set to 545 nm and 
emission to 560-600 nm.
3.12. Angiopep-2 and A-EP Ligand Competition
FITC-Angiopep-2 (ProteoGenix, France) was dissolved in diH2O at 1.75 pM, the 
equivalent of ligand functionalisation in 1.2% (mol) Angiopep-2-POEGMA-PDPA. 
Angiopep-2 or A-EP were added separately or together to the apical transwell 
compartment, and transwells were returned to the incubator. After 10 or 60 minutes, 
transwells were washed 2x with PBS and fixed with 3.7% PFA. Filters were excised 
with a scalpel and mounted on coverslips with VectaShield-DAPI (Vector Labs, U.K.) 
for confocal imaging. Quantification of intracellular fluorescence of A-EP (Cy3 channel) 
or FITC was performed via ImageJ, normalising fluorescence to DAPI.
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3.13. Pharmacological Small Molecule Modulation of Endocytic Processes
For the inhibition of dynamin, 40 μM Dynasore (Sigma-Aldrich) was prepared in PBS 
and filter sterilised. Cells were pre-incubated with CellMask Deep Red (ThermoFisher 
Scientific) (exc. 649 em. 666 nm) for 10 minutes and washed, replacing with new 
media. Dynasore was added to the cell medium and pre-incubated for 10 minutes at 
37°C, followed by the addition of Cy3-labelled A-EP. Cells were incubated with 
polymersomes for 10 or 60 minutes before live confocal imaging. After images were 
acquired, cells were washed with pH 5 PBS before imaging again. 
For the inhibition of NSF, 0.5 mM N-ethylmaleimide (Sigma-Aldrich) was prepared in 
PBS, added to bEnd.3 and incubated at 37°C for 60 minutes. Before the start of 
imaging, cells were incubated with CellMask Deep Red (ThermoFisher Scientific) for 10 
minutes before rinsing 2x with PBS and replacing full media. Cells were incubated with 
Cy3-labelled A-EP with FITC-IgG cargo for a further 5 minutes before live confocal 
imaging. 
3.14. Cholesterol Depletion and Quantification
To deplete bEnd.3 cells of membrane cholesterol, 10 mM methyl-β-cyclodextrin (CD) 
(Sigma-Aldrich) was applied to either the apical or basolateral side of cells grown in 
transwells according to a previously established method.(Tugizov, Herrera et al. 2013) 
Transwells were washed 2x with PBS and media was replaced with serum free media, 
and TEER values were measured. CD was added to bEnd.3 transwell monolayers 
either to the basolateral or apical side, and incubated in 37°C for 15 minutes. After 
incubation, media from both compartments was collected and saved for later 
quantification of cholesterol content. Transwells were rinsed 2x in PBS and serum free 
media was replaced, and TEER values were obtained for all transwells and untreated 
controls (n=3). Cells were incubated with Cy3-labelled A-EP for 60 minutes, before 
rinsing with PBS and fixating transwell filters in 3.7% PFA and permeabilising for 30 
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minutes with 0.1% Triton X-100. Cells were stained for Caveolin-1 by incubating with 
Rb Cav-1 1:250 in room temperature for 2 hours, washed 3x, and incubated with goat 
anti-Rb488 1:200 for 2 hours in room temperature. Filters were washed, excised with a 
scalp and mounted on coverslips with VectaShield-DAPI and assessed under a 
confocal microscope.
Free cholesterol shed into the collected media after CD treatment was measured with a 
cholesterol quantitation kit (Sigma-Aldrich) according to instructions, and compared to 
a serum free media control. Briefly, after the enzymatic assay, sample fluorescence 
was measured against a cholesterol standard curve from the kit in a fluorimeter with 
excitation at 535 nm and emission at 570 nm. Concentration of cholesterol shed into 
the apical and basolateral media was calculated according to the standard.
3.15. Confocal Microscopy
Confocal micrographs were acquired using a Leica TCS SP8 confocal microscope 
equipped with Diode 405, Argon, DPSS 561 and HeNe633 lasers. In all cases where 
more than one fluorophore was used, channel images were obtained by a sequential 
scan to minimise bleed-through. 3D projections of z-stacks were created with the Leica 
Application Suite (LAS X) software.
3.15.1. Real Time 4D Imaging of Live Cells
An incubator with 37°C and 5% CO2 connected to the unit was used and allowed to 
stabilise for 60 minutes before imaging. Cells were immersed in DMEM imaging 
medium (no phenol red) before imaging unless stated otherwise. CellMask Deep Red 
(ThermoFisher Scientific) was applied to cells to stain the plasma membrane, 
incubated at 37°C for 10 minutes before rinsing with PBS. Images were acquired with a 
10X 0.3NA objective in resonant scanning mode with a speed of 700Hz and a 
resolution of 128x512 pixels.
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3.15.2. Immunocytochemistry
For a typical immunofluorescence labelling experiment, cells were fixed with 3.7% 
paraformaldehyde for 10 minutes and washed 3 times with PBS for 5 minutes each 
time. Cells were incubated in 10% BSA and 0.1% Triton X-100 for 30 minutes to reduce 
non-specific antibody binding. Antibodies were diluted in 1% BSA and 0.1% Triton 
X-100 (see table 3.1 for antibody specifics). Following blocking and permeabilisation, 
cells were incubated with primary antibodies for 2 hours in room temperature, washed 
with PBS, followed by incubation with secondary antibodies in room temperature for 2 
hours. Samples were kept in the dark during antibody incubation to avoid 
photobleaching. Cell nuclei were stained using 1 μg/ml Hoechst 33542 with a 10-
minute incubation, alternatively with VectaShield-DAPI when mounted. Cells grown on 
transwell membranes were further processed by using a scalpel to cut out the 
membrane filter, and mounting excised filters onto glass coverslips with Vectashield 
mounting media before imaging. Images were acquired with a 63x xNA oil immersion 
objective at 400Hz and 512x512 pixels.
Target Host Supplier Application 
(+dilution)
Primary antibodies 
LAMP-1 Rabbit Abcam IF (1:200) 
Rab5 Rabbit Abcam IF (1:200) 
Rab7 Rabbit Abcam IF (1:200) 
Rab11 
Claudin 5 Rabbit Abcam IF (1:200) 
Occludin Rabbit IF (1:200) 
ZO-1 Rabbit Abcam 
LRP-1 IF (1:250) 
Caveolin-1 Rabbit Sigma-Aldrich
CD34 Rabbit Abcam IHC (1:200)
  IF (1:200) 
  IF (1:200) 
 Abcam 
Mouse     
IF (1:250)     
Abcam     
Rabbit     Abcam     
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Table 3.1. List of antibodies used. 
For staining with phalloidin, a stock solution of phalloidin-Atto647N (Invitrogen) was 
prepared in methanol. Cells were fixed for 10 minutes in 3.7% paraformaldehyde, 
permeabilised with 0.1% Triton X-100 for 30 minutes, and incubated with 50 μg/ml 
Phalloidin-Atto647N at 4°C for 20 minutes before washing with PBS, excising filters 
and mounting filters on microscopy slides with VectaShield-DAPI.
3.15.3. Image Z-stack Processing and Colocalisation Analysis
Acquired micrographs were analysed with ImageJ (nih.gov). To obtain red/green 
channel localisation, the plug-in ‘Colocalization Finder’ was used (authors: 
Laummonerie, C., Mutterer, J., Institut de Biologie Moleculaire des Plantes, Strasbourg, 
France). Colocalisation analysis is based on pixel intensity, determining how much 
pixels from two channels (e.g. red and green) overlap. Images were converted to 8-bit 
grayscale and analysed for Pearson’s correlation coefficient Rr, to analyse pixel i in the 
images: 
where R is red channel intensity and G is green channel intensity. Sum values can be 
between -1 and 1, with -1 meaning perfect exclusion, 0 for random localisation, and 1 
Secondary antibodies / conjugates
Anti-Goat IgG H&L (6nm gold) Rabbit Abcam TEM (0.1 μg/ml) 
Anti Rabbit-Alexa488 Goat Sigma-Aldrich IF (1:250) 
Anti Rabbit IgG-Alexa488 IF (1:250) 
Anti mouse-647 Donkey Santa Cruz IF (1:200)
Target Host Supplier Application 
(+dilution)
Donkey      Abcam 
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for perfect colocalisation. An example of colocalisation with the plugin is shown in figure 
3.6.
Figure 3.6. Example of colocalisation via Pearson’s correlation coefficient.
3.15.4. Quantitative Fluorescence Analysis of Confocal Images
To quantify channel fluorescence of confocal images acquired in the xy, ImageJ was 
used with the plugin ‘ROI Manager’. Cell outlines were chosen as regions of interest 
(ROI), and fluorescence intensity was measured within the ROIs. Cell fluorescence 
intensity from the ROIs were normalised per nuclei, i.e. the Hoescht/DAPI channel. n=3 
images were used to obtain standard errors. To quantify channel fluorescence of 
confocal images acquired in the xyz dimensions, the Leica SP8 Confocal LAS X 
software was used to automatically measure fluorescence intensity across the z-stacks 
per individual channel. This method was applied to figures 6.16 and 6.26, where data is 
represented across the transwell as 0 where the transwell filter begins, +10 μm at the 
end of the filter and -10 μm to be 10 μm above the filter (where cells are located).
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3.16. Transwell Electron Microscopy of A-EP-Gold
Rabbit 6nm anti-goat IgG-Gold (Abcam) was encapsulated into A-EP via 
electroporation and polymersomes were purified via GPC. bEnd.3 monolayers grown in 
12-well transwells were grown until confluency, and incubated with A-EP-gold for 1 
hour or 3 hours at 37°C and 5% CO2 before washing cells with PBS and fixing in 3% 
glutaraldehyde in 0.1M phosphate buffer, and left in 4°C overnight. Secondary fixation 
was carried out by washing transwell filters 2x with 0.1M phosphate buffer and 
incubating with 1% aqueous osmium in 0.1M phosphate buffer for 20 minutes in 4°C. 
The solution was aspirated and transwells washed 1x in PBS, and gradually 
dehydrated with increasing concentrations of EtOH for 10 minutes each: 25%, 50%, 
70%, 90% and 100%. Resin components Agar-100, DDSA and MNA were weighed out, 
DBMA was added and the mixture was stirred up. The resin was transferred to a 
Corning tube, and the following percentages of EtOH were added for 30 minutes each 
to get 25% resin, 50% resin, 75% resin, and 100% resin. Resin in transwells was 
incubated in room temperature overnight, and removed from the transwells the 
following day. The filters were excised with a scalpel and cut into 2x2mm slivers. 
Transwell filter slivers were placed in the resin in the oven at 60°C for >24h. Ultra-thin 
(50-70nm) sections were obtained with a diatome. Samples were assessed under a 
Jeol 1010 transmission electron microscope.
3.17. In situ rat brain perfusion
Empty A-EP or control EP polymersomes were prepared with a 20% (mol) Cy3 label, 
2x the Cy3 molarity used for in vitro studies. Polymersomes were purified via GPC and 
characterised via DLS and TEM. DLS showed a normal size distribution, with EP 
averaging approximately 80 nm and A-EP 70 nm. TEM showed slight polydispersity in 
the vesicle size obtained, with some smaller vesicles of ~50 nm present in A-EP and 
EP samples. Physicochemical characterisation of polymersomes used for the in vivo 
quantification pilot study is shown in figure 3.7.
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All animal experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 (U.K.) Male adult Wistar rats were anaesthetised with 100 mg/kg 
ketamine and 1 mg/ml medetomidine via intraperitoneal injection. The right and left 
external carotid arteries were isolated from the carotid sheaths and cannulated 
according to a previously established procedure.(Takasato, Rapoport et al. 1984) The 
perfusion fluid was modified Ringer’s solution (6.896 g/L NaCl, 0.350 g/L KCl, 0.368 g/L 
CaCl2, 0.296 g/L MgSO4, 2.1 g/L NaHCO3, 0.163 g/L KH2SO4, 2.383 g/L HEPES, 
additionally 0.5005 g/L glucose (5.5 mM) and 11.1 g/L BSA). The perfusion fluid was 
bubbled with 5% CO2 and heated to 37°C for 20 minutes prior to perfusion. For the 
injection of polymersomes, 20% (mol) Cy3-labelled polymersomes in PBS with our 
without protein encapsulated were diluted to 1 mg/ml in Krebs buffer (pH 7.4, 188 mM 
NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 
10 mM D-glucose, 3 g/dl bovine serum albumin). The polymersome solution was 
supplied via an additional syringe pump connected to the perfusion system via two 
tubes feeding into the system at a rate of 0.16 ml/min, making the overall perfusion rate 
1.5 ml/min. The perfusion time was 10 minutes. At the end of the perfusion time, the 
syringe pump was stopped and the system was flushed for 60 seconds with modified 
Ringer’s perfusate in order to remove unbound polymersomes. After 60 seconds, 
cerebrospinal fluid was extracted via cisternal puncture followed by decapitation and 
removal of the brain.
3.18. Capillary Depletion and Fluorescence Quantification
After decapitation, brains were removed and washed in ice cold 9 g/L NaCl, followed 
immediately by homogenisation on ice to initiate the capillary depletion method 
(Triguero, Buciak et al. 1990). A flowchart of the procedure is illustrated in figure 3.8. 
Briefly, the cerebellum was removed and the cerebrum was weighed, adding 2x brain 
weight in PBS followed by 3x dilution in 30% (w/v) dextran (average mw 64-74k). 
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Centrifugation of homogenates at 8000g for 20 minutes in 4°C resulted in several 
fractions that were carefully separated: capillary depleted fraction (i.e. parenchyma), 
dextran, and the capillary enriched fraction (pellet). The capillary enriched pellet was 
re-suspended in PBS, and 100 μl samples were added to a black 96-wellplate and read 
in a fluorimeter at an excitation wavelength of 540 nm and emission at 565 nm.
 
Figure 3.7. Characterisation of polymersomes used for in vivo studies.
All sample fluorescence readings were normalised to readings obtained from sham 
perfused rats (n=3) for each sample type, i.e. CD, dextran or capillaries. Figure 3.9 
shows the fluorescence obtained for some controls, demonstrating that fluorescence is 
sufficient in order to quantify polymersome fluorescence in homogenates. 
Homogenates from a sham perfused rat was used as a negative control, in order to 
obtain the background fluorescence from the respective fractions resulting from 
capillary depletion. Some background fluorescence was measured from the sham 
homogenate. Normalised fluorescence readings were converted to polymersome (Cy3) 
amount was converted into % injected dose %id of the positive control value for that 
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experiment, where %id = [normalised sample value (mg) ÷ mean positive control value 
(mg)] * 100. This was further converted into fluorescence per whole brain. All statistical 
analysis was one-way ANOVA, *p <0.05.
Figure 3.8. Schematic of in vivo sample processing.
Figure 3.9. Raw fluorescence data obtained from in situ perfusion controls
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3.19. Cryosectioning and Immunohistochemistry
Rats were perfused as described in section 3.17. At the end of the perfusion time, 
whole animal perfusion fixation with 4% PFA was performed for 3 minutes at 1.47 ml/
min according to a previously established method (Gage, Kipke et al. 2012). The brain 
was extracted and rinsed with PBS, followed by incubation in 4% PFA at 21°C for 5 
days. This was followed by incubation in 30% sucrose (w/v) in 0.1M PBS with 0.05% 
sodium azide at 21°C for 7 days. Sectioning was performed with a Leica SM2000R 
freezing microtome. 30 μm transverse sections were cut after freezing rat brains in 
-40°C and mounting with Bright Cryo M-Bed media. Sections were stored in PBS with 
0.05% sodium azide in 4°C after cutting.
Anti-rabbit CD34 (Abcam) concentration was determined through titration. Sections 
were washed in 0.1M PBS for 10 minutes, and incubated for 30 minutes at room 
temperature while shaken with 0.3% H2O2 in 0.1M PBS. Sections were incubated for 1 
hour in 1% BSA/0.05% Triton X-100/0.1M PBS to prevent non-specific binding, 
followed by incubation with CD34 at 1:200 overnight while shaking. Sections were 
washed with 0.05% Triton X-100/0.1M PBS, and incubated for 1 hour with 1:200 goat 
anti-rabbit-Alexa488. Samples were washed 2x in 0.1M PBS for 30 minutes each to 
reduce background staining, and mounted with VectaShield-DAPI on coverslips before 
assessing fluorescence using a fluorescence microscope, acquiring each channel in 
sequence. 
3.20. Statistical Analysis
Statistical analysis was performed as indicated at each experiment. For analysis of two 
groups of data, student’s t-test was performed with *p<0.05. For three or more groups 
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of data, one-way ANOVA was performed with *p<0.05. For all experiments, errors are 
given for n=3 independent experiments unless otherwise indicated. 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Chapter 4.
RESULTS AND DISCUSSION I
Polymersome Physicochemical Properties
_____________________________________________________________________
4.1. Introduction 
This section is dedicated to work undertaken to synthesise and characterise 
polymersomes conjugated with peptide Angiopep-2 designed to target the blood-brain 
barrier. 
4.1.1. Polymersome Preparation Methods
The directed self-assembly of amphiphilic block copolymers in a solvent results in a 
range of morphologies in addition to spherical polymersomes, such as micelles and 
tubular polymersomes (see section 2.6.3 of Chapter 2). This is due to several factors, 
such as the hydrophilic/hydrophobic ratio, the block copolymer chain length typically 
measured by its degree of polymerisation, N, and method of self-assembly i.e. bottom-
up or top-down.
Polymersomes can be prepared via two different approaches: from polymers in bulk 
(top-down approach), or from single block copolymer chains (bottom-up approach). 
The top-down approach consists of gradually hydrating a thin film of polymer in solution 
while applying a source of energy, such as shear stress or ultrasound. The energy 
source causes parts of the film to gradually detach into the solution. As this occurs, 
different phases or structures start to arrange themselves according to the hydrophobic 
effect. These structures are variable, but are often long and ‘worm-like’ as a result of 
the lamellar shape of the polymer film as it becomes hydrated. Given enough time, the 
energy source applied starts to break down the long worms into vesicles. 
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The bottom-up approach triggers self-assembly of dissolved polymer unimers into 
structures. This involves immersing the polymer in a solvent which dissolves both the 
hydrophobic and hydrophilic part of the polymer, and then changing the solvent 
conditions into one which only dissolves the hydrophilic block. This ‘switch’ can be 
changing the solvent, or changing conditions such as pH or temperature (Lomas, 
Canton et al. 2007). Applying the switch causes unimers to progressively add on to 
each other, re-arranging into structures in which the hydrophobic block of the polymer 
avoids the solvent. The vast majority of structures formed by this process are vesicular, 
because vesicles have a packing factor of 1 and are thus the most stable structures in 
equilibrium. However, the extent of unimer addition is difficult to control, and as a result 
yields some structures with asymmetric membranes (Pearson, Warren et al. 2013).
Because both the top-down and bottom-up approaches yield structures other than 
vesicles, it is essential to separate the desired spherical polymersomes from other 
structures. Purification of polymersome populations can be done by size exclusion 
chromatography (SEC), in which the sample is passed through a substrate with porous 
beads, creating longer column retention times for particles of smaller due to 
interactions with the bead interior. An alternative to SEC is centrifugation, which 
separates tubular polymersomes from spherical as a result of differing relative polymer 
mass of the different structures (Robertson, Yealland et al. 2014).
4.1.2. Encapsulation of Cargo into Polymersomes via Electroporation
An advantage of using polymersomes as drug delivery vehicles is the ability to 
encapsulate cargo, protecting it from interaction or degradation with the external 
environment. Polymersomes can carry hydrophobic cargo integrated into the 
membrane, and hydrophilic cargo in the lumen of the polymersome. One strategy of 
cargo encapsulation is including cargo in the polymer mixture prior to polymersome 
formation. However, this approach must often occur in the presence of organic solvents 
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or at a pH harmful to the cargo. Another way to encapsulate cargo is through 
electroporation, a method often applied in biology to load exogenous genes into 
embryos through creating temporary membrane destabilisation. Electroporation 
involves the application of an external electric field to polymersomes, temporarily 
permeabilising the polymersome membrane and allowing the diffusion of materials to 
the vesicle interior. Permeabilisation occurs through the formation of pores in the 
membrane due to electrically induced rearrangement of membrane phospholipids. Pore 
formation occurs on a millisecond scale and resealing within minutes, trapping cargo 
within the membrane (Kotulska, Basalyga et al. 2010). Electroporation has been used 
to load biological macromolecular cargo such as antibodies, proteins and even nucleic 
acids into pH-sensitive polymersomes (Wang, Chierico et al. 2012). Encapsulation of 
cargo into polymersomes via electroporation is a crucial step for enabling delivery of 
macromolecular cargo into the central nervous system. The ability to load fluorescently 
labelled cargo also provides a useful tool for tracking the fate of the cargo, and its 
therapeutic effects where applicable.
RESULTS
4.2. Physicochemical Characterisation of Polymersomes 
Polymersomes were produced via the pH switch method of directed self-assembly, in 
which raising the pH above the pKa of the PDPA block (~pH 6.4) causes the dissolved 
block copolymer mixture to spontaneously self-assemble into vesicles. Size 
measurements via Dynamic Light Scattering (DLS) showed POEGMA-PDPA formed 
via pH switch had an average diameter of around 60 nm, as shown in figure 4.1. The 
average diameter of Angiopep-2-POEGMA-PDPA polymersomes was 80 nm.
Transmission Electron Microscopy (TEM) was used to assess polymersome 
morphology, with the electron dense agent phosphotungstic acid (PTA) as a staining 
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agent. Micrographs in figure 4.2 illustrate the heterogeneity of self-assembled shapes 
present in a polymersome sample prepared via pH switch, before purification. Micelles 
in particular are markedly present, averaging <40 nm in diameter and with slightly less 
contrast in the membrane. A few non-spherical polymersomes can also be seen. 
Figure 4.1. Typical size distribution of A-EP and EP polymersomes obtained via pH 
switch. Peaks are an average of n=3 independent experiments, error bars: S.E.M. 
Figure 4.2. Transmission electron micrographs of A-EP. The sample was made via pH 
switch, and shows a distribution of shapes and sizes.
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4.3. Separation of Polymersomes From Other Nanostructures 
4.3.1. Gel Permeation Chromatography
Gel permeation chromatography (GPC) with sepharose 4B as a substrate was used to 
purify polymersome-enriched fractions from the initial heterogeneous samples obtained 
via pH switch. In this approach, 1 ml of 6 mg/ml polymersomes was added to the top of 
the sepharose and all fractions exiting the column were collected drop by drop (~50 μl). 
Polymersome size and total polymer amount as a function of elution volume was 
quantified via DLS and fluorescence spectroscopy. 
DLS sizing and correlation data was obtained in increments of 0.1 ml, but have been 
merged into a few significant groups for coherence. Figure 4.3 shows the DLS 
correlation data as a function of elution volume. Correlation values for samples 0-3.6 ml 
and 6-9 ml indicated impure samples, or a concentration out of range for measurement. 
Furthermore, these two samples display a slow decay at later delay times, indicating 
that large structures are present in the sample (likely dust). Overall, the reliability of 
sizing data obtained from these two samples is therefore low. Sizing data by numbers 
is displayed in figure 4.4. Sample volumes up to 3.6 ml show the presence of large 
structures, although a low correlation function indicates impurities in these fractions. 
Polymersomes in elution volumes above approximately 5 ml mainly contain micelles. 
The fractions in between 3.7-5 ml contained polymersomes.
Figure 4.5 summarises the cumulative polymer eluted, concentration, and average size 
of all samples collected, and also representative electron microscopy images obtained 
from different stages of the separation. The cumulative polymer mass present in eluted 
samples increased rapidly between 3.5-6 ml, indicating this range as the elution 
volume containing the majority of polymer and thus narrowing down the range of 
interest for further characterisation by DLS. The measured polymersome concentration 
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peaked around 4-4.5 ml, indicating that the average size obtained for these elution 
volumes may represent the majority of polymersomes in solution. DLS showed a 
decreasing trend in average diameter consistent with GPC separation.The purified 
fraction containing polymersomes is contained in the 4 to 5 ml elution range via 
sepharose-based GPC. All subsequent work using GPC-purified polymersomes 
consequently involved harvesting polymersomes in this elution range.
Figure 4.3. Correlation function of A-EP polymersomes as a function of elution volume.
Figure 4.4. Average size of A-EP polymersomes as a function of elution volume.
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Figure 4.5. Characterisation of A-EP polymersome fractions obtained from GPC. 
Representative TEM pictures from different elution volumes. n=3 experiments. Error bars: 
S.E.M. 
4.3.2. Centrifugation
GPC is feasibly limited to separation of small volumes (~<2ml) of polymersomes in 
solution, as the length of the column must increase with sample volume in order to 
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adequately separate structures of different sizes. Robertson et al. reported the 
separation of tubular from spherical polymersomes via centrifugation, where the tubular 
polymersomes pellet due to their higher mass (Robertson, Yealland et al. 2014). A 
method of high-volume size separation is useful for making larger batches of 
polymersomes, e.g. for in vivo work. Centrifugation was hypothesised to be able to 
separate the two populations of polymersomes and micelles akin to the separation of 
polymersomes from tubes. Centrifugation of Angiopep-2-POEGMA-PDPA 
polymersomes resulted in a supernatant and a pellet, the latter of which was 
resuspended in PBS. Figure 4.6 shows DLS size distributions of the pellet and 
supernatant, indicating a predominantly micellar population present in the supernatant. 
The average size of the resuspended pellet population was 78 nm, comparable to 
previously obtained values of POEGMA-PDPA polymersomes purified via GPC 
separation (figures 4.1 and 4.5). Figure 4.7 shows electron micrographs of 
polymersomes before and after centrifugation. The micrographs confirm the pellet 
population as mostly containing polymersomes with a few micelles. By contrast, 
micelles predominate the supernatant with the presence of a few polymersomes.
Figure 4.6. DLS of A-EP separated via centrifugation. 
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Figure 4.7. Electron micrographs of polymersomes before and after centrifugation.
4.4. MTT Viability Test of Polymersome Toxicity
The reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
into a purple formazan salt by mitochondria can be used to quantify cellular metabolic 
respiration. An increase in formazan reduction implies cellular stress, and a decrease 
corresponds to lower metabolic activity due to cell death. MTT was used to assess the 
effect of POEGMA-PDPA or Angiopep-2-POEGMA-PDPA polymersomes on bEnd.3 
metabolic activity. After 24 hours, no significant changes in formazan production were 
 116
Chapter 4
observed in the polymersome-treated groups compared to the PBS-treated controls 
(figure 4.8). This indicates that polymersomes can be used at a concentration of up to 1 
mg/ml in bEnd.3 cells without any changes in cellular metabolism at the time examined. 
Furthermore, the presence of Angiopep-2 in the polymersome membrane does not 
impact mitochondrial activity compared to POEGMA-PDPA alone. 
Figure 4.8. MTT test of A-EP or EP in bEnd.3 cells. 24 hours after incubation. n=3; error bars 
= S.D, *p <0.05.
4.5. Assessing Non-Fouling Properties of Polymersomes
An important characteristic of drug delivery vehicles is to avoid protein fouling, i.e. the 
gradual adsorption of proteins onto the vehicle surface, as this effect can reduce 
plasma circulation half-life. POEGMA is a PEG derivative and has been shown to be 
non-fouling (Alswieleh, Cheng et al. 2014). However, the presence of Angiopep-2 
peptide might create a hot spot for protein adsorption. While the formation of ‘soft’ 
protein coronas is more difficult to assess due to their dynamic nature, ‘hard’ corona 
formation of A-EP and EP polymers can be assessed through GPC coupled with HPLC 
for detection. Through using conditions to obtain clearly separate polymer and protein 
elution times, it is possible to assess potential hard polymer/protein interactions if there 
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are shifts in the elution times when polymer and proteins are run through the column 
together. 
Figure 4.9. GPC-HPLC assessment of EP interactions with IgG.
Figure 4.10. GPC-HPLC assessment of A-EP interactions with IgG.
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The non-fouling properties of Angiopep-2-POEGMA-PDPA and POEGMA-PDPA 
against a model protein IgG were assessed via GPC-HPLC. Under the separation 
conditions used, IgG emits a trace with a wide peak at 60-80 minutes followed by a 
smaller peak at 90-100 minutes. Figure 4.9 shows the elution times of POEGMA-
PDPA, IgG, and POEGMA-PDPA mixed with IgG. The polymer is eluted between 30 
minutes and 40 minutes, with a slight shoulder until ~60 minutes. In the absence of 
IgG, the shoulder of POEGMA-PDPA is negligible and there is no overlap between the 
polymer peak compared to the control protein peak. Mixing of polymer and protein 
showed no shift in the peak sizes or retention times, indicating that no interaction is 
occurring between POEGMA-PDPA and IgG. Similar results were observed for 
Angiopep-2-POEGMA-PDPA, as displayed in figure 4.10. Mixing polymer and protein in 
the same sample resulted in a minor continuation of the polymer shoulder, and where it 
vanishes around 60 minutes in the case of free polymer it instead merges into the 
protein peak. However, this convergence of peaks is occurring at a negligible scale and 
there is no evidence for ‘hard’ corona formation. Nevertheless, experiments are 
required to determine whether ‘soft’ corona formation and protein fouling occurs in the 
case of Angiopep-2-POEGMA-PDPA.
4.6. Encapsulation of Cargo into Polymersomes Via Electroporation
4.6.1. Gold-labelled Polymersomes
An experiment described in section 6.9 of chapter 6 was performed to localise 
polymersomes within brain endothelial cells with electron microscopy. The harsh 
sample fixation processing techniques used in electron microscopy preparation are 
problematic as they destroy the polymersome membrane. By contrast, gold is 
unaffected by fixation and is frequently used as a label in EM studies. IgG with 6 nm 
gold was thus encapsulated into A-EP via electroporation. Figure 4.11 shows the DLS 
and TEM characterisation of polymersomes with gold encapsulated, where electron 
dense gold particles can be seen within the polymersomes.
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Figure 4.11. Morphology and size of A-EP with 6nm IgG-gold encapsulated. Scale bar: 200 
nm.
4.6.2. Encapsulation of Carnosine
For experiments described in section 7.5 of chapter 7, carnosine was encapsulated into 
A-EP polymersomes via electroporation, followed by purification via GPC to remove 
residual unencapsulated protein. Protein content of polymersomes was analysed via 
HPLC after a standard curve of free carnosine had been established. The elution trace 
of carnosine in HPLC detected in the UV Vis channel of 280 nm can be seen in figure 
4.12. Subsequently, area under curve (AUC) integration analyses to obtain 
concentration were used between 1.5-2.5 minutes, with the standard curve displayed in 
figure 4.13. 
Figure 4.12. HPLC elution trace of carnosine. Detection at 280 nm.
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Figure 4.13. Standard curve of carnosine protein concentration at emission of 280 nm. 
Obtained from AUC integration of HPLC traces.
The encapsulation of carnosine was performed with an initial protein concentration of 
1.5 mg/ml. The protein content of GPC-purified polymersomes was determined to be 
approximately 1 mg/ml (table 4.1). The encapsulation efficiency was much higher 
compared to other reports of polymersome encapsulation of macromolecular cargo, 
ranging between 15-40% (O’Neil, Suzuki et al. 2009). However, through changing the 
number of pulses or voltage it may be possible to further increase encapsulation 
efficiency.
Table 4.1. Carnosine content of purified A-EP as determined by HPLC.
4.7. Discussion 
The ability to characterise polymersome transcytosis at the blood-brain barrier depends 
on a reliable method of separating polymersomes from micelles and other structures 
formed in the self-assembly process. Neither gel permeation chromatography nor 
centrifugation provided fully separated populations of vesicles, but make up the 
[Carnosine] before purification 
mg/ml
[Carnosine] after purification 
mg/ml
Encapsulation efficiency %
1.45 0.95 66
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majority of the purified fractions as evidenced by sizing data and electron microscopy. 
Separation by GPC yielded purer populations of vesicles as the eluted fractions were 
collected on the scale of microlitres. By contrast, centrifugation is useful when 
preparing large volumes of sample for e.g. in vivo studies. Ideally, the centrifugation 
method can be further refined to separate micelles (<50 nm) from small polymersomes 
(50-100 nm). Another method to investigate in future work could be hollowfibre filtration 
for the purification of polymersomes to obtain more precise size ranges.(Robertson, 
Yealland et al. 2014)  
A-EP and EP polymersomes showed no cell stress in bEnd.3 cells, showing that they 
are suitable for use in vitro for concentrations of up to 1 mg/ml. Furthermore, through 
GPC-HPLC it was shown that EP polymersomes do not interact with the model protein 
IgG to form a ‘hard’ protein corona. A-EP and IgG may interact on a minuscule level, 
possibly due to the peptide sticking out of the polymersome corona. However, overall 
A-EP appears to be a suitable vector for drug delivery to the CNS in terms of 
physicochemical properties. 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Chapter 5.
RESULTS AND DISCUSSION II
Polymersome Interactions With an In Vitro 
Blood-Brain Barrier Model
_____________________________________________________________________
5.1. Introduction 
This section is dedicated to work undertaken to establish a simplistic in vitro model of 
the blood-brain barrier, formed by brain endothelial cells. Subsequent characterisation 
of the model was performed to ensure the model possessed the phenotype of brain 
endothelial cells, such as TEER values and expression of BBB-specific tight junction 
proteins. The section is concluded with characterisation of polymersome transcytosis in 
the transwell model, including kinetics of transcytosis on the macroscale and efficiency 
of transcytosis as a function of variation of the number of targeting ligands.
5.1.1. The In Vitro Model of the Blood Brain Barrier
There are a variety of established in vitro models of the blood brain barrier, and 
choosing the appropriate model depends on research aims and applications (for a 
comparison between common in vitro models, refer to  section 1.8 of chapter 1). The 
immortalised mouse brain microvasculature endothelial cell line bEnd.3 has been used 
extensively as a BBB model, with average TEER values around 100-140 Ω/cm2 
(Neumann, Schaefer-Ridder et al. 1982, Brown, Morris et al. 2007). These cells have 
been used for the purpose of investigating transcytosis (Bien-Ly, Yu et al. 2014), 
making it a good cell line for the work undertaken in this project. Use of a mouse cell 
line gives the advantage of quick translation into in vivo murine studies used later in 
this project. Moreover, the co-culture of additional neurovascular unit cell types with 
brain endothelial cells has been reported to enhance barrier-like properties and bridge 
the gap between in vitro and in vivo TEER values (Zysk, Schneider-Wald et al. 2001)
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(Lippmann, Weidenfeller et al. 2011). The addition of astrocytes or pericytes to the 
transwell setup is a quick and easy way to expand the model and examine the effects 
of neurovascular unit interactions as an element of transcytosis.
5.1.2. Fluorescence Colocalisation by Pearson’s Correlation Coefficient
There are a number of ways to assess protein-protein colocalisation from fluorescence 
microscopy, either directly measuring physical proximity of the target proteins (e.g. via 
Forster Resonant Energy Transfer), or indirectly through calculating overlap of 
fluorescence of two targets acquired in separate channels. Pearson’s correlation 
coefficient (Rr) gives the linear correlation between X and Y values from fluorescence 
channels, with resulting output values between -1 and +1. The formula can be applied 
to protein-protein colocalisation through immunocytochemical labelling the targets of 
interest with fluorophores, detecting emission in the red and green channels to provide 
X and Y values of fluorescence intensity. The fluorescence overlap is calculated 
according to the coefficient, where values +1 equates to full colocalisation and -1 
complete exclusion of targets from one another. See Chapter 3 (Materials and 
Methods) for further details of Pearson’s correlation coefficient calculations applied to 
work presented in this section and in chapter 6.
RESULTS
5.2. bEnd.3 Properties
To obtain a three-dimensional BBB mimicking environment, immortalised mouse bEnd.
3 brain endothelioma cells were seeded on top of a porous transwell filter membrane 
(pore diameter = 400 nm), which separates the well into two compartments (figure 5.1). 
The transwell membrane was coated with collagen to mimic the basal lamina onto 
which brain endothelial cells (BECs) adhere to in vivo. Seeding brain endothelial cells 
on the top side of the membrane corresponds to the ‘blood’ side of the BBB, and the 
bottom compartment to the ‘brain’ side.
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Figure 5.1. Transwell BBB model of BEC monoculture and co-culture configurations. 
Insert: Transmitted light micrograph of bEnd.3 monolayer seeded on top of the porous transwell 
filter. n: nucleus. Scale bar: 10 μm.
The transwell model was used in two different configurations, as shown in figure 5.1. A 
setup containing a bEnd.3 monolayer only was used to characterise polymersome 
interactions with endothelial cells, in which the presence of other cells could have 
interfered e.g. by internalising the polymersomes. A second setup in which mouse 
astrocytes or pericytes were cultured on the opposing side of the transwell membrane 
was also utilised in order to more closely mimic the BBB, and to enable investigating 
the fate of polymersomes after transcytosis.
5.2.1. Expression of Brain Endothelium Tight Junction Proteins 
To ensure confluent bEnd.3 monolayers grown in a transwell setting expressed the 
appropriate brain barrier-like properties, immunocytochemistry was performed for tight 
junction markers specific to the blood brain barrier: zonula occludens-1 (ZO-1), 
occludin and claudin-5. Claudin-5 and occludin immunoreactivity was present in 
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confluent bEnd.3 monolayers cultured in a transwell setup, with some claudin-5 
localisation along the plasma membrane (figure 5.2). ZO-1 expression was also 
present, although weaker than occludin and claudin-5 and more localised to the 
cytoplasm. The presence of all three proteins is consistent with a blood brain barrier 
phenotype.
Figure 5.2. Tight junction markers in bEnd.3 grown in transwells. Expression of brain 
endothelial phenotype specific tight junction markers (red) in the cell line bEnd.3 grown in 
transwells as monoculture. Cell nuclei counterstained with Hoescht (blue).
5.2.2. TEER Values of bEnd.3 in Monoculture or Co-culture
Further to tight junction protein expression, trans-endothelial electrical resistance 
(TEER) measurements were measured an indicator of in vitro barrier tightness. TEER 
values of fully confluent bEnd.3 monolayers were assessed for 7 days after seeding, 
shown in figure 5.3. BECs grown as a monoculture started at values of 150 Ω/cm2 on 
day 1, rising to an average of 176±18 Ω/cm2 at day 7 (n=5 wells per n=3 experiments). 
Culturing endothelial cells with pericytes in non-contact co-culture on the basolateral 
membrane side resulted in a rapid increase in TEER values from day 2. At day 7, the 
measured co-culture TEER values were 217±27 Ω/cm2 (n=5 wells per n=3 
experiments), significantly higher than the values obtained from bEnd.3 cells alone 
(student’s independent t-test, *p<0.05). bEnd.3 cells alone had TEER values higher 
than previously reported in literature, indicating these cells show sufficient barrier 
properties when used as a monoculture (Brown, Morris et al. 2007). 
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Figure 5.3. TEER values of bEnd.3 in mono- or co-culture. The addition of pericytes to the 
transwell culture caused a significant increase in barrier tightness at day 7 of co-culture 
compared to bEnd.3 alone. Error bars: S.D., p <0.05. 
5.2.3. bEnd.3 Expression of LRP-1
LRP-1 expression by bEnd.3 cells is essential to probe transcytosis of Angiopep-2. 
Unfortunately, few antibodies against the large (585kDa) ligand-binding extracellular 
domain of LRP-1 are currently commercially available. The expression of LRP-1 was 
thus probed with an antibody against the 85 kDa intracellular domain of the receptor 
(LRP-1ICD). Figure 5.4 shows the expression of LRP-1 in bEnd.3 cells in the absence of 
A-EP as a ligand. Fluorescence is mostly diffuse throughout the cytoplasm, somewhat 
demarcating the elongated shape of the cell in some cases. Nevertheless, it was 
confirmed that bEnd.3 cells express LRP-1.
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Figure 5.4. LRP-1 expression by bEnd.3. Immunofluorescence of LRP-1 (green), nuclei 
stained with DAPI (blue). Scale bar: 10 μm.
5.3. In Vitro Transcytosis of Polymersomes
Having established a cell culture setup expressing a blood brain barrier phenotype with 
the appropriate tight junction markers and TEERs comparable to reports in literature, 
the next step was to investigate polymersome transcytosis across the transwell model.
5.3.1. Polymersome Colocalisation with LRP-1
In order to confirm that Angiopep-2-POEGMA-PDPA polymersomes (A-EP) interact 
with the LRP-1 receptor in brain endothelial cells, immunocytochemistry of LRP-1ICD 
was performed after incubation with A-EP for 10, 60 or 120 minutes. Figure 5.5 shows 
the association of A-EP with LRP-1ICD after 60 minutes.
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Figure 5.5. A-EP uptake by LRP-1 in bEnd.3. LRP-1ICD (green) and A-EP (red) colocalisation 
in bEnd.3 after 60 minutes. Cell nuclei stained with DAPI (blue). Scale bar: 20 μm.
At 60 minutes, the A-EP signal is seen in many different areas of the transwell and is 
observed in cytoplasmic puncta. At higher magnification, many puncta of LRP-1ICD and 
A-EP are visibly colocalising within the cell. This is in contrast to the diffuse LRP-1ICD 
pattern observed in unstimulated bEnd.3 cells. 
To elucidate the extent and time that A-EP associates with LRP-1ICD, red/green 
fluorescence was quantified with Pearson’s correlation coefficient (Rr). After 10 minutes 
of incubation Rr was 0.78 for A-EP and LRP-1ICD colocalisation, and remained high at 
0.75 after 120 minutes (figure 5.6). The continuously high Rr values indicate that A-EP 
remains associated with the intracellular domain of LRP-1 in the intracellular trafficking 
stages of transcytosis.
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Figure 5.6. LRP-1ICD and A-EP colocalisation in bEnd.3 cells over time. Calculated with 
Pearson’s correlation coefficient (Rr) of red/green fluorescence intensity overlap. n=3 
experiments, error bars: S.D.
5.3.2. LRP-1 Transcytosis Ligand Competition Assay
To confirm that Angiopep-POEGMA-PDPA polymersomes are internalised by bEnd.3 
cells via LRP-1-mediated transcytosis, cells positive for polymersomes in the presence 
of transcytosis ligands was quantified via fluorescence activated cell sorting (FACS). 
Lactoferrin is a LRP-1 antagonist (Mantuano, Lam et al. 2013). Poly-L-lysine has been 
reported to inhibit transcytosis of cationic macromolecules, and should not have an 
effect on A-EP transcytosis (Herve, Ghinea et al. 2008). Figure 5.7. shows bEnd.3 
uptake in the presence of transcytosis inhibitors. After 60 minutes, 37±11% of cells 
were positive for A-EP. Uptake of polymersomes in cells incubated in 4C was non-
existent after 60 minutes, confirming that internalisation is an active process. 
Furthermore, incubation with poly-l-lysine yielded 37±2% of cells positive for 
polymersome fluorescence. Incubation with lactoferrin resulted in an uptake of 23±4%. 
Neither of the pharmacological agent treatments significantly inhibited A-EP 
internalisation (one-way ANOVA, p <0.05, n=3). However, this may be due to the larger 
standard deviation obtained for the polymersome control group. Furthermore, it is 
possible that lactoferrin antagonises a different ligand binding domain of LRP-1 than 
the A-EP binding domain.
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Figure 5.7. bEnd.3 internalisation of A-EP after 60 minutes in the presence of transcytosis 
inhibitors. error bars: S.D., one-way ANOVA, p<0.05. 
5.4. Transcytosis Kinetics
5.4.1. Permeability of bEnd.3 Monolayers to Polymersomes
To assess the permeability of bEnd.3 monolayers in transwells and simultaneously 
obtain polymersome flux kinetics, quantification of apical-to-basolateral flux of 
polymersomes was compared to a fluorescently labelled dextran. FITC-Dextran does 
not interact with transcytosis receptors and is frequently used as an indicator of barrier 
tightness in transwell permeability assays (Sanders, Madara et al. 1995). After addition 
of 1 mg of polymersomes or FITC-dextran to the apical compartment, fluorescence 
over time was quantified in the basolateral compartment. Flux behaviour of 
polymersomes in the presence of bEnd.3 monolayers were compared to controls 
without any cells, where apical-to-basolateral transport occurs by gradual diffusion 
through the porous transwell membrane. Furthermore, A-EP flux was compared to non-
targeting POEGMA-PDPA (EP) polymersomes. Polymersome and FITC-dextran apical-
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to-basolateral flux over time is shown in figure 5.8. FITC-dextran fluorescence was 
steadily increasing over time in the no-cell control. This indicates that 70 kDa FITC-
dextran is able to move across the porous membrane provided that it is allowed to 
diffuse freely. In a bEnd.3 monolayer, basolateral fluorescence increase of FITC-
Dextran over time was markedly lower, although not completely absent. The apical-to-
basolateral movement of POEGMA-PDPA polymersomes across bEnd.3 over time was 
higher than that of FITC-Dextran, but lower than any of the free diffusion controls. 
Finally, the pattern of cell-free A-EP diffusion is similar to that of FITC-dextran, but 
increases drastically in the presence of bEnd.3 cells. After 12 hours, the full initial 
apical concentration of A-EP has shifted to the basolateral compartment. This 
behaviour indicates that the bEnd.3 monolayer is not impairing but rather enhancing 
the apical-to-basolateral flux of A-EP polymersomes, strongly reinforcing that A-EP 
crosses bEnd.3 monolayers via active transcellular transportation or transcytosis.
Figure 5.8. Cumulative apical-to-basolateral flux of A-EP or EP over time. Compared to a 
70 kDa FITC-dextran control. n=3, error bars: S.D. 
5.4.2. Kinetics of Polymersome Transcytosis In Vitro
Quantification of fluorescence in basolateral media is useful for assessing monolayer 
permeability, but may give inaccurate results when measuring transcytosis over time as 
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it does not account for reverse (basolateral to apical) transport. To quantify 
polymersome transcytosis over time, media was collected from both compartments 
after incubation with 1 mg/ml polymersomes, and fluorescence was measured at 
different collection time points. Figure 5.9 shows polymersome fluorescence over time 
in the apical and basolateral compartments, and the different experimental conditions 
are depicted in the insets (top right corner). Non-targeting EP does not shift to the 
basolateral compartment, indicating an intact monolayer (figure 5.9a). A-EP 
polymersomes added to filter-only transwells (figure 5.9b) showed a linear and gradual 
decrease in apical compartment fluorescence, with a corresponding basolateral 
increase. This is consistent with passive diffusion of polymersomes through the 
transwell pores into the opposing compartment, with apical-basolateral and basolateral-
apical exchange reaching equilibrium after 24 hours.
By contrast, A-EP polymersomes added to the apical compartment of bEnd.3 
monolayer (figure 5.9c) resulted in the transfer of the majority of A-EP to the 
basolateral side within 60 minutes. This basolateral fluorescence was accompanied by 
a corresponding decrease in fluorescence in the apical compartment. Finally, in a 
transwell setup with astrocytes seeded on the basolateral side of the membrane (figure 
5.9d), the decrease in apical fluorescence corresponding to transcytosis ceased after 3 
hours. However, a corresponding increase in the basolateral compartment was low 
compared to the endothelial-only setup. This is likely due to the endocytosis of 
polymersomes by astrocytes, reducing the polymersomes available in media.  
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Figure 5.9. Polymersome transcytosis kinetics. Fluorescence quantification of polymersome 
transcytosis over time, in the presence or absence of astrocytes.
5.4.3. Visualising Polymersome Location Over Time in Transwells
The transcytosis assay of polymersome fluorescence in media over time is useful for 
examining the kinetics and extent of endothelial cell transcytosis, but does not 
discriminate between fluorescence decrease in either compartment due to 
polymersome presence within cells, or when passively diffusing through the 10 μm 
transwell membrane pores. To complement the transcytosis assay, live cell 3D confocal 
microscopy was used to visualise polymersomes location in the transwell. This method 
of acquiring serial z-stacks allows for visualising the entire length of the transwell filter, 
as well as any cells adhering to the filter. Figure 5.10 shows xyz confocal micrographs 
of the transwell filter reconstructed into 3D projections.
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Figure 5.10. Live 3D imaging of A-EP or EP location in transwells. Confocal z-stack 3D 
projections of A-EP or EP distribution (red) in live bEnd.3 cells. Cell nuclei counter-stained with 
DAPI (blue).
Live cell imaging of A-EP polymersomes at 30 minutes showed polymersomes 
accumulating below the cell nuclei at the filter pore area, indicating that transcytosis 
was already occurring at this stage. A similar distribution of materials seen at the 60 
minute time point. The EP signal was absent at 10 and 30 minutes (not shown) and 
very faintly detected at the cell area at 60 minutes, but not underneath the cells in the 
filter (figure 5.10). 
To confirm that polymersome apical-to-basolateral movement occurs within 60 minutes 
and is the result of transcytosis rather than paracellular movement, incubation times 
were extended and followed by fixation and counter-staining for claudin-5 as a tight 
junction marker. Images acquired in the xy plane on the apical (top) side of the cells are 
shown in figure 5.11 Rapid accumulation of polymersome fluorescence was confirmed, 
peaking at 60 minutes. This fluorescence was very low at the examined xy plane at 3 
and 6 hours. Polymersome fluorescence as observed after 60 minutes was 
predominantly intracellular, strongly indicating that the mechanism by which A-EP 
traverses the transwells is transcytosis as opposed to paracellular leakage due to 
inadequate monolayer barrier properties.
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Figure 5.11. Polymersome transcytosis assessed by confocal microscopy. Confocal 
micrographs of polymersomes (green) in transwells, displayed from the apical side of bEnd.3 
cells. Counterstained for claudin-5 (red) to mark tight junctions. Scale bar: 25 μm.
3D reconstructions of the filter and monolayers are shown in figure 5.12. Here, 
polymersome fluorescence can be seen inside the transwell pores from as early as 10 
minutes and up to the 6 hours examined. This illustrates that the passive diffusion of 
polymersomes across the 10μm pores occurred significantly more slowly than the 
active transportation of polymersomes across brain endothelial cells. Furthermore, the 
method of confocal 3D imaging of the transwell filter area was shown to be a quick 
method for determining whether polymersome location is intracellular or within the filter 
pores.
5.5. Comparison of Polymersome Uptake by Endothelial Cells and Astrocytes
In order to elucidate whether the transient intracellular residence time of A-EP is unique 
to cells capable of transcytosis, intracellular polymersome fluorescence over time was 
compared between bEnd.3 and astrocytes. Figure 5.13 shows A-EP fluorescence after 
0.5-6 hours in bEnd.3 or astrocyte monocultures. A moderate signal from A-EP could 
be observed in endothelial cells at 0.5-1h, after which the polymersomes no longer 
appeared to remain intracellular. By contrast, astrocytes showed modest signs of A-EP 
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endocytosis after 0.5 hours, with the signal intensity becoming marked at 6 hours. This 
indicates an ongoing internalisation of polymersomes by astrocytes, compared to a 
transient intracellular residence time in brain endothelial cells. 
Figure 5.12. 3D projection of polymersome transcytosis. A-EP (red) transwell location over 
time relative to a bEnd.3 monolayer counterstained for claudin-5 (green), acquired in xyz. Scale 
bar: 25 μm.
The A-EP fluorescence intensity was quantified via ImageJ, and normalised to the 
Hoechst signal from nuclei. This quantification further demonstrated the difference 
between bEnd.3 and astrocytes, with fluorescence in the astrocytes increasing over 
time (figure 5.14). Polymersome fluorescence in endothelial cells was overall much 
lower, and decreased over time. 
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Figure 5.13. A-EP fluorescence over time in bEnd.3 and astrocyte monocultures.
Figure 5.14. Polymersome fluorescence in different LRP-1 expressing cells of the CNS. 
Error bars: S.D., student’s independent t-test, p <0.05.
Because the overall internalisation of polymersomes was higher in astrocytes, data 
displayed in figure 5.14 was further normalised to the highest intensity values obtained 
for each group. The general trend of uptake is shown in figure 5.15. From this 
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normalisation it is shown more clearly that A-EP fluorescence in brain endothelial cells 
peaked at 1 hour in contrast to in astrocytes, where maximum internalisation was seen 
at 6 hours.
Figure 5.15. Normalisation of figure 5.14. Results normalised to the highest intensity values 
obtained for each group. Error bars: S.E.M.
5.6. Real Time 4D Confocal Imaging of Transcytosis at the Macroscale
To examine the timescale of apical to basolateral polymersome transcytosis as it 
occurs in real time, live four-dimensional (xyz, t) confocal videos were acquired of the 
transwell filter area in transwells with or without endothelial cells. Videos were captured 
with a 10X objective in order to observe transcytosis of a high concentration of 
polymersomes applied to the apical transwell compartment, observing the ‘macroscale' 
transcytosis of a population of polymersomes. Z-stacks were acquired in resonant 
imaging mode on a millisecond resolution, effectively providing real time z-stack 
imaging or 4D imaging. Snapshots from the video can be seen in figure 5.16a, where 
polymersome fluorescence is visible on the basolateral side of the monolayer at the 
snapshot taken at 8 minutes. To obtain a more precise view of polymersome 
fluorescence in the transwell area, fluorescence intensity of A-EP in the z plane 
(corresponding to transwell filter depth) over time was converted into a heat map as 
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shown in figure 5.16b. Red corresponds to higher intensities and green to lower. 
Polymersome movement was slow in the control filter without cells, indicative of 
passive diffusion. Here, the majority of fluorescence remained within the transwell 
membrane itself or slightly beneath it after 30 minutes. In the bEnd.3 monolayer 
transwell, fluorescence had shifted from above the membrane to below it by 20 
minutes. Fluorescence can be observed below the membrane in less than a few 
minutes from the start of the video, showing rapid transcytosis. Overall, polymersomes 
moved across the porous membrane faster in the presence of a bEnd.3 monolayer 
compared to the cell-free control, and also further away from the membrane in the 
same incubation time.
5.7. Transcytosis Efficiency of A-EP and Free Angiopep-2
To investigate whether transcytosis of Angiopep-2-POEGMA-PDPA occurs at rates 
comparable to the Angiopep-2 peptide alone, the intracellular fluorescence of A-EP 
(final concentration of Angiopep-2 in polymersomes: 1.75 pM) or free Angiopep-2 (1.75 
pM) was compared over time in bEnd.3. Figure 5.17 shows fluorescence quantified 
from confocal images obtained after 10 or 60 minutes of incubation with either the 
peptide or polymersomes. Angiopep-2 fluorescence was low at 10 minutes, but had 
doubled after 60 minutes. Conversely, A-EP fluorescence started relatively high at 10 
minutes and had decreased after 60 minutes. This indicates that transcytosis of 
Angiopep-2 is much slower than A-EP transcytosis. The decrease in A-EP fluorescence 
from 10 to 60 minutes indicates that ‘net’ endocytosis has already stopped and shifted 
to net exocytosis. Overall, it can be concluded that A-EP transcytosis is more efficient 
than the peptide alone.
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Figure 5.16. Real-time 4D confocal imaging of transcytosis. a) Snapshots from the video 
acquired from live cell confocal 4D imaging. b) Heat map of polymersome location in the 
extended transwell area over time, obtained through real time 4D imaging.
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Figure 5.17. Intracellular fluorescence of A-EP compared to free Angiopep-2. Error bars: 
S.E.M., n=3, student’s independent t-test, p <0.05.
Co-incubation with polymersomes and free peptide provides an indirect way to 
understand whether transcytosis is more efficient of Angiopep-2 alone or when 
attached to polymersomes. Representative confocal images obtained at 10 and 60 
minutes are displayed in figure 5.18, showing an overlap between free peptide and 
polymersomes. 
Quantification of fluorescence of the Angiopep-2 and A-EP channels is shown in figure 
5.19, alongside that obtained from incubating peptide or polymersomes only (figure 
5.17) for comparison. After 10 minutes of co-incubation, A-EP fluorescence is of similar 
intensity as Angiopep-2, and much lower than that of A-EP after 10 minutes with no 
competing ligand. The free peptide fluorescence remains similar to levels without 
competition. On the contrary, A-EP fluorescence at 10 minutes has decreased 
drastically when co-incubated with free peptide than without competition. This shows 
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that Angiopep-2 and A-EP compete for LRP-1 binding and endocytosis, which is 
expected, but also that the free peptide is more likely to inhibit polymersome 
internalisation than vice versa at 10 minutes. When co-incubated, the intensity of A-EP 
and Angiopep-2 are both markedly higher at 60 minutes compared to when they are 
added without competition. However, competing A-EP shows a biphasic shift in 
behaviour compared to the A-EP only control: decreased endocytosis at 10 minutes, 
and increased intracellular residence i.e. decreased exocytosis at 60 minutes. The 
biased inhibition of A-EP transcytosis rather than Angiopep-2 may be due to a more 
rapid or efficient endocytosis, intracellular trafficking and exocytosis pathway occurring 
for A-EP than for Angiopep-2.
Figure 5.18. Confocal images of A-EP and Angiopep-2 co-incubated in bEnd.3.
The biased enhanced transcytosis of A-EP compared to Angiopep-2 cannot be due to 
differences in a concentration-dependent response as the same molarity of Angiopep-2 
(1.75 pM) was used between the peptide and in polymersomes. Other factors must be 
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modulating transcytosis efficiency, such as the density of Angiopep-2 in the polymer 
brush.
Figure 5.19. Quantification of Angiopep-2 and A-EP fluorescence when co-
incubated. Comparison of intracellular fluorescence intensity in bEnd.3 of Angiopep-2 
unconjugated or when attached to polymersomes. n=3, error bars: S.E.M, student’s 
independent t-test, *p<0.05.
5.8. Improving Transcytosis Efficiency by Tuning Angiopep-2 Ligand Density 
Ligand-receptor interactions (and subsequent receptor-mediated internalisation) are 
determined by a number of factors, including ligand density. Work by Tsourkas et al. 
demonstrated an intermediate optimal ligand density for cell-targeting nanoparticles 
(Elias, Poloukhtine et al. 2013). Similarly, the number of OX26 antibodies per 
immunoliposome was determined to be around 30 to achieve optimal CNS delivery via 
the transferrin receptor (Huwyler, Wu et al. 1996). The number of Angiopep-2 ligands 
per POEGMA-PDPA polymersome were thus calculated, and the transcytosis 
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efficiencies of polymersomes with increasing ligand densities were determined in a 
transcytosis assay.
5.8.1. Calculations of Number of Angiopep-2 Ligands per Polymersome
Through calculating the number of polymers in the membrane (Nagg) of a POEGMA-
PDPA vesicle of the radius r, it is possible to derive the number of Angiopep-2 ligands 
(NLigand) per polymersome. For Methodology and full calculations, refer to section 3.10 
of chapter 3. For an average 80nm vesicle of POEGMA25-PDPA114 as used in this 
project, the number of Angiopep-2 peptides per vesicle are given in table 5.1:
Table 5.1. Calculations of NLigand with increasing molarity of A-EP.
5.8.2. Transcytosis Efficiency as a Function of NLigand
Measuring the apical and basolateral concentrations of a ligand over time provides an 
estimate of the transcytosis efficiency, i.e. the percentage of total ligand present in the 
basolateral compartment after a given incubation time. The transcytosis efficiency of 
polymersomes as a function of number of Angiopep-2 ligands was quantified in a 
transwell assay. Figure 5.20 shows transcytosis efficiency of A-EP polymersomes after 
60 minutes as a function of increasing Angiopep-2 in the polymer brush (denoted A-EPx 
for number of Angiopep-2 ligands). POEGMA-PDPA polymersomes without Angiopep-2 
Molar % of Angiopep-2-
POEGMA-PDPA
NLigand per 80nm vesicle
0 0
1 13
2 26
3 40
4 53
5 66
6 79
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did not migrate to the basolateral compartment, whilst A-EP13 had a transcytosis 
efficiency of 72±8% (n=3) of total polymersome fluorescence intensity present in the 
basolateral compartment. Increasing ligand density to 26 caused the highest 
transcytosis efficiency of 93±6% (n=3) after 60 minutes. Values rapidly declined at the 
use of Angiopep-2 above A-EP26, with a slight increasing trend from A-EP40 to A-EP79. 
Overall, these results are consistent with the hypothesis that ligand density is optimal 
for cell uptake in an intermediate range, with 26 Angiopep-2 per 80nm polymersome 
inducing the highest amount of transcytosis at 60 minutes.
Figure 5.20. Transcytosis efficiency after 60 minutes as a function of Angiopep-2 ligand 
functionalisation. 0 is POEGMA-PDPA without Angiopep-2. Statistical analysis: ordinary one-
way ANOVA. Error bars: S.E.M. *p <0.05.
A caveat of measuring transcytosis efficiency as the apical-to-basolateral transfer of 
materials over time is the bilateral expression of LRP-1 at the apical and basolateral 
BEC plasma membrane. In order to account for the potential basolateral-to-apical 
transcytosis of Angiopep-2-POEGMA-PDPA, the transwell assay was repeated to 
explore whether the transcytosis trends observed change over time. Polymersome 
fluorescence in the basolateral compartment measured over 24 hours is displayed in 
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figure 5.21. In addition to displaying the highest transcytosis efficiency after 60 minutes 
(figure 5.20), A-EP26 also showed depletion from the basolateral compartment at later 
times, indicating polymersomes have shifted either to the transwell pores or recycled to 
the apical compartment. A-EP13-53 formulations all showed a decreasing presence in 
the basolateral compartment over time, indicating recycling to the apical compartment. 
This effect was not observed in A-EP66 to A-EP79, where transcytosis has plateaued 
after 6 hours in both cases. This effect persisted at 24 hours, which may be due to 
complete bilateral saturation of LRP-1.
Figure 5.21. Transcytosis over 24 hours as a function of NLigand. n=3, error bar: S.E.M.
5.9. Discussion 
The bEnd.3 in vitro blood-brain barrier model used herein provided some blood-brain 
barrier characteristics sufficient for experiments elucidating simplistic interactions 
between Angiopep-2-polymersomes and endothelial cells. The model expressed the 
correct set of tight junction protein markers, but had a lower immunoreactivity than 
expected with some protein expression also seen in the cytoplasm as opposed to along 
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the plasma membrane. However, TEER values were higher than reported in literature 
for bEnd.3 cells. The absence of transcytosis of non-targeting POEGMA-PDPA further 
reinforces a restrictive monolayer. The addition of pericytes raised the average TEER 
values, indicating an enhancement of the BBB phenotype. However, there is still a 
large gap between in vitro and in vivo TEER values, and the low amount of FITC-
dextran as well as POEGMA-PDPA diffusion in the permeability assay seems to 
indicate a low amount of paracellular leakage. Overall, although the bEnd.3 BBB model 
has shortcomings, it is in this case an adequate model to use for probing transcytosis.
An advantage of using an in vitro model is the methods available to probe cell-
polymersome interactions, such as 4D confocal resonant imaging where z-stacks of the 
transwell filter membrane can be obtained on a millisecond scale. The real time 
imaging of polymersome movement through a cell-free or BEC transwell illuminated the 
drastic difference in speed between active transportation and random diffusion of 
polymersomes across the filter pores. This finding was supported by other kinetics 
experiments, such as the transwell assays with FITC-dextran as a control. It is unclear 
why fluorescence intensity increases rapidly underneath the filter, as polymersome 
access across the filter is limited by diffusion. The relatively high intensity underneath 
the filter in the heatmap may be an artifact of the normalisation calculations by the 
confocal software. Nevertheless, A-EP increase within the z stacks corresponding to 
the cells showed a trend of increased movement across the bEnd.3 monolayer 
compared to the cell-free control. This is consistent with the idea that transcytosis is a 
rapid process and contrasts passive diffusion.
The low availability of antibodies to the extracellular domain of LRP-1 complicates 
assessing the interaction of the ligand binding domains to polymersomes. In an 
unstimulated state, antibody immunofluorescence against the intracellular domain of 
the antibody is diffuse within the cytoplasm. However, when bEnd.3 were incubated 
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with A-EP, the distribution of LRP-1ICD became punctate and heavily based around the 
plasma membrane. It is highly likely that the intracellular domain of LRP-1 contains the 
spatial cue to transcytosis. Indeed, when LRP-1 is internalised the extracellular domain 
is shed into the extracellular space. Further work is required to obtain the receptor 
recycling rates, and to elucidate the relative contributions of domains to transcytosis.
Variation of Angiopep-2 density showed a bell-shaped distribution of transcytosis 
efficiencies. The ability to control ligand density confers a huge advantage when 
adjusting targeting to in vivo. Increasing the amount of targeting peptide does not 
equate to a higher transcytosis rate and may result in vastly different ligand-receptor 
interactions compared to lower ligand density. 
Importantly, the kinetics of A-EP internalisation by bEnd.3 cells differ from that of non-
transcytosing cells, i.e. astrocytes in this case. Uptake by endothelial cells displayed a 
much lower fluorescence compared to astrocytes. Furthermore, endothelial cell 
fluorescence peaked at 30-60 minutes and was nearly absent at 3-6 hours, whereas 
astrocyte fluorescence gradually increased over time. This difference highlights the 
differential internalisation behaviour by astrocytes and endothelial cells, with 
endocytosis by astrocytes being a significantly slower process than transcytosis. 
Work within this section has utilised a 3D model of brain endothelial cells to confirm 
that transcytosis of Angiopep-POEGMA-PDPA polymersomes is mediated by LRP-1 
and that it occurs within 10-15 minutes on the macroscale, as evidenced by 
polymersome fluorescence in the transwell filter pores. A-EP remained associated with 
LRP-1 for longer periods of time, which may be due to LRP-1 remaining at the 
opposing plasma membrane. Future work should examine LRP-1 receptor recycling 
rate to obtain a clearer view of the bidirectional transcytosis occurring at the BBB, and 
its effect of net cargo movement. 
 149
Chapter 6
Chapter 6.
RESULTS AND DISCUSSION III
Elucidating Blood Brain Barrier Transcytosis 
Mechanisms
_____________________________________________________________________
6.1. Introduction
Work presented in this section was undertaken with the aim to advance understanding 
of the cellular processes mediating transcytosis in brain endothelial cells. A 
combination of qualitative and quantitative confocal microscopy was used in 
conjunction with antibodies or small molecule inhibitors against proteins of interest. 
Here Angiopep-2-conjugated polymersomes had a dual role: contributing to the general 
understanding of how transcytosis works at the blood brain barrier, but also more 
specifically how A-EP polymersomes might traverse the barrier for drug delivery. 
Knowledge of the latter is useful for bridging the gap into clinical translation.
6.1.1. Small Molecule Modulators of Endocytosis
There are a number of pharmacological small molecule drugs available which inhibit 
specific protein mediators of endocytosis. These can be applied to explore 
mechanisms of transcytosis. A frequently used method to investigate the role of a 
protein is to genetically modify the cell to overexpress or underexpress the gene 
encoding the protein of interest. However, attempts to transfect brain endothelial cells 
often result in the recession of barrier-like properties and cellular stress (Zhang, Mitin et 
al. 2009, Abbott 2016). On the other hand, small molecule inhibitors are more practical 
to use as they immediately cause inhibition, allowing the short-term use before the 
onset of detrimental effects. Therefore, small molecule inhibitors are more convenient 
than genetic modification of the target.  
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6.2. Role of Caveolae in Transcytosis
Ultrastructural studies alone are insufficient to identify the nature of intracellular 
vesicles carrying cargo in transcytosis. Because caveolae are frequently implicated as 
the ‘primary’ mediators of transcytosis in pulmonary microvasculature, the 
colocalisation of polymersomes with caveolar protein caveolin-1 was examined in 
bEnd.3. In an unstimulated state, caveolin expression can be seen at the plasma 
membrane along the cells (figure  6.1).
Figure 6.1. Expression of caveolin-1 by bEnd.3 cells. Cav-1 (green), DAPI (blue): nuclei. 
Next, A-EP polymersome fluorescence was tracked in brain endothelial cells, obtaining 
colocalisation profiles with caveolin-1. Partial overlap was observed initially at 10 
minutes of incubation as visualised from on top of the cells (figure 6.2). However, 3D z-
stack projections (figure 6.3) show no apparent colocalisation at 10 minutes, and 
furthermore the appearance of A-EP in pores at this time. A few cytoplasmic puncta 
with fluorescence overlap were observed at 60 minutes (figure 6.4). However, 
Pearson’s correlation coefficient were low at 0.2±0.11 (n=3) and -0.02±0.04 (n=3), at 10 
and 60 minutes respectively (figure 6.5). Overall, these findings fail to show a role 
caveolae as essential structures for apical to basolateral transcytosis, particularly as a 
higher colocalisation would have been expected at around 10 minutes when the 
majority of transcytosis is occurring.
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Figure 6.2. Polymersome colocalisation with Cav-1 after 10 minutes. A-EP (red) 10 minutes 
after addition to bEnd.3 cells, counterstained for caveolin-1 (green) and nuclei (blue).
Figure 6.3. 3D projection of caveolin-1 and A-EP location in bEnd.3 cells after 10 minutes. 
Cav1 (green) and A-EP (red).
Figure 6.4. A-EP colocalisation with cav-1 after 60 minutes in bEnd.3. A-EP (red), cav-1 
(green) and DAPI (blue). Areas of colocalisation are highlighted in red circles.
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Figure 6.5. Quantification of colocalisation of caveolin-1 and A-EP polymersomes. n=3, 
error bars: s.d.
6.3. Disruption of Membrane Lipid Rafts with Methyl-β-Cyclodextrin
Caveolae are dependent on cholesterol-enriched lipid rafts in the plasma membrane, 
and depletion of cholesterol with agents such as methyl-β-cyclodextrin (CD) causes the 
disruption of caveolae (Le and Nabi 2003). However, depletion of cholesterol also 
inhibits formation of clathrin-coated structures (Rodal, Skretting et al. 1999). If 
extraction of cholesterol from the bEnd.3 plasma membrane causes inhibition of 
transcytosis in addition to disappearance of Cav-1 immunoreactivity, it could indicate 
that caveolae mediate transcytosis of A-EP. CD was used to deplete cholesterol from 
either the apical or basolateral plasma membrane by adding the agent to the apical or 
basolateral compartment of the transwell. TEER values were assessed in order to 
ensure that tight junction integrity and monolayer tightness remained intact after 
treatment, and showed no significant difference after treatment on either polarity of 
plasma membrane as shown in figure 6.6. Next, amount of cholesterol shed into the 
cell media was quantified via a fluorescence assay. This was done in serum free cell 
media in order to avoid false positives by cholesterol from FBS-supplemented media. 
Addition of CD to the basolateral transwell compartment caused a 4-fold increase in 
free cholesterol in basolateral media, as well as a 2-fold increase in free cholesterol 
into the apical media (figure 6.7). These effects were different when CD was added to 
 153
10 60
0.0
0.2
0.4
0.6
0.8
1.0
Time (min)
A
-E
P
 / 
C
av
-1
 c
ol
oc
. (
R
r)
Colocalisation of Angiopep-POEGMA-PDPA 
and caveolin-1
Chapter 6
the apical side of the cells, resulting in a less than 2-fold increase in cholesterol into the 
apical media and approximately 3.5-fold increase into the basolateral media. In both 
cases cholesterol depletion was more efficient in the basolateral plasma membrane. 
Figure 6.6. TEER values of a bEnd.3 monolayer before and after CD treatment. Student’s 
independent t-test, p<0.05, n=5.
Figure 6.7. Cholesterol release into media after depletion from the plasma membrane by 
CD. Student’s independent t-test, p<0.05, n=5.
Next, cells depleted of cholesterol either in the apical or basolateral plasma membrane 
were incubated with A-EP polymersomes for 60 minutes, fixed and counter-stained for 
cav-1. Surprisingly, cells stained positive for caveolin-1 even after disruption of 
caveolae by cholesterol depletion, with the protein appearing uniformly distributed 
along the entire plasma membrane (figure 6.8. Many cells positive for polymersomes 
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had assumed a different morphology to control cells, rounding up towards the centre 
rather than their normal thin elongated shapes. Overall, the cells were larger and 
several showed signs of blebbing, regardless of which side CD was added to. 
However, because the TEER values were at control levels after one hour of CD 
incubation, cells were still viable. Strikingly, the polymersome signal reached near 
saturation in many cells when CD was added to the basolateral side. This effect was 
not seen when CD was added at the apical side, consistent with the higher amount of 
cholesterol depletion in the basolateral membrane as quantified by the cholesterol 
quantitation assay. When CD was added to the basolateral compartment, many cells 
were completely saturated with polymersomes.
Figure 6.8. Confocal images of A-EP in cholesterol depleted bEnd.3. Intracellular location of 
A-EP (red) in basolateral membrane cholesterol-depleted bEnd.3 cells counterstained for 
caveolin-1 (green). Scale bar: 5 μm.
 155
Before treatment After treatment
0
50
100
150
200
250
TE
ER
 (
/c
m
2)
n.s.n.s.
- CD (control)
+CD apical compartment
+CD basolateral compartment
Ap
ica
l
Ba
so
lat
era
l
Ap
ica
l
Ba
so
lat
era
l
Ap
ica
l
Ba
so
lat
era
l
0
1
2
3
4
Fr
ee
 c
ho
le
st
er
ol
  (
ng
/m
l)
Apical Basolateral
0
2
4
6
F
ol
d 
in
cr
ea
se
 in
 
fre
e 
ch
ol
es
te
ro
l
* ****
* **
+C
D
 B
L 
A-EP Cav-1 Merge 
C
O
N
TR
O
L 
+C
D
 A
 
a
b
c d
Chapter 6
Figure 6.9 shows another image obtained after basolateral plasma membrane 
cholesterol depletion, counter-stained for caveolin-1. Interestingly, the cells positive for 
polymersomes have a high degree of colocalisation between caveolae and A-EP. This 
is markedly enhanced compared to control cells, where caveolin-1 and A-EP hardly 
colocalise (figures 6.2, 6.4).
Figure 6.9. bEnd.3 swelling with polymersomes after cholesterol depletion. Cav-1 (green) 
and A-EP (red) in bEnd.3 depleted of cholesterol on the basolateral side.
In summary, depletion of cholesterol from the basolateral but not apical plasma 
membrane resulted in cells maintaining their ability to internalise A-EP polymersomes, 
but unable to exocytose materials. As a result cells positive for polymersomes swelled 
up drastically. These data suggest that cholesterol is required for exocytosis but not 
endocytosis of A-EP.
6.4. Role of Clathrin
Because data indicated that caveolae are not involved in A-EP transcytosis, the 
colocalisation of clathrin with A-EP was investigated. High magnification confocal 
images were obtained of A-EP in bEnd.3 cells with an antibody against the heavy chain 
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of clathrin, counterstained with phalloidin to visualise the cytoskeleton. A-EP 
fluorescence after 60 minutes is closely associated with clathrin (figure 6.10). Every A-
EP puncta appears associated with a heavy chain of clathrin. However, this data is 
qualitative and is thus only an indication that clathrin is involved in the transcytosis of A-
EP. 
Figure 6.10. A-EP association with clathrin after 60 minutes. A-EP (red), phalloidin (cyan) 
and clathrin heavy chain (green).
6.5. Role of Actin in Transcytosis
Transcytosis assays combined with 3D confocal microscopy consistently indicated the 
appearance of A-EP inside the filter pores within 10 minutes after the start of 
incubation. Cytoskeletal motor proteins can quickly transport cargo from one side of a 
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cell to another, and were therefore of particular interest for their potential involvement in 
transcytosis. A study reported the caveolae-dependent endocytosis of the virus SV40 to 
occur through caveolar recruitment of actin and dynamin, causing temporary 
destabilisation of the actin stress fibres and formation of actin ‘tails’ (Pelkmans, 
Puntener et al. 2002). Subsequently, the role of actin in brain endothelial cell 
transcytosis was investigated.
The organisation of the actin cytoskeleton in a bEnd.3 monolayer is shown in figure 
6.11. The image was acquired close to the bottom of the cells where they attach to the 
filter, and stress fibres are pronounced.
Figure 6.11. Actin cytoskeleton of bEnd.3. Phalloidin (green), nuclei: DAPI.
The organisation of the actin cytoskeleton was investigated in fixed bEnd.3 incubated 
with Cy5-labelled A-EP, stained with phalloidin-488 for F-actin. After five minutes there 
was a large overlap in fluorescence from the phalloidin and A-EP. The red/green 
correlation coefficient was quantified at 10, 30 and 60 minutes of incubation (figure 
6.12). Confocal images of A-EP in bEnd.3 counter-stained for phalloidin are displayed 
in figure 6.13, with a magnification of an area of interest (arrow).
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Figure 6.12. Correlation coefficient values of phalloidin and A-EP. n=3, error bars: s.d., 
student’s independent t-test, p<0.05.
Figure 6.13. Phalloidin and A-EP fluorescence in bEnd.3 cells over time. Some 
polymersome clusters are indicated (ellipses).
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From this experiment actin appears to have a role in transporting polymersomes from 
the apical to basolateral membrane within the first few minutes of endocytosis. The loss 
of colocalisation between actin and A-EP has occurred already at 30 minutes, but is 
pronounced after 60 minutes. However, the loss of colocalisation is independent of the 
vastly decreased concentration of polymersomes at 30 and 60 minutes. Future 
experiments should ideally utilise actin inhibitors to observe whether A-EP transcytosis 
inhibited. However, such inhibitors are often highly toxic to cells.
6.6. Role of Dynamin in Transcytosis
Both caveolar and clathrin-mediated endocytosis requires dynamin GTPase for the 
scission of an elongated membrane neck into a discrete intracellular vesicle. Therefore 
regardless of what kind of coat the vesicle bears, inhibition of dynamin should impair 
exocytosis of polymersomes. The role of dynamin in transcytosis was investigated 
using Dynasore, a cell permeable small molecule inhibitor of dynamin (Macia, Ehrlich 
et al. 2006). Cells were pre-incubated with Dynasore for 30 minutes before adding A-
EP onto the monolayer and performing confocal live cell z-stack imaging. Pre-
incubation with Dynasore caused polymersomes to form large aggregates on top of the 
cells (figure 6.14). A reconstructed z-stack shows the faint presence of A-EP 
underneath the monolayer, but with the majority of polymersomes closely associated 
with the cell surface. The inhibition of endocytosis was reversible, as addition of A-EP 
after washing out the Dynasore resulted in a higher fluorescence in the filter pores. The 
fluorescence intensity across all acquired z-stacks was quantified, and is displayed in 
figure 6.15 as a function of distance from the pores. This strongly indicates that 
dynamin is required for internalisation of A-EP in transcytosis.
 160
Chapter 6
Figure 6.14. Treatment with dynasore inhibits internalisation and transcytosis of A-EP 
polymersomes. Confocal micrographs of live cells before and after Dynasore treatment.
Figure 6.15. Quantification of polymersome z-stack fluorescence before and after 
treatment with Dynasore. 0 marks the beginning of pores, negative values above the filter and 
positive values within the filter. n=3, error bars: S.D.
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6.7. Intracellular Transport
Clathrin-mediated endocytosis is the most common endocytosis to occur, resulting in 
intracellular cargo sorting through a series of endosomal compartments increasingly 
acidic in pH (McMahon and Boucrot 2011). Endosomes at different stages of this 
pathway have their own distinct protein and lipid composition, and can be distinguished 
as such. The intracellular fate of A-EP polymersomes was probed by using antibodies 
against different Rab GTPases marking certain stages of the endosomal pathway: 
Rab5 for early endosomes, Rab7 for early/late endosomes, Rab11 for recycling 
endosomes, and lysosomal associated membrane protein 1 (LAMP1) for lysosomes. 
Incubation times of 15, 60 and 120 minutes were chosen in order to account for the 
long times intracellular sorting can take (Canton and Battaglia 2012). Consistent with 
the hypothesis of a different non-endosomal pathway operating in brain endothelial cell 
transcytosis, no colocalisation was observed between A-EP polymersomes and any of 
the endo/lysosomal markers at any of the times examined (figure 6.16). In order to 
ensure that the lack of colocalisation was not because the A-EP signal was relatively 
low, z-stacks were acquired of the entire transwell membrane after 15 minutes of 
incubation and constructed into 3D projections (figure 6.17). The majority of 
polymersomes were present in the transwell membrane pores at this time in addition to 
minor intracellular presence, indicating that transcytosis of the majority of the material 
had already occurred at this time. Quantification with Pearson’s correlation coefficient 
was trending towards negative, (figure 6.18) i.e. polymersomes were excluded from the 
Rab-positive compartments. In summary, A-EP transcytosis does not seem to involve 
the ‘traditional’ intracellular sorting through acidifying endosomal compartments.
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Figure 6.16. A-EP does not associate with common endosomal organelles. Colocalisation 
of A-EP polymersomes (red) with markers of endosomal and lysosomal pathways (green). Scale 
bar: 10 μm.
Figure 6.17. 3D projections of A-EP and endosomal markers in the transwell after 15 
minutes. A-EP (red), counterstained for endo/lysosomal markers (green) and DAPI for cell 
nuclei (blue). Scale bar is 5 μm in the xy and yz direction.
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Figure 6.18. Quantification of A-EP colocalisation with endosomal markers. Rr, Pearson’s 
correlation coefficient.
6.7.1. Fate of IgG-Alexa488 in Polymersomes Crossing the BBB In Vitro
Exclusion of trafficking via acidifying organelles is particularly important to transcytosis 
of A-EP because of the pH sensitive property of the PDPA polymer block, causing 
disassembly at a pH below ~6.4. To confirm that polymersomes do not disassemble 
during transcytosis, fluorescent IgG-Alexa488 was encapsulated as cargo into A-EP via 
electroporation. Figure 6.19 shows confocal micrographs of A-EP with IgG-Alexa488 in 
live bEnd.3 (a) or astrocytes (c) after 60 minutes. A 3D rendering of A-EP colocalisation 
with IgG is shown in figure 6.19b, where cargo fluorescence had the same morphology 
and size as the polymersomes. On the contrary, in astrocytes the IgG-Alexa488 signal 
(figure 6.19c) had dispersed from A-EP. The correlation coefficient (Rr) given in figure 
6.20 was 0.74±0.09 in bEnd.3 and 0.23±0.09 in astrocytes (n=3, S.D.). These data 
show that A-EP is transcytosed by endothelial cells in a non-acidifying pathway, 
retaining integrity to carry cargo from one side of the cell to the other. In contrast, in 
astrocytes A-EP undergoes endocytosis and reaches the acidic pH to cause 
polymersome disassembly, releasing cargo.
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Figure 6.19. Confocal tracking of fluorescently labelled cargo in bEnd.3 or astrocytes. A-
EP (red) colocalisation with encapsulated IgG-Alexa488 (green) after 60 minutes. Cells are 
counterstained for nuclei with DAPI (blue) and plasma membrane marker CellMask (cyan). Rr: 
Pearson’s correlation coefficient. N, nucleus, M, membrane. Scale bar: 15 μm.
Figure 6.20. Correlation coefficient of A-EP and IgG-Alexa488 in bEnd.3 or astrocytes 
after 60 minutes. n=3, student’s independent t-test, p<0.05. Error bars: S.D.
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6.8. Exocytosis: Role of the SNARE Complex
Next, the role of cellular machinery involved in exocytosis was examined. N-
ethylmaleimide soluble factor (NSF) is a SNARE complex component with known roles 
in pulmonary endothelial cell transcytosis (Predescu, Predescu et al. 2001). N-
ethylmaleimide (NEM) is a small molecule inhibitor for NSF (Söllner, Whiteheart et al. 
1993). It was hypothesised that inhibition with NEM would cause inhibition of 
exocytosis but not endocytosis, making cells swell up in a morphology similar to that 
observed when depleting cholesterol from the basolateral plasma membrane (figure 
6.9). 3D live confocal imaging of A-EP transcytosis was performed in cells pre-
incubated with NEM (figure 6.21), counter-stained with CellMask to visualise the 
plasma membrane. NEM caused the complete inhibition of transcytosis, with 
polymersomes remaining on top of the cells unable to enter. To get a quantitative 
understanding of polymersome location in the transwell filter, polymersome 
fluorescence intensity was obtained for every z-slice obtained of the extended transwell 
filter. Fluorescence underneath the cells was negligible after NEM treatment (figure 
6.22), further indicating that no transcytosis was occurring.
Figure 6.21. N-ethylmaleimide effect on transcytosis of A-EP in bEnd.3. Live cell confocal 
imaging of A-EP (red) with IgG-Alexa488 (green), cell membranes stained with CellMask (cyan) 
Scale bar: 5 μm.
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Figure 6.22. Quantification of polymersome fluorescence in NEM treated cells versus 
control. 0 marks the beginning of pores, negative values above the filter and positive values 
within the filter. n=3, error bars: S.D. Control shared with figure 6.15.
6.9. Ultrastructural Studies of Transcytosis in bEnd.3 Cells
Finally, electron microscopy was applied to investigate the transcytosis of A-EP through 
bEnd.3 cells. In order to do so, IgG labelled with 6nm gold nanoparticles (AuNPs) were 
used as an electron dense contrast agent encapsulated into A-EP via electroporation. 
For the morphology and size distributions of A-EP with AuNPs as assessed by DLS 
and TEM, refer to section 4.6.1 of chapter 4.
bEnd.3 monolayers on transwell filters were incubated with AuNP-loaded A-EP for 60 
minutes before fixation and processing for sectioning. Single section micrographs of 
cells 1 hour after incubation are displayed in figures 6.23 and 6.24. In both of these 
figures several electron dense clusters corresponding well to the size of A-EP (96±19 
nm, n=9) are present in the cytoplasm, as marked.  Note the close proximity of these 
clusters to each other at the bottom of figure 6.23. The clustering of polymersomes to 
certain parts of the cell is consistent with the formation of channels or pores to facilitate 
rapid transcytosis. Furthermore, a putative tubular structure is indicated in figure 6.24 
and can be seen better in the contrast enhanced magnification in figure 6.25. Similarly, 
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in figure 6.26 a series of apparently closed vesicles align into a straight line. These 
ultrastructural studies indicate that transcytosis of A-EP may occur through the 
alignment of intracellular vesicles into ‘tubular’ networks. However, these sections are 
two-dimensional, and proof of elusive transendothelial channels cannot be given 
without reconstructions of electron micrographs obtained in successive serial sections.
Figure 6.23. AuNP clusters (circled) in bEnd.3 after 60 minutes.
Figure 6.24. An indicated putative transendothelial channel. AuNP clusters 
in bEnd.3 cells after 60 minutes (ellipse).
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Figure 6.25. Magnification of the marked area of figure 6.24. Contrast enhanced to better 
illustrate the channel.
Figure 6.26. A series of aligned intracellular vesicles. bEnd.3 cells, incubated with AuNP-
loaded polymersomes for 60 minutes.
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6.10. Discussion and Proposed Mechanism
Little is known about how receptor-mediated transcytosis occurs at the brain 
endothelium. In this section, a 3D model of brain endothelial cells was used to track the 
fate of fluorescently labelled Angiopep-2-POEGMA-PDPA during the different stages of 
LRP-1-mediated transcytosis. Discussion regarding LRP-1 binding and clustering 
events can be found in chapter 5. Actin and dynamin appeared to be a conserved 
mechanism of initiating internalisation, consistent with reports of an essential role for 
dynamin in transcytosis in pulmonary endothelial cells (Predescu, Predescu et al. 
2001). The initial colocalisation of actin with A-EP is consistent with a role of actin in 
apical-to-basolateral transfer: addition of the actin disrupting agent Cytochalasin D 
impaired internalisation from the apical but not basolateral plasma membrane in 
polarised epithelial cell lines MDCK and Caco-2 (Gottlieb, Ivanov et al. 1993, Jackman, 
Shurety et al. 1994). 
Previous work investigating transcytosis in endothelial cells have frequently implicated 
caveolae as the main vesicular structures mediating transcytosis. However, the 
majority of these studies have been performed in endothelial cells of other origins than 
the brain microvasculature. Brain endothelial cells are known to express a different 
phenotype to peripheral cells, including a much lower density of vesicles in the 
membrane (Coomber and Stewart 1985). Immunoreactivity of caveolin-1 in bEnd.3 was 
mostly localised along the plasma membrane, but some cytoplasmic staining was also 
observed. These findings are surprising considering that caveolae are relatively rare 
structures in brain endothelial cells compared to peripheral endothelial cells, but may 
be due to the bEnd.3 model not achieving a full degree of BBB differentiation as shown 
by the tight junction markers. Nevertheless, confocal tracking of LRP-1 targeting A-EP 
polymersomes showed poor colocalisation with caveolin-1, reinforcing the hypothesis 
of differential roles for caveolae in peripheral and brain endothelial cells. Caveolin-1 
immunofluorescence increased upon removal of cholesterol from the membrane, which 
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would explain the sudden colocalisation between caveolin-1 and A-EP. Furthermore, 
the depletion of cholesterol from the apical membrane did not inhibit transcytosis. This 
indicates that caveolae do not mediate transcytosis, as the removal of these 
cholesterol-dependent structures from the apical membrane should have inhibited 
transcytosis. On the other hand, some colocalisation between A-EP and the heavy 
chain of clathrin was observed. Nevertheless, no definite answer has been obtained 
regarding the nature of the vesicles mediating transcytosis in brain endothelial cells.
Immunocytochemistry of markers for various endosomal organelles confirmed that 
polymersomes internalised by endothelial cells do not interact with the acidifying 
membrane-bound trafficking compartments part of ‘canonical’ endocytosis. These 
findings are consistent with reports of cargo taking around 15 minutes to reach the first 
trafficking stage of early endosomes (Tjelle, Brech et al. 1996), whereas live confocal 
imaging of transcytosis showed that A-EP had already started appearing in the pores 
beneath the endothelial cell monolayer at 15 minutes. The timing of the canonical 
endosomal trafficking pathway is inconsistent with the kinetics presented herein, further 
discounting the possibility of a canonical endo-lysosomal pathway operating in brain 
endothelial cell transcytosis. Tracking the fate of cargo encapsulated into pH sensitive 
polymersomes revealed that these drug delivery vehicles enter and exit brain 
endothelial cells without releasing its cargo. This effect was not observed in astrocytes, 
where cargo was released due to the acidic endosomal pH encountered upon 
endocytosis. Taken together, these findings are significant as they discount the 
possibility of a canonical endocytosis pathway being conserved in transcytosis at brain 
endothelial cells, and further show that transcytosis by these cells is unlikely to be 
mediated by previously implicated caveolae. Taking into account the very thin apical-to-
basolateral span of brain endothelial cells, it is concluded that the endosomal sorting 
system is a separate mechanism at the BBB reserved for cargo destined for the 
endothelial cells. 
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Surprisingly, inhibiting the SNARE complex member NSF completely stopped 
transcytosis before internalisation had occurred. Because the SNARE complex 
mediates membrane fusion, it is possible that transcytosis may not consist of discrete 
events of membrane fission and fusion of vesicular membrane as previously thought. 
Alternatively, transcytosis may cause the membrane to re-organise in an elongated 
tubular manner, ending with simultaneous scission and fusion events at the opposing 
sides mediated by dynamin and a SNARE complex, respectively. This hypothesis is 
supported by the requirement of cholesterol for the exocytosis stage. Work by Jahn et 
al. identified clustering of SNAREs into lipid rafts in the plasma membrane in a 
cholesterol-dependent manner, where depletion of cholesterol significantly impaired 
exocytosis (Lang, Bruns et al. 2001). It is possible that inhibited apical-to-basolateral 
transcytosis due to cholesterol depletion could be due to failure of SNAREs in the 
basolateral membrane to cluster and thus failure to mediate fusion of the vesicular and 
target membrane.
The shape of internalised transcytosis vesicles has traditionally been assumed to be 
vesicular, particularly due to electron microscopy morphological studies of endothelial 
cells (Ghitescu, Fixman et al. 1986). However, structural EM has overwhelmingly been 
investigating single sections of cells or tissue. Bundgaard et al. reconstructed 3D 
projections from serial section electron micrographs of hagfish brain endothelial cells, 
where the intracellular membranes arising from transcytosis were rarely single vesicles, 
but instead part of large multidimensional dendritic networks or ‘tubes’ (Bundgaard, 
Frøkjaer-Jensen et al. 1979). The deformation of the plasma membrane into a ‘tube’ 
connecting the apical and basolateral membranes via the shortest distance certainly 
seems an efficient mechanism to quickly transfer macromolecular nutrients across the 
BBB. The electron microscopy results from this section are somewhat consistent with 
this hypothesis, but cannot be taken for definite without serial 3D images to explore 
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whether the putative tubes observed in bEnd.3 transcytosis are real structures or 
artifacts.
A summarising cartoon of the proposed mechanism for brain endothelial cell 
transcytosis is depicted in figure 6.27. Confocal microscopy showed transcytosis to be 
dynamin-dependent with a likely role for actin in the initial transportation stage, but 
without a clear role for caveolae unlike previously implicated in reports. More 
surprisingly, brain endothelial transcytosis occurred without the acidification associated 
with endosomal trafficking organelles. Finally a role for the SNARE complex was 
implicated in brain endothelial cell transcytosis, which was disrupted by cholesterol 
depletion and also inhibition of NSF. These findings shed some light onto the 
mechanisms of LRP-1-mediated transcytosis.
Figure 6.27. Summary of proposed transcytosis mechanism of A-EP at the BBB.
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Chapter 7.
RESULTS AND DISCUSSION IV
In Vivo Validation and Applications for 
Polymersomes Targeting the Brain
_____________________________________________________________________
7.1. Introduction 
Work presented in this section was undertaken with the aim to validate use of A-EP as 
a CNS drug delivery vehicle. The first part is dedicated to obtain injected dose (%ID) 
values, in order to allow comparison of A-EP with other CNS drug delivery vehicles 
reported in literature. A technique was used to separate capillaries from the brain 
parenchyma to minimise false positives of transcytosis in which polymersomes are 
stuck within capillaries. Immunohistochemistry was used as a qualitative means to 
investigate polymersome distribution in the rat brain. The second part of the section 
aimed to explore therapeutic avenues using A-EP as a drug delivery vehicle in vivo. 
The di-peptide carnosine was encapsulated into A-EP and delivered intravenously in 
mice, and effects of carnosine neuroprotectant in stroke was investigated in mouse 
models of stroke.
7.1.1. In Situ Brain Perfusion
Even successful CNS drug delivery vehicles face the issue of a low delivery to the 
brain. For example, for OX26 %ID lies between 0.2-0.3% (Friden, Olson et al. 1996). 
This can be problematic for quantification of uptake into the brain, if enough dilution 
occurs to cause the signal from the material to fall below detection threshold. 
Furthermore, full body biodistribution studies inevitably cause the uptake of material 
into other organs, where they may be eliminated or retained without reaching the 
target. One way to circumvent these issues to investigate CNS uptake, and the 
subsequent distribution of materials within the parenchyma, is to use in situ brain 
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perfusion (ISP). This method involves surgical intervention to connect a perfusion 
apparatus to the carotid arteries, bypassing the rest of circulation and directly supplying 
the brain with a plasma-like perfusate containing the material of interest (Takasato, 
Rapoport et al. 1984). The setup is illustrated in figure 7.1. While ISP does not give 
accurate pharmacokinetics, it is useful for enhancing uptake into the CNS to 
quantifiable levels. ISP is especially advantageous if the aim is to look at where 
fluorescently or radiolabelled material becomes distributed within the brain.
Because the cerebellum receives a different blood supply (i.e. the vertebral artery), it is 
not perfused via ISP. The cerebellum is thus removed at the end of the experiment and 
not part of subsequent homogenisation or quantification.
Figure 7.1. Setup of in situ perfusion. (Takasato, Rapoport et al. 1984)
7.1.2. Capillary Depletion Technique
In situ brain perfusion is often coupled with a capillary depletion technique. This 
involves homogenisation of the brain at the end of perfusion time, and separation of the 
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brain parenchyma from the capillaries through centrifugation (Triguero, Buciak et al. 
1990). Dextran is added to the homogenate in the sample preparation process, and 
acts as a separating phase between parenchyma and capillaries, as the latter 
sediments into a pellet during centrifugation. This technique is useful to eliminate false 
positives in assessing cerebrovascular transfer of a material to the CNS, in the event of 
a CNS delivery vehicle remaining stuck within the capillaries instead of completing 
transcytosis.
7.2 Pilot Immunohistochemistry
After the preparation of polymersomes, it was important to establish whether it is 
feasible to quantify A-EP polymersome fluorescence from rat brain homogenates after 
perfusion. In vitro, A-EP consistently entered the transwell filter pore area underneath 
endothelial cells within 10-15 minutes. Therefore, similar times were hypothesised for 
transcytosis in vivo. ISP was performed with fluorescently labelled A-EP with perfusion 
times between 5 and 20 minutes. At the end of the perfusion times, the syringe pump 
supplying the plasma was allowed to run for another 60 seconds in order to ‘flush’ out 
unbound polymersomes from the capillaries. Half of the cerebrum was used for 
homogenisation and quantification, and the other half sectioned for fluorescence 
microscopy in order to visually confirm polymersome fluorescence inside the brain.
Figure 7.2 shows immunohistochemistry of three of the pilot study mice with A-EP 
perfusion times of 7 minutes, 15 minutes and 20 minutes, respectively. A-EP 
fluorescence was observed in the cerebral cortex at the earliest perfusion time of 7 
minutes. Fluorescence at this time was closely associated with nuclei, indicating a 
predominantly intracellular location. Similar fluorescence distribution was seen in the 
20 minute perfused sample. Sections from the 15 minute perfused mouse had a large 
amount of fluorescence in capillaries, but also visibly some intracellular fluorescence in 
areas both proximal and distal from the supplying vessels. Furthermore, a choroid 
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plexus section was obtained from the 15 minute perfused rat and contained a large 
amount of A-EP. It is unclear whether A-EP is undergoing transcytosis by the choroid 
plexus epithelial cells, or whether they had simply been internalised. 
Figure 7.2. Rat brain fluorescence of A-EP after in situ perfusion. A-EP (red), nuclei: DAPI 
(blue). Perfusion times given on the top right corner of images.
7.3. Quantification of Polymersome Uptake into the Rat Brain
Fluorescence of the capillary fraction and capillary depleted (corresponding to the 
parenchyma) was measured in rats perfused with Cy3-labelled A-EP (n=6) or EP (n=6) 
for 10 minutes, as displayed in figure 7.3. After 10 minutes of perfusion and one minute 
of flushing the capillaries, the % injected dose per gram of brain tissue in the 
parenchyma was 3.3±2.0 for EP and 8.2±2.6 for A-EP. In the capillary depleted fraction, 
%ID/g was 2.7±1.8 for EP and 4.1±2.1 for A-EP. More than 8% of the injected dose of 
A-EP was present in the parenchyma after 10 minutes, which is a considerably high 
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value. However, some presence of non-targeting EP was also detected. It is not known 
whether this is because of a false positive, whether the BBB integrity has been 
affected, or whether POEGMA-PDPA polymersomes do interact with cells. 
Fluorescence in capillaries was not significantly different between A-EP and EP, both 
around 3-4% of the injected dose. At 10 minutes, this is a reasonable amount to expect 
inside endothelial cells for A-EP as some transcytosis is likely still occurring.
Figure 7.3. Fluorescence quantification of A-EP uptake into the brain parenchyma in vivo. 
One-way ANOVA, p<0.05. n=6 for A-EP and n=6 for EP. Error bars: S.E.M.
7.4. Immunohistochemistry to Investigate Polymersome Distribution in Rat Brain
Next, the location of A-EP in perfused rat brains was examined via 
immunohistochemistry. Previous studies showed uptake of intravenously injected A-EP 
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into the hippocampus and choroid plexus of mice (Tian, Nyberg et al. 2015). 
Furthermore, initial rat brain immunofluorescence studies (figure 7.2) located A-EP 
fluorescence to the choroid plexus and cortex. As a result, these three areas were 
chosen for investigation in this experiment, with sections of the corpus callosum 
chosen to be the area most proximal to a ventricle. Brains perfused with Cy3-labelled 
A-EP for 10, 30 or 60 minutes were compared to a sham perfused control. Sections 
were counter-stained for the blood vessel marker CD34 in order to distinguish between 
polymersomes inside capillaries and polymersomes which had migrated further out in 
the parenchyma (Pusztaszeri, Seelentag et al. 2006). Images obtained at a 5X 
magnification are shown for the cerebral cortex (figure 7.4), hippocampus (figure 7.5), 
and corpus callosum (figure 7.6). 
It is difficult to observe polymersome fluorescence at 5X, but images obtained at this 
magnification provide a good orientation and overview of the area of interest. At the 
cerebral cortex and corpus callosum, A-EP fluorescence can be seen in a few 
scattered areas between 10 and 60 minutes. Images obtained from the hippocampus 
show higher red channel fluorescence, although the large red area in the 30 minute 
section is possibly an artifact from the staining procedure. However, polymersomes can 
be seen faintly surrounding hippocampal blood vessels at 60 minutes.
Images obtained at 20X give a better view of polymersome fluorescence. In the 
hippocampus (figure 7.7), polymersomes had migrated within the parenchyma but were 
still closely associated with blood vessels. At 30 minutes, some polymersome 
fluorescence was observed further away from vessels and also located close to nuclei. 
This migration was more pronounced after 60 minutes of perfusion, where many cells 
have internalised polymersomes and fluorescence was mostly in the perinuclear area.
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Figure 7.8 shows the distribution of A-EP in the cortex at 20X magnification. Although 
some polymersomes were closely associated with a major vessel, there was 
fluorescence coming from a distal area and appeared to be intracellular. Fluorescence 
was radiating from the vessels at 30 minutes, and at 60 minutes there was a diffuse 
and background-like signal. A-EP was seen both in perinuclear areas and close to 
vessels. The least amount of fluorescence was observed in the corpus callosum, as 
displayed in figure 7.9, where only a few red puncta could be seen. However, A-EP was 
seen in the choroid plexus at 10 minutes, a magnification of which is seen in figure 
7.10. This is consistent with the observations made of A-EP presence in the choroid 
plexus from 15 minute perfusion (figure 7.2). However, in this case fluorescence is 
more associated with blood vessels than the epithelial cells. At 10 minutes, 
polymersomes may still be migrating across the blood-brain barrier. 
Figure 7.4. A-EP distribution in cerebral cortex, 5X magnification. A-EP (red), counter-
stained for CD34 (green) and DAPI (blue).
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Figure 7.5. A-EP distribution in hippocampus, 5X magnification. A-EP (red), counter-
stained for CD34 (green) and DAPI (blue).
Figure 7.6. A-EP distribution in corpus callosum, 5X magnification. A-EP (red), counter-
stained for CD34 (green) and DAPI (blue). CP: choroid plexus.
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Figure 7.7. A-EP distribution in hippocampus, 20X magnification. A-EP (red), counter-
stained for CD34 (green) and DAPI (blue).
Figure 7.8. A-EP distribution in cortex, 20X magnification. A-EP (red), counter-stained for 
CD34 (green) and DAPI (blue).
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Figure 7.9. A-EP distribution in corpus callosum, 20X magnification. A-EP (red), counter-
stained for CD34 (green) and DAPI (blue).
Figure 7.10. Magnification of A-EP at 10 minutes in the choroid plexus. A-EP fluorescence 
(red) can be seen in close association with CD34 positive blood vessels (green).
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7.5. Application: Polymersomes with Carnosine for Neuroprotection in Stroke
7.5.1. Background
The high mortality rate and lack of treatment options available for stroke has been 
discussed in Section 1.1.2 of chapter 1. Recent research suggests that anti-oxidants 
can provide neuroprotectant benefits in rodent models of stroke (Majid 2014). One way 
to assess efficacy of novel stroke therapeutics in rodents is to measure the effect of the 
therapeutic on the total infarct area, i.e. the area of dead tissue resulting from 
ischaemia. Ischaemic stroke can be reproduced in mice using the transient middle 
cerebral artery occlusion (tMCAO) technique. It involves surgical arterial occlusion 
through a clamp, and can either be focal (i.e. localised to a specific area) or general. 
Carnosine is a dipeptide with antioxidant properties (Bellia, Vecchio et al. 2011). Pre-
clinical studies have shown neuroprotective effects of carnosine in animal models of 
stroke. However, the dosages required to obtain therapeutic effects in rats were in the 
range of 1000-2000 mg/kg, which may be too high to be a feasible dose to use in 
clinical settings (Bae, Serfozo et al. 2013). It was hypothesised that the delivery of 
carnosine encapsulated within Angiopep-2-POEGMA-PDPA would be able achieve the 
same effects at a much lower dosage rate, due to the targeting peptide and due to 
encapsulation of carnosine protecting it from premature degradation. Refer to section 
4.6.2 of chapter 4 for the encapsulation of carnosine into A-EP.
7.5.2. Effect of Carnosine on Infarct Area
Previous studies investigating the neuroprotectant effect of carnosine injected 1000 
mg/kg of the peptide in rats. Stroke volume was assessed in tMCAO rats pre-treated 
with 1000 mg/carnosine, empty A-EP (vehicle) or A-EP containing 1 mg/ml carnosine. 
Because the maximum allowed intravenous injection volume in rats is 1 ml, the dose 
roughly converts to 0.25 mg/kg in a 250 g rat. The infarct area of saline treated rats 
was 53.5 ± 24 mm3 (n=10) (figure 7.11). In the A-EP vehicle treated rats, the area was 
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59 ± 22 mm3 (n=14). Treatment with 1000 mg/kg carnosine dissolved in saline resulted 
in a reduction in the infarct area to an average of 36 ± 27 mm3 (n=10). In rats pre-
treated with carnosine encapsulated in A-EP, the stroke area was 34 ± 28 mm3 (n=10). 
Free carnosine and A-EP carnosine both significantly reduced the infarct area against 
that of A-EP vehicle treated rats, but not saline treated. However, the standard 
deviations obtained were high and the n number per group should be increased to 
obtain more accurate results.
Figure 7.11. Infarct area in rat brains after pre-treatment with A-EP-carnosine, free 
carnosine, or vehicle. Error bars: S.E.M. Student’s independent t-test, *p<0.05.
7.6. Discussion
The in vivo quantification of fluorescently labelled polymersomes was possible due to 
the high molarity of label in the polymersome membrane. The slight uptake of 
POEGMA-PDPA polymersomes in both capillary fractions and parenchyma may either 
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be a false positive, background fluorescence, or due to compromised blood-brain 
barrier integrity. However, A-EP fluorescence in the parenchyma was more than 8% of 
total fluorescence only 10 minutes after injection. This injected dose value is much 
higher than previously reported in literature, e.g. 3-4% for HIR and 0.2-0.3% for OX26. 
The high uptake can also be attributed to in situ perfusion, bypassing degradation and 
uptake by the rest of the body.
Immunohistochemistry of A-EP perfused rats showed the uptake into the hippocampus 
and cerebral cortex. Polymersome uptake into the hippocampus is consistent with A-
EP uptake into hippocampus in mice following intravenous administration.(Tian, Nyberg 
et al. 2015) Furthermore, the presence of A-EP in the choroid plexus after 15 minutes 
is interesting. It is unclear whether this is because choroid plexus take up a large 
amount of A-EP through endocytosis, or whether it is an elimination route. 
A-EP containing carnosine were injected at 1 mg/ml. And yet, the intravenous injection 
of A-EP with carnosine into mouse models of stroke resulted in the same amount of 
infarct area reduction that 1000 mg/kg free carnosine did. However, the values were 
not statistically significant to the saline perfused control, but only to the A-EP vehicle. 
The n number should be increased as in vivo results tend to display huge variation. An 
important next step would be validation in other stroke models. A caveat of animal 
models of stroke is that they are predominantly rodent based, and the methods used 
for models differ.
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Chapter 8. 
Discussion and Future Directions__________________________________________
Understanding how the barriers protecting the CNS work and how their transport and 
regulation systems work is key to enable drug delivery to the CNS beyond small 
molecules with a narrow range of physicochemical properties. The cellular mechanisms 
involved in macromolecular transport at the blood-brain barrier are poorly understood. 
Further work is required to give a comprehensive overview brain endothelial cell 
transcytosis, from ligand-receptor binding to membrane trafficking and exocytosis. 
Understanding BEC transcytosis is important both from a disease point of view and to 
use smart materials exploiting this system to deliver drugs past the blood-brain barrier.
In vitro models of the blood-brain barrier are useful for investigating fundamental brain 
endothelial cell properties. Work presented in this thesis has characterised the 
interaction of bEnd.3 cells and polymersomes mostly in a monoculture setting. The 
bEnd.3 model used fell short on expression of tight junction proteins, but did obtain 
higher TEER values than average. Future work may include the addition of pericytes to 
enhance barrier properties more closely mimic the BBB. Furthermore, ideally work 
should be compared between a cell line and primary endothelial cells, which is likely to 
have a different expression pattern of tight junction proteins, receptors and 
transporters.
The nature of the intracellular vesicles mediating transcytosis in brain endothelial cells 
is still to be confirmed, but data failed to find an involvement of acidifying endosomal 
compartments in bEnd.3 transcytosis. This is consistent with the hypothesis that brain 
endothelial cells may reserve such organelles for ‘traditional’ endocytosis, i.e. where 
cargo is destined to remain within the endothelial cells. The hypothesis that 
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transendothelial channels may form to enhance transcytosis is controversial, because 
the putative presence of an open channel between two environments negates the 
presence of tight junctions and would entail a low TEER. However, the hypothesis may 
be partially true in that some networks of vesicles closed off from the plasma 
membrane may form, as observed by Bundgaard and colleagues. Data indicated that 
caveolae were not the vesicles involved in A-EP transcytosis, whereas clathrin 
appeared in close proximity to A-EP at the time examined. Furthermore, electron 
microscopy studies indicated that the transendothelial vesicular network hypothesis 
may be true for brain endothelial cells, but further work needs to utilise serial 3D 
reconstructions of sections to gain context of these vesicles.
Modifying Angiopep-2 ligand density drastically altered transcytosis rates, providing a 
simple future tool for increasing uptake into the CNS. However, the relative 
contributions of receptor saturation, basolateral-to-apical recycling and ligand-receptor 
affinity in LRP-1 transcytosis kinetics remain to be elucidated. It is unclear why A-EP 
transcytosis reached saturation in some of the kinetics studies, i.e. no net apical-to-
basolateral or basolateral-to-apical transcytosis was occurring. It is possible that LRP-1 
recycling occurs more slowly than previously expected, or that transcytosis is a 
polarised event. Future work should investigate ligand-receptor interactions and 
receptor recycling rates, in order to fine-tune receptor binding and transcytosis 
efficiency for use of pH sensitive polymersomes in CNS drug delivery in vivo. Future 
work should also investigate the integrity of A-EP after transcytosis, e.g. by 
characterising size before and after a transwell assay, as to explore whether 
polymersome physicochemical properties change and as a result modify interactions 
with the endothelial monolayer.
The uptake of Angiopep-2-polymersomes into the rat brain reached an impressive 8% 
only 10 minutes after injection. However, the high dose could partly be attributed to 
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administration via in situ perfusion. Further experiments should be performed with 
intravenous injection to obtain a comparable injected dose value to other nanocarriers 
reported in literature. Additionally, endeavours to further characterise A-EP protein 
corona formation would be useful as this may affect uptake significantly. 
Overall, results presented within this thesis have shown that polymersomes with a 
blood-brain barrier targeting mechanism can be used as CNS drug delivery vehicles. 
The very same targeting mechanism facilitates transcytosis by brain endothelial cells, 
followed by endocytosis by LRP-1-expressing cells of the CNS where cargo is 
released. Because polymersomes can encapsulate hydrophobic or hydrophilic cargo 
even of macromolecular nature, there is a wide range of potential therapeutics that 
polymersomes could deliver to the CNS. Thus, A-EP polymersomes are a promising 
CNS drug delivery system which exploits transcytosis at the blood-brain barrier to 
obtain widespread delivery. 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